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A mis seres queridos. Mamá, papá, os quiero 
incondicionalmente. A mi familia y a mis 
amigos. A los que están, y a los que ya se 
fueron pero todavía recuerdo. 
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“Y luego, cuando ante ti se abran muchos caminos y no sepas 
cuál recorrer, no te metas en uno cualquiera al azar: siéntate y 
aguarda (…). Quédate quieta, en silencio, y escucha a tu 
corazón. Y cuando te hable, levántate y ve donde él te lleve.” 
Va´dove ti porta il cuore. Susanna Tamaro (1994) 
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Resumen 
El principal propósito de esta tesis ha sido ahondar en el conocimiento del mecanismo 
neural subyacente a la influencia de la emoción y el sistema motor en la memoria. El 
primero de los estudios presentados incide sobre la posibilidad de disminuir la memoria 
episódica, mientras que el segundo estudio presentado incide sobre la viabilidad de 
aumentarla.  
En el primer capítulo, se resumen las principales teorías sobre los procesos de memoria, 
desde las teorías clásicas a las más actuales. El segundo capítulo repasa los principales 
sistemas de neurotransmisores del sistema nervioso central y su relación con la emoción y 
la memoria, presentando los principales estudios en humanos o en animales. En el tercer y 
cuarto capítulos, se presentan dos estudios novedosos, que son una réplica y ampliación de 
dos estudios previos. 
 Las teorías clásicas han considerado la memoria como una facultad monolítica e inmutable 
de la mente. Sin embargo, las nuevas actualizaciones provenientes de las investigaciones 
realizadas en las últimas décadas, abren una puerta a la modificación de memorias 
previamente consolidadas. La  teoría de la reconsolidación establece la posibilidad de  
reactivar de nuevo una memoria mediante la presentación de una “clave” relacionada con la 
misma. Una vez la memoria es reactivada es susceptible de ser modificada dentro de una 
ventana de tiempo, mediante la administración de diferentes tipos de manipulaciones, tanto 
de carácter conductual como farmacológico; necesitando ser consolidada de nuevo  después 
de la reactivación. La reconsolidación de la memoria ha sido observada en diferentes 
especies animales y en humanos, así como con diferentes tareas y tipos de memoria.  
 El primer estudio presentado (capítulo 3) se basa en la hipótesis de la implicación del 
sistema GABAérgico en el deterioro de la reconsolidación de una memoria emocional 
episódica. Para la realización de este experimento se contó con la participación de pacientes 
que iban a someterse a una prueba de endoscopia y por lo tanto, recibir una sedación 
programada. Los resultados obtenidos muestran la disminución de la memoria emocional 
mediante la administración del agente anestésico propofol, inmediatamente después de la 
reactivación. Una proporción importante de la población está afectada por trastornos 
psiquiátricos que tienen en su origen una memoria emocional de carácter traumático o 
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desadaptativo. La posibilidad de modificar este tipo de memorias, abre un abanico a nuevos 
tratamientos y terapias coadyuvantes a las ya existentes.  
El segundo estudio presenta la relación entre en sistema motor y la memoria. Este estudio 
analiza cómo realizar una acción motora simple es capaz de aumentar la memoria 
episódica, al mismo tiempo que, inhibir esa misma acción no la disminuye. El propósito de 
este estudio fue comprobar la hipótesis de la relación entre estructuras temporo-mediales y 
el aumento de la memoria episódica mediante la acción de la noradrenalina liberada por el 
locus coeruleus.  La tarea consistía en la realización de una tarea de tipo “Go-NoGo”, en la 
que los participantes han de realizar una acción o inhibirla de acuerdo a una serie de claves 
previamente aprendidas. Antes del inicio de la prueba, se les administraba a los 
participantes un fármaco beta-bloqueante (propranolol) o un placebo, en un estudio de 
diseño doble-ciego. A las 24 horas de la realización de la tarea “Go-NoGo”, los 
participantes regresaban al hospital para realizar una tarea de reconocimiento de memoria 
sorpresa. No fue posible mostrar una correlación directa entre la manipulación 
farmacológica y el bloqueo de la mejora de la memoria.  Sin embargo, se demostró una 
correlación entre la excitación (arousal) experimentada por los participantes, traducida en 
un aumento de presión arterial sistólica y el porcentaje de estímulos correctos recordados. 
El principal propósito a la hora de realizar los estudios que se exponen en esta tesis fue 
siempre las probables implicaciones clínicas. Modificar una memoria, que por exceso, este 
creando un trastorno y un sufrimiento, ofrece una posibilidad de alivio tanto al paciente 
como a sus familias. Así mismo, la posibilidad de aumentar la memoria episódica mediante 
la realización de una acción motora a través del sistema noradrenérgico puede tener 
potenciales implicaciones clínicas en el tratamiento de las primeras etapas de trastornos 
degenerativos como el Alzheimer. En este tipo de demencias,  el sistema noradrenérgico 
dependiente del locus coeruleus se halla comprometido desde las primeras etapas. 
 Ambos estudios tienen, no sólo el objetivo de aumentar el conocimiento y comprensión 
sobre diferentes enfermedades o trastornos mentales, así como del mecanismo que subyace 
a las mismas, sino de modificar la percepción y estigmas que la sociedad tiene de las 
enfermedades que afectan a nuestro sistema nervioso central. 
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Abstract 
The main objective of this thesis has been to deepen the knowledge of the neural mechanism 
underlying the influence of emotion as well as the motor system in memory. The first of the studies 
presented focuses on the possibility of decreasing episodic memory, while the second study refers 
to the feasibility of increasing it. 
In the first chapter, the main theories about the processes of memory are summarized, from the 
classic theories to the more actual ones. The second chapter reviews the main neurotransmitter 
systems of the central nervous system and its relation to emotion and memory, presenting the main 
studies in humans or animals. In the third and fourth chapters, two novel studies are presented, 
which are a replication and extension of two previous studies. 
Classical theories have considered memory as a monolithic and immutable faculty of mind. 
However, new updates from the research carried out in the last decades, opens a door to the 
modification of previously consolidated memories. The theory of reconsolidation postulates that 
upon reactivation, memories can become labile and susceptible to manipulation, requiring a new 
restabilization process in order to maintain them. The reconsolidation of memory has been observed 
in different animal species and in humans, as well as with different tasks and types of memory. 
The first study presented (Chapter 3) is based on the hypothesis of the implication of the 
GABAergic system in the deterioration of the reconsolidation of an episodic emotional memory. 
For the accomplishment of this experiment it was counted on the participation of patients who were 
going to undergo an endoscopy procedure and therefore, to receive a scheduled sedation. The 
results show the impairment of the emotional memory by the administration of propofol, an 
anesthetic agent, immediately after the reactivation. A significant proportion of the population is 
affected by psychiatric disorders that have at their core a traumatic or maladaptive emotional 
memory. The possibility of modifying this type of memory opens a range to new treatments and 
adjuvant therapies to those already existing. 
The second study presents the relationship between motor system and memory. This study analyzes 
how performing a simple motor action is able to increase episodic memory, and yet, inhibiting that 
same action, does not decrease it. The purpose of the study was to test the hypothesis of the 
involvement of the medial temporal structures in this enhacement of memory by the action of the 
noradrenaline released from the locus coeruleus. The study consisted of a Go-NoGo task, in which 
the participants had to perform an action or inhibit it according to a series of keys previously 
learned. Prior to the performance of the task, a beta-blocker (propranolol) or placebo was 
administered in a double-blind design study.  24 hours after completing the "Go-NoGo" task, the 
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participants returned to the hospital to perform a surprise memory test. It was not possible to show a 
direct correlation between pharmacological manipulation and the blocking of memory 
enhancement. However, a correlation between the arousal experienced by the subjects, translated in 
systolic blood pressures and the percentage of correct remembered stimuli was shown.  
The main purpose in carrying out the studies that are exposed in this thesis was always the probable 
clinical implications. Modifying a memory, which by excess, is creating a disorder and suffering, 
offers a possibility of relief to both the patients and their families. Likewise, the possibility of 
increasing episodic memory by performing a motor action via the noradrenergic system may have 
potential clinical implications in the treatment of the early stages of degenerative disorders such as 
Alzheimer's. In this type of dementia, the noradrenergic system dependent on locus coeruleus is 
compromised from the early stages. 
Both studies have not only the goal of increasing knowledge and understanding about different 
diseases or mental disorders, and the underlying mechanism, but also to modify the perception and 
stigmas that society attached at the diseases that affect our central nervous system. 
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Chapter 1 
Memory processes 
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1.1 Introduction to long-term memory in humans 
 It is increasingly accepted that memory is not a monolithic faculty (Poldrack & Packard, 
2003), but more than a century ago, the divisions and subdivisions of memory, the stages 
through which the information goes through the brain, and the brain systems that support 
the different kinds of memory were unknown.  
In 1890, William James proposed that memory was not a unitary system, but a double 
system composed of a primary and a secondary memory, being described primary memory 
as the one that is held momentarily in consciousness and secondary as the one permanent 
but unconscious. This was a first approximation of the organization of memory in humans, 
which Hebb, (1949) converted into a division between short-term memory (STM) and long-
term memory (LTM).   
Following this assumption the information is transferred from one store (STM) to another 
(LTM); more than erasing information, it means that the information is “copied without 
affecting its status in the original store” (Shiffrin & Atkinson, 1969, p.179). The elements 
are supposed to be attended in order of entrance. If the subject does not attend the item, it 
would be lost in a short period of time within around 30 seconds, or even less. The control 
processes, such as for example rehearsal, allow the subject maintain the information in the 
STM for longer time periods. This STM was also assumed to act not only as an information 
maintenance store, but also as a working memory (Baddeley, 1992; Shiffrin & Atkinson, 
1969), in which manipulations of information may take place on a temporary basis. Once 
the information is transferred to the LTM, it is supposed to be permanent. The Atkinson- 
Shiffrin (1965, 1968, and 1969) model about the dissociation between STM and LTM 
rapidly aroused serious doubts.  
In 1974,  Baddeley & Hitch replaced the simple unitary STM with a more complex system, 
that they termed “working memory”. Working memory was assumed to comprise an 
attentional controller, the central executive, assisted by two subsidiary systems, the 
phonological loop and the visuospatial sketchpad. The phonological (or articulatory) loop 
is a store that holds memory traces for a few seconds, combined with a sub-vocal rehearsal 
process. The visuospatial sketchpad (or scratchpad) is supposed to permit the temporary 
storage and manipulation of visual and spatial information. The third component of the 
model, the central executive, is assumed to be a system that provides  attentional control of 
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the subsystems of working memory, bind information from a number of sources into 
coherent episodes, helps to vary the attention between tasks or recovery strategies and 
coordinates selective attention and inhibition to the stimuli (Baddeley, Kopelman & 
Wilson, 2002). With the passage of time it became evident that the model did not cover all 
the needs, and a fourth element was added: the episodic buffer (see Figure 1.1.). The 
episodic buffer is assumed to be an intermediate storage, prior to LTM, where information 
is integrated from different modal codes and can be retrieving consciously and manipulated 
or modified if necessary. It is controlled by the central executive. It is named episodic in the 
sense that is able to hold episodes where information is integrated (Baddeley, 2000).  
 
Figure 1.1. The current version of the multimodal working memory model. The episodic buffer is 
assumed to be capable to integrated information in multiples codes. The buffer is an intermediate store before 
the LTM, controlled by the central executive. The information that handles is able to be retrieving 
consciously. (Adapted from  Baddeley, 2000) 
 
Even though, Baddeley, among many other authors (see section 1.1.1), helped to build the 
concept of a memory system, it was not until 1979 that the term “memory system” appears 
for the first time in the title of a paper. It was an article written by Warrington, (1979), 
where she made a discussion about the neuropsychological evidence supporting a 
distinction between short-term and long-term memory systems, and a subdivision of long-
term memory system in two: event memory and semantic memory. 
1.1.1. Declarative and non-declarative memory 
Since the beginning of psychology, different distinctions between different types of 
memory have been made, according to the predominant zeitgeist.  Bergson, Mitchell, 
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Pearson, & Kolkman, (1911) distinguished between  memory and habit; Schactel (1947), 
formed the terms autobiographical and practical memory;  Ryle, (1949), reflected about 
knowing how and knowing that; Bruner (1969) conceptualized “memory with record” 
(recollection of the “facts we acquire and events we experience in daily life”) and “memory 
without record” (“ some processes that changes the nature of an organism, changes his 
skills, or changes the rules by which he operates, but are virtually inaccessible in memory 
as specific encounters”) (p.254) ; Winograd, (1975) and Winston, (1977) distinguished 
between declarative and procedural (the first one using the term “declarative” was 
Anderson in 1976) (Squire, 1992). These studies among others with healthy populations or 
amnesic patients (e.g., the ability to resolve stereoscopic images, Benzing & Squire, 1989; 
cognitive skill learning, Squire & Frambach, 1990; artificial grammar learning, Knowlton, 
Ramus, & Squire, 1992; and category learning, Knowlton & Squire, 1993) helped to make 
a distinction between declarative memory and non-declarative memory. Also other terms 
for similar dichotomies have been used, e.g., explicit (intentional or conscious recollection 
of past episodes) and implicit memory (unintentional, non-conscious use of previously 
acquired information) (Graf & Schacter, 1985; Schacter, 1987); or memory and habit 
(Mishkin, Malamut, & Bachevalier, 1984).  
Today, the main differentiation commonly used is between declarative and non-declarative 
(usually also referred to as explicit (declarative) or implicit (non-declarative), both terms 
can be used interchangeably) memory. Double dissociations in neuropsychological findings 
from amnesic patients have mainly formed these concepts (Graf & Schacter, 1985; Squire, 
1992; Squire, 2004). 
The term declarative (explicit) memory is used in the sense that a person can bring to mind 
or declare the content of this memory. It also includes memory for faces, spatial layouts, 
and other material that can be verbalized or that brings an image to the mind; in this sense, 
declarative memory is considered to be a conscious memory; while the other type or types 
of memory that are dissociable from this one  (non- conscious) are referred to as non-
declarative or implicit memories (Squire, 1992) (see Figure 1.2.).  
Squire and Zola (1996) consider the episodic and semantic memory as two parallel side-by-
side subsystems of a higher division of the declarative memory. The beginning of this 
fragmentation of the declarative memory goes back to 1966 when Ross Quillian used for 
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the first time the term “semantic” memory in his doctoral dissertation (Tulving, 1972). 
Quillian developed a program called TLC (the teachable language comprehender); a series 
of assumptions to understand how meaning might be stored, using hierarchical organization 
minimizing the storage demand (Baddeley, 2001). Tulving & Donaldson, (1972) organized 
a conference where this new line of research was well represented, and led Tulving to make 
the distinction between “episodic” and “semantic” memory. Previously, psychologists 
began to use this model to investigate how humans store knowledge, how statements and 
features of the world can be accessed and verified (Baddeley, 2001).  
Tulving (1972) used the term “episodic” to refer to the other kind of memory that was not 
semantic; suggesting that there were sufficiently fundamental differences between the two 
forms of memory to consider the two categories separately (Tulving, 1972).  According to 
Tulving (1972), episodic memory receives and stores information about temporally dated 
episodes or events, and temporal - spatial relations among these events; while semantic 
memory, reflects a kind of organized knowledge of a person about words and other verbal 
symbols (such as their meaning and referents, about relations among them, about rules for 
the manipulation of those symbols, concepts and relations). 
In summary, semantic memory is a conscious and propositional memory that can be either 
true or false. It is based on a recollection of facts and events, fast in acquisition and flexible.    
It is assumed to reflect our knowledge of the world, holding generic information acquired 
across different contexts and being able to use it in different situations. In contrast, episodic 
memory  is assumed to recollect personal experiences, specific individual events with 
spatial-temporal features (Baddeley, 2001).  
Non-declarative (or implicit) memory is a non- conscious form of memory. Performance 
changes as a result of practice and experience, without conscious awareness and usually 
slows in acquisition (except priming). It refers to a heterogeneous collection of skills, 
habits, and other dispositions such as simple forms (classical, operant) of conditioning and 
priming, that are influenced by our behavior and mental life, and are a necessary part of 
what defines us as individuals  (Squire, 2009). 
The best understood example of non-declarative memory is simple classical conditioning; 
specifically delay conditioning that is a simple associative learning and represents the 
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quintessential paradigm of non-declarative memory. In delay conditioning, the conditioned 
stimulus (CS), is presented, and then, immediately the unconditioned stimulus (US) is 
presented; being both stimuli presented at the same time and co-terminate at the same time 
either (overlap in time, there is no time delay between presentations). Repeated CS-US 
pairings are learned and the conditioned response (CR) is elicited by the CS in advance of 
the US (Clark & Squire, 1998). The other form of classical conditioning that obeys to the 
principles of declarative memory is trace conditioning. It is a different version of classical 
conditioning in which the “CS is presented and terminated and then a short interval is 
imposed before the presentation of the US. The name comes from the fact that the CS must 
leave some trace in the nervous system for a CS-US association to be established” (Clark & 
Squire, 1998; p.77). The main difference between both conditionings is thought to be that 
trace conditioning depends on conscious knowledge about the CS-US association, whereas 
a conscious representation of the CS-US contingency is not necessary in delay 
conditioning. Nevertheless, in a typical fear conditioning study with humans, participants 
“may not always acquire a genuine fear response, because the level of aversiveness of the 
UC is selected by the participant” (Weike, Schupp, & Hamm, 2007; p.170) . In other 
words, participants may be able to learn that the CS predicts the occurrence of the US, but 
without learning to “fear” the CS. Participants have the explicit declarative knowledge of 
the CS-US association [‘‘contingency learning,’’ (Rescorla, 1988); or ‘‘propositional 
learning,’’ (Lovibond & Shanks, 2002)], but did not acquire the emotional features in order 
to activate the fear system in the brain (Weike et al., 2007). Weike, Schupp, & Hamm, 
(2007) suggested that fear responses can be acquired by implicit learning without 
necessitating the explicit knowledge of the contingencies (see Öhman & Mineka, 2001). 
Taken together, their results suggest that in trace conditioning (CS-US presentations are 
separated in time) the acquisition of declarative knowledge may be a necessary condition 
for learning, while in delay conditioning, (CS-US presentation overlap in time), the 
acquisition of a fear response is not related to explicit awareness; being these learnings 
dependent of different neural circuits (Weike et al., 2007). 
Referring to the classification of memory, many of the theories have been elucidated by the 
study of patients with different types of brain lesions. The term “global anterograde 
amnesia” was used for referring patients that were no longer able to “learn” more 
information or to retain new life experiences. Nevertheless,  investigators started to see that 
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these kind of patients were able to retain new experiences of a certain type or in a certain 
way (Mishkin, Malamut, & Bachevalier, 1984). One of the most important works in this 
area (memory classification) came from the demonstration by Warrington and Weiskrantz 
(1968) that these densely amnesic patients were capable of learning (even though, the 
patients were not aware of their learning) and show that learning, of pictures or words. 
They showed patients a word or a line drawing, and then asked them to identify a partial or 
degraded version of the previous word or picture (Warrington & Weiskrantz, 1968). This 
new form of learning is now known as “perceptual priming”, and at the moment of it 
discovery it was obvious that it was not based on episodic or semantic memory (Schacter & 
Tulving, 1994), but on “some other, as yet little understood, memory system” (Tulving, 
Schacter, & Stark, 1932, p.341). Nowadays, priming is a very well-studied form of non-
declarative memory, and it is defined as the capacity to improve the perception of stimuli 
under degraded conditions by prior presentation (Baddeley, 2001). 
Skill and habits are two subtypes of a higher subdivision usually known as “procedural” 
memory, and is a memory acquired by trial and error. Examples of our daily life of 
procedural memory are: riding a bicycle, typing, reading words… (Mochizuki-Kawai, 
2008). This kind of memory involves the acquisition of new behavioral capacities through 
feed-back guided learning without the mediation of conscious (declarative) memory 
(Poldrack, Prabhakaran, Seger, & Gabrieli, 1999).  
 
 
Figure 1.2.Classification of long-term memory. Declarative memory includes memory for facts and 
events. Non-declarative memory refers to a heterogeneous collection of distinct learning and memory abilities 
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where performance changes but without affording access to the experience or experiences that caused the 
change (Reproduce from Zola-Morgan, S., & Squire, L. R., 1990; Squire, 1992) 
As Nadel pointed in 1992 on the section “What is a system?” of the book “Memory 
systems 1994” (Schacter & Tulving, 1994), two criteria are necessary for distinguishing 
among systems: the length of time the information is stored in them (see section 1.1.) and 
different neural architectures  (Schacter & Tulving, 1994) (see section 1.2.) 
1.2. Brain structures 
Different types of retention processes imply different storage mechanisms, or even entirely 
different neural systems (see Figure 1.3.) (Mishkin, Malamut & Bachevalier, 1984). 
 
Figure 1.3.The neuroanatomical and behavioral distinctions between declarative and non-declarative 
memory (Reproduce from Squire, 1992). 
 
1.2.1 The Medial Temporal Lobe 
As said before, much of the relevant information of the various kinds of memory and its 
different stages comes from the study of brain-damaged patients, usually with selective 
memory impairments (Tulving, 1995). Although Ebbinghaus, William James and many 
others performed different experimental studies of memory (Dickerson & Eichenbaum, 
2010) it was not until  the middle 1950s, with the famous studies done by Brenda Milner 
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(Scoville & Milner, 1957) that  the role of the different brain structures and thus the 
biological substrate of memory came to light. 
In 1954, the surgeon Scoville reported a grave impairment of recent memory which he had 
observed as a sequel to bilateral medial temporal lobe (MTL) resection in two patients, one 
psychotic patient and one patient with intractable seizures (Scoville, & Milner, 1957). At 
that time, psychosurgeons used to perform fractional lobotomies on serious ill 
schizophrenic patients who were resistant to other forms of treatment. The purpose of these 
fractional lobotomies was to ensure the beneficial effects of a complete frontal lobotomy 
but also to preserving as much as possible the overall personality. At the age of 27, patient 
H.M. had a radical bilateral medial temporal lobe resection due to his long history of 
intractable seizures. The doctors considered justifiable the surgery because the patient was 
totally unable to lead a normal daily life, due to his seizures. Other justifications for surgery 
were the known epileptogenic qualities of the uncus and hippocampal complex, and the 
relative absence of post-operative seizures in other temporal-lobe resections performed 
before. Among with patient H.M. and the other schizophrenic patient who had the same 
radical resection, Scoville and Milner in his article published in 1957 analyzed other eight 
cases who had undergone similar, but less radical, bilateral medial temporal lobe resections. 
They analyzed all these cases, dividing them into three groups according to different 
degrees of memory impairment. Group I, was the group of H.M and the schizophrenic 
patient, both with severe memory impairment. Both patients seemed to forget the incidents 
of their daily life as fast as they occurred, with no other cognitive impairments; the IQ in 
the case of H.M. was even higher than preoperative. The resection in these two cases, 
according to Scoville, was about 8 centimeters (cm) from the midpoints of the tips of the 
temporal lobes. Among these two patients, in Group I was also another psychotic patient 
but with a resection of 5.5 cm, showing the same severe memory impairment. Group II was 
composed of five patients with a moderate to severe memory impairment, with a bilateral 
medial temporal-lobe resection of about 5 to 6 cm, posteriorly from the temporal tips. 
These patients were able to recall some impressions of new places and events, but were 
unable to make any new association such as people´s name. Finally, there was Group III 
with only two patients diagnosed with a non-persistent memory defect. 
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The anterograde amnesia of H.M. was profound (Scoville & Milner, 1957), but what was 
exactly the extension of the damage that caused such a severe memory impairment 
compared to other medial temporal lobe amnesia with less severe memory deficits? In 
1978, a patient known as R.B. had an episode of global ischemia at the age of 52, and 
developed memory impairment. During the next 5 years that he managed to survive, he had 
no other cognitive deficits beyond his anterograde amnesia, a less severe amnesia than 
H.M. After his death, the cerebral histological examination revealed a bilateral lesion 
involving the entire CA1 field of the hippocampus (Zola-Morgan, Squire, & Amaral, 
1986). In the mid-nineties, and for the first time, Corkin and her colleagues, (1997) were 
able to evaluate the neurosurgical resection in H.M., and to determine precisely which part 
of the medial temporal lobe were included in his resection and thus may be responsible for 
his amnesic syndrome. The magnetic resonance imaging (MRI) indicated that the lesion 
was bilaterally symmetrical, but smaller than Scoville thought (5.4 cm left and 5.1 cm 
right), and that the severe memory impairment in H.M. compared with that in other 
amnesic patients with selective hippocampal lesions (R.B), may be related to the inclusion 
of portions of the entorhinal, perirhinal, and parahippocampal cortices in the medial 
temporal lobe removal (Corkin, Amaral, González, Johnson, & Hyman, 1997). These 
studies revealed two main findings. First, that the hippocampus itself is a key component of 
the MTL memory system; and second, that structures outside the hippocampus must be 
important for memory, too (Squire & Zola-Morgan, 1991).   
The MTL is critical for declarative memory (conscious) and contains structures such as the 
hippocampus, CA fields, the dentate gyrus, the subicular complex, and the 
parahippocampal cortex (the adjacent perirhinal, entorhinal and parahippocampal cortices)  
(Squire, Stark, & Clark, 2004); see also the term “hippocampal region”, Scoville and 
Milner (1957); see Figure 1.4.). 
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Figure 1.4.The medial temporal lobe structures. S (subicular complex); DG (dentate gyrus); CA1, CA3, 
the CA fields of the hippocampus. (Adapted from Squire, Stark, & Clark, 2004). 
 
The other conclusion that the work of Milner helped to elucidate was that MTL is only 
temporary, since the damage in this cerebral area produces temporarily retrograde amnesia 
(Alvarez & Squire, 1994). This phenomenon was highlighted more than 100 years ago by 
Theodore Ribot in The diseases of memory (1882).  Ribot (1882) pointed his famous 
Ribot´s Law about the temporal gradient, and the extent of retrograde amnesias, ranging 
from more recent to more remote memory dysfunctions.  
In 1968, Milner published an article about the residual learning capacities of patient H.M. 
He was able to acquire new motor skills, using a mirror drawing task, and also showed 
some evidence of perceptual learning (Milner, Corkin, & Teuber, 1968).  At this time it 
became increasingly clear that heavily “amnesic patients were able of certain types of 
learning, including priming, the acquisition of motor skills, classical conditioning and habit 
learning” (Baddeley, 2001, p.1346); emphasizing a third important dissociation between 
explicit and implicit memory. These elegant neuropsychological studies of Milner, of the 
noted amnesic patient H. M., demonstrated convincingly that declarative memory depends 
on the integrity of the MTL; and also established the fundamental principle that memory 
could be dissociated from other intellectual functions (Squire, 1992).  At that time, and due 
to the motor skills that H.M. was able to learn even though he denied it, led to the view that 
motor skills are considered a less cognitive form of memory (Squire, 2004). The subjacent 
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idea was that motor skills were represented in a different brain area, and the rest of the 
memory was implemented in another region.  
1.2.2. Other brain structures of non-declarative memory in humans  
As noted before, the hippocampal function is fundamental for declarative memory, but not 
for other non-declarative learning (priming, the acquisition of motor skills, classical 
conditioning and habit learning). By the 80’s, studies from animals and amnesic patients 
started to highlight what other cerebral areas, besides the MTL, were involved in different 
types of memory.   
Another important finding was to discover the role of the neostriatum in feedback-guided 
learning, a way the brain has to learn how some situations and actions predict positive or 
negative outcomes (San Martín, 2012) in order to learn an habit. In summary, the 
neostriatum and its connections with the neocortex form part of a system supporting the 
incremental learning of habits and reward driven non-motor habits, guiding behavior and 
cognition (Knowlton, Mangels, & Squire, 1996). 
Different studies with amnesic patients have probed that priming is a non-conscious 
memory process totally independent of the medial temporal lobe (Squire, 2009). Research 
on this kind of memory came from the observation that amnesic patients could perform as 
good as control subjects in a sort of memory tests of words where the patients do not have 
to recall or recognize a previously set of words presented (e.g., TABLE and CHAIR; and 
they are instructed to complete the stems from English words, e.g., TAB--- and CHA---) 
(Graf & Mandler, 1984). priming is the facilitation to identify or process stimuli, that have 
been  previously presented (Squire, 2009).  
Using electrophysiological recording of neural activity during a very simple and well-
characterized form of associative learning, such as paired training trials (delay eyeblink 
conditioning of the rabbit nictitating membrane, also known as a third eyelid) from 
different regions of the rabbit´s ipsilateral cerebellum, Thompson et al., (1982) suggested 
an important role of the cerebellum in coding the learned response. This study 
demonstrated that the hippocampus is not critical for the acquisition of delay memories, 
where the conditioned stimulus (CS)  and the  unconditioned stimulus (US) overlap in time 
(Beylin et al., 2001). While for trace (eyeblink) conditioning the hippocampus is necessary 
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for the associative learning of the conditioned (eye-blink) response (Kim, Clark, & 
Thompson, 1995; Moyer, Deyo, & Disterhoft, 1990). 
In relation to other brain structures important for memory, it is necessary to emphasize the 
role of the amygdala in fear learning (but see section 1.4.) 
1.3. Stages of memory 
1.3.1. Encoding-Consolidation-Retrieval 
“Memory refers to the knowledge that is stored in the brain, and to the processes of 
acquiring, consolidating and retrieving such knowledge” (Baddeley, Kopelman,  & Wilson, 
2003, p. 17) 
Already in 1859, William Hamilton, made an explicit division of the process of memory 
into three stages: acquisition, retention and reproduction. Analogous to the classical view of 
memory formation involving three steps: encoding, consolidation and retrieval (see Figure 
1.5.).  
 
Figure 1.5. Memory encoding, traditional view. Adapted from Nadel, Hupbach, Gomez, & Newman-
Smith, (2012). 
 
Encoding can be defined as the processes whereby information is registered. The most 
typical way of studying this process is by “varying the nature of the material and/or the way 
that it is processed during learning” (Baddeley, Kopelman& Wilson, 2002; p. 9). The 
subsequent recall of the information will be affected by the characteristics of the material at 
the time of the encoding. For example, when processing the visual features of a word, the 
subsequent recall or recognition will be poorer than if processing that word in terms of 
meaning (Baddeley, Kopelman & Wilson, 2002). 
During the encoding the representations of the different entities involved in the process are 
activated in the nervous system; mainly in the cortical systems, but also in the hippocampal 
formation. The hippocampal system encodes spatial and temporal characteristics and also 
30 
 
provides an “index” that allows the retrieval of the information. The discovery of the place 
cells in the hippocampus by O´Keefe and Dostrovsky in 1971, led to the idea that the 
hippocampus was in charge of a particular form of memory based on the “representation of 
experience within a specific context (O´Keefe and Nadel, 1978, p.381). This particular role 
of the hippocampus in context led to the conclusion of the fundamental role of the 
hippocampus in representing spatial context (Nadel & Willner, 1980). The hippocampus, as 
said before, is specialized in the contextual attributes and temporal features. The coding 
mechanism in the hippocampus allows it to differentiate between close representations; this 
forms boundaries between similar contexts. Hippocampal dysfunctions provide, among 
other manifestations, a loss of the ability to encode and discriminate between contexts 
(Nadel et al., 2012). 
 The cortical systems are specialized in extracting the semantic characteristics of the 
entities, their regularities to form categories and concepts.  Once the entities have been 
processed according to their features, there are also linkages between the hippocampus and 
the cortical systems, for encoding all features of each entity (Nadel et al., 2012). 
In 1900,  Georg Elias Müller, professor at the University of Göttingen, Germany, and his 
student Alfons Pilzecker coined the term consolidation in their seminal monograph 
Experimental Contributions to the Science of Memory. What they proposed was that the 
learned information does not produce instantaneous, permanent traces of memory, but that 
time is needed to fix or consolidate that trace. During this necessary time period, memory 
remains vulnerable to disruption (Lechner, Squire & Byrne, 1999). Memory formation 
occurs slowly over time, but once consolidation is over, by definition is permanent, 
unchangeable and the memory trace that results cannot be disrupted in the normal course of 
events (Nadel, Hupbach,  Gomez & Newman-Smith, 2012).  
A second important finding is related to Milner et al., (1968) and the proposal that Alvarez 
and Squire (1994) did about the role of the MTL. It seems clear that the hippocampus and 
its related cortical structures consolidated memory through a process that is time dependent, 
but it is not the place where information would remain forever.  Ribot (1882) formulated a 
hypothesis (later confirmed by Squire, Slater, & Chace, (1975) using electroconvulsive 
therapy) about the susceptibility of a memory; and that this susceptibility to disruption was 
inversely proportional to the age of the memory. According to this notion, both fact (or 
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semantic) memory and event (or episodic) memory are impaired together in a graded 
manner depending on the extent of damage to the hippocampal system as a whole 
(Knowlton, Squire, & Gluck, 1994). Instead, another proposal stated that the core defect in 
temporal-lobe amnesia is a loss of context- rich episodic memory, that could be why in  
some amnesic cases, semantic memory, which is free of context, appears to have been 
relatively preserved (Tulving, 1995).  The debate about if both memories, semantic and 
episodic, depend on the hippocampus, was open.   Vargha-Khadem et al., (1997), provided 
findings that support the view that only the episodic component of the cognitive memory is 
fully dependent on the hippocampus. They described three different cases of early bilateral 
hippocampal pathology (one case at birth, in another by age 4, and in the third at age 9), 
where despite the pronounced anterograde amnesia for the episodes of everyday life, all 
three patients attended mainstream schools and attained levels of speech and language 
competence, literacy, and factual knowledge that are within the average. The findings 
provide support for the view that the episodic and semantic components of cognitive 
memory are partly dissociable. In a review of different studies later carried out by  Tulving 
& Markowitsch, (1998), they saw that what Vargha-Khadem et al., (1997)  proposed fit 
perfectly with the episodic theory. Vargha-Khadem et al.,(1997) suggested that the 
acquisition of factual knowledge can occur independently of the episodic memory, being 
the neuroanatomical reference for the semantic memory the perihippocampal cortical 
regions and for the episodic memory the hippocampus. According to this proposal, perhaps 
only when the hippocampus and underlying cortices are damaged together, as in the famous 
case of H.M. (Scoville, W. B., & Milner, 1957), does the anterograde amnesia affect both 
components of cognitive memory equally (Vargha-Khadem et al., 1997). 
Squire et al., (1975), measured the temporal gradient of memory loss in retrograde 
amnesias. Typically, as the interval between learning and amnesic treatment, such as 
electroconvulsive therapy (ECT) (ECT was used in this study with highly depressed 
patients) increases, the following amnesia is diminished. This phenomenon has been taken 
to highlight that the neural substrate of memory changes or consolidates over the time. 
There are other brain structures, such as the neocortex, where memory is stored in a slower 
way, but where it would last longer in a supposedly invariably manner. This idea was 
proposed by Marr, (1971); he conceived the hippocampus as a temporary “simple” storage 
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of data, while the neocortex was the permanent store. McGaugh, (1966) pointed the idea 
that the higher levels of recruitment of neocortical areas during retrieval of remote when 
compared to recent memories points to the existence of dynamic interactions between the 
hippocampal formation and cortical areas during the consolidation process. According to 
more contemporary models of consolidation (McClelland, McNaughton, & O’Reilly, 1995; 
Squire & Alvarez, 1995), experience is initially encoded in parallel in hippocampal and 
cortical networks. Then, “reactivation of the hippocampal network reinstates activity in 
different cortical networks. This coordinated replay across hippocampal–cortical networks 
leads to gradual strengthening of cortico-cortical connections, which eventually allows new 
memories to become independent of the hippocampus and to be gradually integrated with 
preexisting cortical memories” (Frankland & Bontempi, 2005, p.122).  
Dudai & Morris, (2000), in order to avoid any confusion with the term consolidation 
decided to make a differentiation between the memory stabilization process that only takes 
minutes to hours, what they referred as “synaptic consolidation” and could be assigned to 
any kind of memories. And the longer process, that may take years, using the term “systems 
consolidation”, which it could only apply to the memories that are initially hippocampus 
dependent.  
However, the neurobiological mechanism that is behind the synaptic consolidation of a 
memory in the hippocampus and the mechanism that is responsible of transforming that 
memory into a hippocampus independent one over the time are the same. As outlined 
before, Müller & Pilzecker, (1900) already noticed that performance can be impaired 
between two new competing learning events (Gordon & Spear, 1973), if they occur close in 
time. Also, memory performance can be impaired with invasive treatments such us 
electroconvulsive shock (Duncan, 1949) or proteins synthesis inhibitors (Flexner, Flexner, 
& Stellar, 1965) given almost immediately after learning, but not if given after hours. 
Contrary, retention can be enhanced via administration of different pharmacological 
compounds, such as strychnine (Gordon, 1977b). These three lines are believed to support 
the existence of a synaptic consolidation process, that distinct between a short-memory 
trace that lasts not more than some hours or days and a long- term memory trace that is 
supposed to be more permanent over time. 
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The hippocampus is considered to be active during consolidation processes (Dudai, & 
Morris, 2000), so studies at the cellular level of consolidation includes long-term 
potentiation (LTP) in this structure.  The LTP in hippocampal slice preparations is the  
“long-lasting enhancement in signal transmission between two neurons following high-
frequency stimulation of a chemical synapse” (Nader & Einarsson, 2010, p.28), analogous 
to the real cellular machinery in the brain. LTP can be divided in two phases, the early 
transient phase (E-LTP) and the late phase (L-LTP), a more lasting phase, but this line is 
very abstract. LTP, needs protein synthesis to take place (Bliss & Lømo, 1973; Martin, 
Grimwood, & Morris, 2000). Also, LTP can be modulated by the action of 
neurotransmitters, for example, glutamate, through the NMDA receptors activate the LTP 
process (Bliss & Collingridge, 1993). Dopamine is able to produce an enhancement of  the 
early stages of LTP (Otmakhova & Lisman, 1996); while, GABA agonist (such as 
benzodiazepines like midazolam) are able to reduce LTP through the action of GABAA 
receptors (Evans & Viola-McCabe, 1996).  
1.4. Emotional memory 
“An impression may be so exciting emotionally as almost to leave a scar upon the cerebral 
tissues” (James, 1890) 
Emotional memory deserves an independent section due to the main topic of this thesis; and 
because, emotional events usually have a privileged status in memory, and build our 
personal history (LaBar & Cabeza, 2006). But, what is special about emotional information 
processing? How emotion influences memory? Which are the neural correlates of that 
influence? And how may we be able to reduce that influence in pathological memories? It 
is what is going to be analyzed. Broca named the limbic lobe (hippocampus, the amygdala 
and the entorhinal cortex) because it forms a rim (in Latin, limbus means “rim”) around the 
corpus callosum. The idea that the limbic lobe was involved in different emotional and 
viscerosomatic reactions in the mammals was developed by Papez, (1937) as one of the 
first propositions of the anatomical mechanism of emotion. Papez (1937) in his 
“Mechanism of emotion”, pointed that the structures that may elaborate the emotions in the 
brain, and may participate in emotional expression were the hypothalamus, the anterior 
thalamic nuclei, the gyrus cinguli, the hippocampus and their interconnections. At that time, 
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the main idea was that the hippocampus and the entire limbic lobe were involved in 
olfactory functions. 
1.4.1 The human amygdala 
Today, one of the main theoretical frameworks of emotions is a dimensional approach that 
organizes emotion around two motivational systems: the appetitive and defense systems. 
These two opposing systems are reflected by the dimension of valence (pleasantness and 
unpleasantness). Further, arousal is the intensity which with these systems can be activated 
(Lang, 1995; Lang, Bradley, & Cuthbert, 1990). Arousal can be defined as an emotion´s 
dimension that oscillates between calm and excitement (LaBar & Cabeza, 2006).  In 1990, 
Cahill & McGaugh proposed for the first time that the amygdala influence on emotional 
memory is mainly driven by arousal. They hypothesized that the degree of arousal of an 
emotional stimulus indicated the degree of the amygdala´s involvement in memory storage 
of that stimulus. The more arousing is the stimulus, more participation of the amygdala, and 
better subsequent recall. The theory of the main role of arousal, rather than valence, on 
amygdala activation and later recall was supported by Hamann, Ely, Grafton, & Kilts, 
(1999). Using Positron Emission Tomography (PET), they showed that bilateral amygdala 
activity during memory encoding is associated with enhanced episodic recognition memory 
for both pleasant and aversive stimuli compared to neutral stimuli, and that this relationship 
is specific to emotional stimuli. 
The main studies focusing on the amygdala´s influence of arousal and its interaction with 
other brain regions such as the hippocampal and medial- temporal lobes were carried out 
mainly in episodic memory, and in fear conditioning. These studies have showed that 
amygdala  influences memory indirectly, by modulating the activity of the hippocampus 
and temporal lobes (Hamann et al., 1999; McGaugh, Cahill, & Roozendaal, 1996; Packard 
& Teather, 1998). 
The amygdala comprises about 12 different regions; and each region can be differentiated 
into several sub-regions.  The most relevant areas for fear conditioning and episodic 
memory are the lateral (LA), basal (B), accessory basal (AB) and central (CE) amygdala, 
and their interconnections. Usually, the areas lateral and basal are referred together as the 
basolateral (BLA) amygdala (LeDoux, 2000).  
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In the fear conditioning paradigm, the conditioned tone (CS) includes projections from the 
auditory system to the lateral nucleus of the amygdala (LA), and from there, to the central 
nucleus of the amygdala (CE). In contrast, conditioning to the apparatus or contextual cues 
that were present at the time when the CS and US are paired, involves the hippocampus for 
the representation of the context and the projection between the hippocampus and the basal 
(B) and accessory basal (AB) nuclei of the amygdala, which communicates to CE. For tone 
conditioning, CE is in charge of the expression of the responses (LeDoux, 2000,) 
The knowledge of how emotional memory is based on the integrity of the amygdala comes 
from studies of patients with amygdala lesions with memory for emotional stimuli  
disproportionately impaired (Adolphs, Cahill, Schul, & Babinsky, 1997; Babinsky et al., 
1993). In humans, brain damage affecting only the amygdala is quite rare (Adolphs et al., 
1997). So, the greatest contributions have been made by patients with unilateral damage of 
the MTL due to lobectomies in intractable epilepsy, or from patients with Urbach-Wiethe 
syndrome, a rare condition that sometimes can causes bilateral amygdala pathology  
(Adolphs, Tranel, Damasio, & Damasio, 1995; Hofer, 1972; Strange, Hurlemann, & Dolan, 
2003). 
 Fear conditioning: the role of the amygdala 
As Pavlov (1927) have already said, during fear conditioning an initially neutral stimulus [a 
conditioned stimulus (CS)] can acquire the fear properties after repeated temporal pairings 
with a biologically significant event [the unconditioned stimulus (US)]. Once the CS-US 
relation is learned, innate physiological and behavioral responses now occur under the 
presence of the CS. In animals, for example, if a rat is given a tone (CS) followed by an 
electric shock (US), after a few tone-shock pair-associations, freezing responses (rat´s 
defensive response that occurs in the presence of danger) will be elicited by the tone 
(LeDoux, 2000) (see Figure 1.6.). This form of conditioning is highly conserved across 
species, including humans (see for reviewLaBar & Cabeza, 2006). 
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Figure 1.6. Fear conditioning involves the presentation fearful US (footshock), at the end of the occurrence 
of a neutral CS (a light or a tone), (A). Once the pairing has succeeded, the CS elicits a wide range of 
behavioral responses that are elicited by the animals in the presence of threatening or fear-arousing stimuli 
(bottom). Reproduced from LeDoux, (2000). 
 
The amygdala processes the information about the CS and US in conditioned fear, and also 
controls the fear reactions by it projections to the response control system in the brainstem 
(an area that is in charge of the autonomic and endocrine response) (LeDoux, 2000). The 
control of the motor fear responses are in charge of the periaqueductal gray matter (PAG), a 
neural structure placed in the midbrain that, among other functions, integrates defensive 
behavior (Graeff, 2004); lesions in the periaqueductal gray it is been showed to interfere 
with freezing responses in rats (LeDoux, Iwata, Cicchetti, & Reis, 1988) .  
Studies with animals with lesions of the BLA and central nuclei of the amygdala have 
shown the prevention of acquisition of fear cues and environmental contexts; the emotional 
CS responses can be elicited also by placing the animal in the chamber where the aversive 
US was previously experienced (Phillips & LeDoux, 1992). Patients with amygdala lesions, 
similarly as in animals, have impaired fear conditioning and fear-potentiated startle 
responses (Bechara, Tranel, Damasio, & Adolphs, 1995; LaBar, LeDoux, Spencer, & 
Phelps, 1995; Peper, Karcher, Wohlfarth, Reinshagen, & LeDoux, 2001). These patients are 
able to verbalize the reinforcement contingency and can generate unconditioned skin 
conductance responses (SCRs) to harmful stimuli; this points to an affected implicit 
37 
 
emotional learning mechanism. Instead, amnesic patients with MTL damaged have 
impaired explicit memories about emotions; but intact implicit emotional memories (LaBar 
et al., 1995). This dissociation along with neuropsychological data points towards a neural 
dissociation between the declarative and non-declarative aspects of simple forms of fear 
learning  (LaBar & Disterhoft, 1998).  
1.4.2. Memory modulation 
Classic theories of memory differentiate between four memory stages (see section 1.4.): 
encoding, consolidation, storage and retrieval. Psychopharmacological studies have partly 
elucidated which neurotransmitter systems are involved in these different memory stages 
(Ferry & McGaugh, 1999; Introini-Collison, Arai, & Mcgaugh, 1989; Oitzl & De Kloet, 
1992).  
The basolateral amygdala selectively mediates the memory-modulating effects of adrenal 
stress hormones and different neurotransmitters such as acetylcholine and cortisol (Introini-
Collison, Arai, & Mcgaugh, 1989; Oitzl & De Kloet, 1992) . Animal studies have shown 
that BLA modulates the consolidation of memory via efferent to other brain areas, such as 
the hippocampus (Beylin & Shors, 2003), the caudate nucleus (Packard & Teather, 1998; 
Petrovich, Canteras, & Swanson, 2001), nucleus accumbens (Roozendaal & McGaugh, 
1996) and the neo-cortex (Power, Thal, & McGaugh, 2002; Price & Amaral, 1981) . Also, 
human brain neuroimaging studies indicated that subsequent recall of emotionally arousing 
material (pleasant or unpleasant) is influenced by the degree of activation of the amygdala 
(Anderson & Sobel, 2003; Small et al., 2003). 
Different studies using beta adrenergic drugs have elucidated the role of this 
neurotransmitter in the amygdala, and in other memory-related regions (see Figure 1.7.). 
For example, Ferry and McGaugh (1999) showed that the administration of the specific 
beta-2-adrenergic agonist clenbuterol into the basolateral (BLA) amygdala after training 
enhances retention in an inhibitory avoidance task. They were able to demonstrate the 
involvement of the beta-adrenergic system of the BLA in the modulation of memory 
consolidation for inhibitory avoidance training in rats. On the other hand, post-training 
infusion in the BLA of beta-adrenergic antagonist blocks the enhancement in memory 
produced by adrenaline (Liang, Juler, & McGaugh, 1986)  
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Emotional  situations trigger the hypothalamic-pituitary-adrenal axis at central 
[paraventricular nucleus (PVN) of the hypothalamus (Feldman, Conforti, & Weidenfeld, 
1995)]and peripheral [adrenal cortex (Feldman et al., 1995)] sites of action, which activates 
the adrenergic and glucocorticoid systems. Noradrenaline stimulates the glutamatergic 
synaptic plasticity in the BLA, a place for learning and memory functions (Wang et al., 
1996). 
Emotional arousing experiences produce the engagement of stress hormones that can affect 
both types of memory (emotional and non-emotional forms) in humans (McGaugh & 
Roozendaal, 2002). The first evidence suggesting the modulatory role on memory by a 
stress hormones was provided by Gold & Van Buskirk, (1975). During encoding, 
administration of cortisol or stress-induced endogenous cortisol release generally enhances 
emotional learning and memory (Buchanan & Lovallo, 2001). Buchanan & Lovallo, (2001) 
showed that stress-level cortisol treatment in humans enhances memory for emotional 
material. However, during retrieval, similar manipulations of cortisol, impairs recall for 
earlier memories (see Chapter 2). 
 
Figure 1.7. The influence of emotional arousal on memory mediates by the amygdala. MTL, medial 
temporal lobe; PFC, prefrontal cortex. Solid arrows indicate direct connections, dashed arrows indicate 
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indirect connections and blue labels indicate connections with subcortical structures. Reproduce from LaBar 
& Cabeza, (2006). 
 
The modulatory effect of the amygdala in emotional memories was summarize in a set of 
experiments conducted by Strange et al., (2003). They showed that beta adrenergic 
modulation enhanced recall and forgetting associated with emotional stimuli, and that these 
enhancements are amygdala dependent.  
In summary, BLA adrenergic activity has a key-role in the memory-modulatory effects of 
adrenal stress hormones released by emotional arousal (Cahill & McGaugh, 1998; 
McGaugh et al., 1996). Several findings suggest that BLA neuronal activity modulates 
stress-induced memory consolidation processes in the hippocampus (Cahill & McGaugh, 
1998; McGaugh et al., 1996). In another set of experiments, Roozendaal, Nguyen, Power, 
& McGaugh, (1999) examined whether β –adrenoceptor activation in the BLA allows the  
facilitation of memory consolidation produced by activation of glucocorticoid receptors 
(GR) in the hippocampus. Roozendaal et al., (1999) provide further evidence for the 
mediating stress hormone effects on memory consolidation driven by the β –adrenoceptors 
in the BLA. They also showed that the BLA modulates the strength of memories in other 
brain structures, such as the hippocampus, reflecting their emotional significance 
(Roozendaal et al., 1999). 
1.4.3. Context and fear 
The amygdala receives information (inputs) from cortical sensory processing regions (see 
Figure 1.8.) and sends outputs back to those areas as well; these connections allows the 
amygdala to “know” where the danger is in the sensory world (McDonald, 1998; Turner, 
Mishkin, & Knapp, 1980). The initial acquisition of fear conditioning cues is driven by the 
amygdala but other aspects of the conditioning are carried out by the hippocampus, for 
example contextual cues learning (Kim & Fanselow, 1992; Phillips & LeDoux, 1992) (see 
Figure 1.9.).  
One example of the roles of contextual cues in fear learning is the spontaneous recovery 
after extinction learning. After acquisition trials (CS-US pairings), the CS is presented 
alone and the fear response the CS extinguishes over the trials. However, a single 
presentation of the US after extinction can recover the fear response to the CS (Bouton, 
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2004; Robbins, 1990). The reinstatement of extinguished fear depends on the context and is 
a hippocampal-dependent process  (LaBar & Phelps, 2005). The suppressed conditioned 
fear by extinction is very sensitive to contextual cues, so the extinguished responses may 
“recover” over time [renewed (Rodriguez, Craske, Mineka, & Hladek, 1999) or reinstated 
(Rescorla & Heth, 1975)], within the context where the CS had been presented (LaBar & 
Phelps, 2005). Studies in lesioned animals have shown that the contextual recovery of 
extinguished fear relies on the integrity of the hippocampus (Corcoran & Maren, 2004). 
Also, studies in humans have confirmed that extinguish fear can be recovered due to the 
context. This contextual reinstatement of fear is not shown in amnesic patients with 
hippocampal damage; these patients are able to learn implicitly but are not able to retrieve 
based on contextual cues (LaBar & Phelps, 2005) . Another region involved in extinction is 
the ventromedial prefrontal cortex (vmPFC), which is implicated in the storage and recall 
of extinction memories, probably by inhibiting the CR via suppression of the amygdala. 
Hobin, Goosens, & Maren, (2003) indicated that the activation of the vmPFC after 
extinction is context dependent.  Kalisch et al., (2006) suggested that the hippocampus 
sends contextual information to the vmPFC. Both structures, among others, are important in 
extinction of contextual memories but also, are probably important for the contextual 
reinstatement of previously extinct memories (Kalisch et al., 2006).  
The understanding of how these contextual cues exert their effects on extinguished fear 
responses is fundamental to also better understand anxiety disorders that are characterized 
by generalizations of the fear response to other situations due to contextual factors (Mineka, 
Mystkowski, Hladek, & Rodriguez, 1999). “Flashbacks” in traumatic memories also rely 
on contextual cues. Due to these implications, the control of the context may be 
fundamental on the treatment of these disorders (LaBar & Cabeza, 2006).  
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Figure 1.8. Conditioning to a CS implicates projections from the different nucleus of amygdala. In this 
case, if the CS would be an auditory tone, this would be processed by the lateral amygdala (LA) and project to 
the central nucleus of the amygdala (CE). Reproduced from LeDoux, (2000). 
 
Figure 1.9. Conditioning to other cues, such as the context present when the CS and the US are paired 
depends on the hippocampus and the basal (B) and accessory basal (AB) nuclei of the amygdala; and the 
projections to the central nucleus (CE). Reproduced from LeDoux, (2000). 
 
1.4.4. Neuroimaging of fear conditioning  
Modern techniques such as event-related fMRI have led to the possibility to study the 
signal changes during acquisition, without mixing the signals of the CS or the noxious US; 
revealing activations in a thalamo-amygdalo-cingulate (mainly the anterior cingulate and 
dorsomedial prefrontal cortex) network (LaBar & Cabeza, 2006). Humans studies with 
delay (CS-US presentation is overlap in time, non-declarative learning) and trace (the 
presentation of the CS-US is separated by a gap of time, declarative learning) fear 
conditioning suggest that the hippocampus codes temporal information during trace 
conditioning, while other brain regions, important for working memory processes to 
maintain the CS-US representation during the time interval (Knight, Cheng, Smith, Stein, 
& Helmstetter, 2004).  
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One study using event-related fMRI imaging during aversive trace conditioning was able to 
characterize the brain regions involved in associative learning. Büchel, Dolan, Armony, & 
Friston (1999) paired neutral auditory tones (CS) with an aversive sound (US). The neural 
responses evoked by the paired CS, related to conditioning were localized in anterior 
cingulate and anterior insula, regions associated to delay fear conditioning, too. They 
observed also activation of the hippocampus and the amygdala (Büchel et al., 1999).  
Another study used two angry faces as target visual stimuli, with only one of the faces 
associated with a burst of white noise during classical conditioning. They also prevented 
the subjects' knowledge of the angry faces by fast presentation (30 ms) and backward 
masking them with a neutral face in half of the trials (Morris, Öhman, & Dolan, 1998).  The 
results of this study showed that the subliminal fear conditioned angry face expressions also 
depend on the amygdala and produce  greater functional interactions between the thalamus 
and superior colliculus than during the “unseen” condition (Morris et al., 1998) . 
To better understand fear conditioning, and above all to get better insight in the treatment of 
fear-related disorders, it is as important to know how the association is learned as how these 
learned fears are diminished. In another study, the authors used  fMRI to examine fear 
extinction in humans (Phelps, Delgado, Nearing, & Ledoux, 2004). Previous findings in 
non-human animals have paid attention to two brain regions: the amygdala and the 
ventromedial prefrontal cortex (vmPFC) (Morgan, Romanski, & LeDoux, 1993; Quirk, 
Russo, Barron, & Lebron, 2000). In this typical fear-conditioning paradigm studies, 
extinction happens when a CS is presented alone, without the US pairing, for a number of 
trials and eventually the conditioned response (CR) is diminished or even, eliminated. 
Extinction rather than “erased” an old memory, produce a new learning that competes with 
the old one (Bouton, 2004). This vision of the extinction as a “new” learning is supported 
by studies showing that after extinction the CR can return in a number of situations, such as 
after time (spontaneous recovery) (Bouton, 2004; Robbins, 1990),  after the presentation of 
the US alone (reinstatement) (Rescorla & Heth, 1975),  or if the animal is placed in the 
context where the initial CS-US pairing was learned (Phelps, Delgado, Nearing, & Ledoux, 
2004).   
The first one who mentioned the vmPFC as a neural region implicated in fear extinction 
was Morgan et al., (1993), by demonstrating that lesions in this area produced an 
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impairment in extinction. Some years later Quirk et al., (2000), showed that damage in this 
area result in impairment in the retention of extinction learning over the following days, 
rather than in an impairment of extinction learning overall.  
In 2002, Milad & Quirk, (2002), in a study with rats, demonstrated that if the tone CS is 
paired with stimulation of the vmPFC, this diminish the expression of the conditioned fear, 
pointing a role for the vmPFC in the inhibition of the CR. In a recent study Moratti, 
Giménez-Fernández, Méndez-Bértolo, & de Vicente-Pérez, (2017) showed increased 
neuromagnetic response in vmPFC during extinction by source localizing real time neural 
activity as recorded by Magnetoencephalography.  
The vmPFC and the amygdala are specific areas for fear conditioning, and are 
interconnected. The central nucleus (CE) of the amygdala has been related with the 
physiological expression of conditioned fear, through its connections to the lateral (LA) 
nucleus of the amygdala. The CE projects to different brain areas, also related with the 
expression of conditioned fear. The response rate of the CE output neurons can be changed 
via input from LA by the stimulation of the vmPFC, suggesting that the CE is primarily 
modulated by the vmPFC (Quirk, Likhtik, Pelletier, & Paré, 2003).  
More recent brain imaging studies have examined the mechanisms of fear inhibition but 
without conditioning.  Phelps et al., (2004) did it by presenting negative and neutral scenes 
and asked subjects to try to diminish their fear responses to the scenes by paying attention 
to positive or non-emotional aspects of the scene. They showed decreased amygdala 
activation relating to diminishing negative affect during the re-evaluation of the negative 
scenes (Phelps et al., 2004).  Also, they found that the right lateral PFC was activated when 
reappraisal succeeds, and that this activation correlated with a reduced amygdala response. 
This area of the PFC is supposed to have a role in working memory, executive processing, 
or the active maintenance of online information (Ochsner, Bunge, Gross, & Gabrieli, 2002). 
The connections between this PFC area and the amygdala are not direct; it happens through 
the medial PFC regions projections that are more directly connected with the amygdala 
(Groenewegen, Wright, & Uylings, 1997). 
Phelps et al., (2004) found that the predicted CR in acquisition and early extinction 
involves the amygdala in humans. This finding along with the ones made by Quirk et al., 
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(2000) contribute to the idea that the roles of the amygdala and vmPFC are conserved along 
species.  
In summary, the different stages of memory processing are engaged and influenced by 
emotion; as well as the different brain areas involve in those stages too.  
1.4.5. Episodic emotional memory 
“Human emotional experience is typically associated with enhanced episodic memory” 
(Strange & Dolan, 2004; p. 11454). 
One of the most cited study with episodic arousal material is the one performed by Cahill 
(1994). They examined the effect of a beta-adrenergic receptor antagonist (propranolol) or 
placebo on the memory of an emotionally arousing story accompanied by pictures. 
Participants that took placebo remembered better the pictures of the emotional part of the 
story, while participants that were administered with propranolol (beta-adrenergic receptor 
antagonist) did not show that memory enhancement for the pictures of the emotional part of 
the story. Another study using PET showed that emotional long-term memory is directly 
related to the degree of amygdala activation during encoding (McGaugh et al., 1996).  As 
outlined before, the BLA is a location for encoding and memory consolidation, but it is not 
the actual memory storage. If a BLA lesion is done some time after learning, the retention 
is not affected; but if the treatment is administrated immediately after learning, LTM is 
impaired (Liang et al., 1982; Parent, Quirarte, Cahill, & McGaugh, 1995). Also, human 
amygdala lesions have demonstrated that enhanced memory for emotional events is an 
amygdala dependent process and involves the beta adrenergic receptor activation (Cahill, 
Babinsky, Markowitsch, & McGaugh, 1995). These processes seem not to be necessary for 
non-emotionally arousing material retention (Cahill et al., 1995). 
Kleinsmith & Kaplan, (1963) , showed that the effects of emotion on memory retention 
increase as a function of  time between encoding and testing (see also Hu, Stylos-Allan, & 
Walker, 2006). It has been shown that retention is greater for emotionally arousing 
compared to neutral words, and that this memory is better if tested after a period of time 
(1hour to 1 day) rather than if tested immediately (LaBar & Phelps, 1998; Sharot & Phelps, 
2004). The facilitation on consolidation by emotional arousal needs time to take place. 
Several studies have shown that the emotion effects are either absent or much smaller when 
memory is tested immediately, and they tend to increase in magnitude after a few hours 
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(Anderson, Yamaguchi, Grabski, & Lacka, 2006; Kleinsmith & Kaplan, 1963; Ritchey, 
Dolcos, & Cabeza, 2008; Sharot & Phelps, 2004; Sharot & Yonelinas, 2008). This 
enhanced facilitation process was found to be absent in patients with temporal lobectomy. 
These patients showed equal forgetting rates for neutral and emotionally arousing words 
after different time intervals (from immediate to 1 hour).  
The time-dependent memory advantage may be due because item–emotion bindings are 
supported by the amygdala and are forgotten more slowly than item–context bindings 
supported by the hippocampus (Yonelinas & Ritchey, 2015). The lesion and imaging 
results show that the amygdala plays a central role in producing the emotion advantage in 
episodic memory (Mackiewicz, Sarinopoulos, Cleven, & Nitschke, 2006; Ritchey et al., 
2008). 
Another “benefit” (in terms of higher memory recall) of emotional arousal is the focus of 
attention on specific stimuli, that can benefit from prioritized processing (Kensinger & 
Corkin, 2004), in detriment of peripheral information. “Attentional focusing ensures that 
emotionally salient features of complex events are preferentially retained in memory, which 
confers evolutionary advantages” (LaBar & Cabeza, 2006; p.55). This beneficial effect is 
not present in patients with amygdala lesions; but they are able to benefit from the 
facilitated effect of arousal. This kind of patients remember better words relative to 
pleasantness and unpleasantness (which are on the valence extremes) but have no the 
intensity to activate the amygdala because (the words) are low in arousal (a dimension that 
goes from calm to excitement) when compared to neutral. They are also able to take 
advantage of  neutral words encoded in emotional sentence contexts relative to neutral 
contexts ( Phelps et al., 1998; Phelps, LaBar, & Spencer, 1997) So, it is probable that some 
emotional advantages can occur besides the amygdala, especially if the lesions occur later 
in time life. The patients are able to substitute the arousal engaging processes by an 
emotional valance related cognitive processes (Talmi & Moscovitch, 2004).  
All these studies, converged to the conclusion that at the time of encoding, enhanced 
memory for emotional stimuli may be due by an enhancement of amygdala activation, that 
also modulates hippocampal processing (Strange & Dolan, 2004). The amygdala facilitates 
LTM consolidation of emotionally arousing events in other brain structures, and an 
enhancement in recall of emotional stimuli may reflect amygdala-hippocampal interactions 
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thanks to the influence of the adrenergic and glucocorticoid systems (Paré, 2003; 
Roozendaal et al., 1999; Strange & Dolan, 2004). 
To summarize all the influences of the amygdala in emotional memory, it can be said that: 
- Memories need time to be formed. 
- Emotional arousal facilitates the consolidation of episodic memory, and this 
facilitation effect is mediated by the amygdala. 
- This facilitation effect of arousal is mediated by the amygdala through the stress 
hormones. 
- The storage place of emotionally charged episodic memory is not the amygdala, but 
are more hippocampus-dependent and on cortical regions. 
- These modulation effects of the BLA occur in humans. 
 1.5. Post-consolidation modulation of memory 
The classical view of memory formation (see section 1.3.) needs to be updated (Nadel et 
al., 2012). Apparently it is possible to render labile again an initially fixed memory (Nader, 
Schafe & Le Doux, 2000). This challenged the consolidation theory from two fronts. From 
one side, the inability to recall a previous memory imprinted in the brain after the 
application of different interventions such as electroconvulsive shock (Duncan, 1949) or 
protein synthesis inhibitors (Flexner et al., 1965). And in the other hand, several studies 
showing that consolidated memories can become labile again after retrieval, and then re-
stabilize (i.e.: Lewis, 1979; but see review by Nader & Einarsson, 2010) (see Figure 1.10.). 
During the last decades, the idea that retrieval of a memory can be an opportunity to update 
or modulate what was originally learned (Monfils, Cowansage, Klann, & LeDoux, 2009) or 
even erase that memory (Nader,  Schafe & Le Doux, 2000), has been receiving increased 
attention. The term “reconsolidation” refers to the process by which a LTM transiently 
returns to a labile state and its subsequent stabilization. In order to initiate the process of 
reconsolidation, it is necessary to activate the target memory again; this process is called 
reactivation. When the reactivated memory enters in a labile state it becomes vulnerable to 
change in ways that a non-reactivated LTM cannot be (Nadel et al., 2012). This change can 
include for example: weakening or even erasure (Nader et al., 2000; Walker et al., 2003), 
strengthening, or alteration (Hupbach, Gomez, Hardt, & Nadel, 2007). 
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Three lines of evidence were established to support the existence of a re-stabilization 
process. First, performance can be impaired if amnesic electroconvulsive shock are given 
shortly after reactivation (Misanin, Miller, & Lewis, 1968). Second, performance can be 
impaired if new competing learning occurs shortly after reactivation (Gordon, 1977a). And 
finally, via administration of different compounds (i.e.: strychnine, highly toxic 
alkaloid usually used as a pesticide) retention can be enhanced (or impaired) after 
reactivation (Gordon, 1977b). “Critically, all three manipulations are effective only when 
given shortly after memory reactivation but not when given after a delay” (Nader & 
Einarsson, 2010, p.28). These findings, coming from  several investigators, in different 
tasks (Debiec, LeDoux, & Nader, 2002; Nader, Schafe  & Le Doux, 2000; Rose & Rankin, 
2006) and species (Nader,  Schafe & Le Doux, 2000; Rose & Rankin, 2006; Sangha, 
Scheibenstock, & Lukowiak, 2003), fundamentally support reconsolidation theory as 
challenge the consolidation one. 
 
Figure 1.10. Possible effects of reactivating a memory. Reproduced from Nadel et al., (2012). 
 
One of the principal supportive studies of reconsolidation was published in 1979 by Lewis. 
His paper made a theoretical argumentation based on several findings of other authors, for 
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example  Craik & Lockhart, (1972) or Shiffrin & Atkinson, (1969), about the impossibility 
that a failure in memory formation (consolidation) between short-term memory (STM) and 
long- term memory (LTM) could explain the recovery of the memory traces (i.e.: after 
pharmacological stimulation, Braun, Meyer, & Meyer, 1966),  previously disappeared. He 
concluded that with the lines of evidence that were available at that time was better to make 
a distinction between active and inactive memory.  For Lewis, an active memory (AM) did 
not occupy a specific site or sites in the brain. He preferred to conceive AM as “a patterned 
state of neural firing that cannot be localized; different active memories in the brain reflect 
different densities of firing” (Lewis, 1979, p.1066), and it is totally conscious and 
accessible no matter if is new or old; while an inactive memory (IM) is not conscious or 
accessible.  Posner (1967) proposed that interference and forgetting would probably take 
place when the memory is in an active state; giving the understanding that an active 
memory is not only a new memory, but that an old memory can be reactivated later when 
the stimuli are presented again (Lewis, 1979). In 1968, Misanin challenged the conception 
of a consolidated memory as immutable by reporting that using a cue reminder rendered 
consolidated memories labile again  and susceptible to disruption (McKenzie & 
Eichenbaum, 2011). Using an auditory fear conditioning procedure, they trained rats to 
associate a conditioned stimulus (a CS tone) to an unconditioned stimulus (US), in this case 
an electroconvulsive shock (ECS). When the training was followed immediately by the 
ECS, the memory for the association was disrupted, but if they waited for 24 hours to 
administer the ECS, nothing happened to the memory for the CS.  
Misanin (1968) also performed another experiment, with the same CS-US association, but 
in this case, the rats that had already learned that association were exposed to the CS before 
they received ECS, 24 hours after learning. The results were that the memory, measured by 
the freezing response in rats, for the consolidated tone-shock was disrupted. On the other 
hand, rats who were not exposed to the CS, and did not activate their memory of the 
association, showed no memory impairment due to ECS  (Misanin et al., 1968). 
Misanin and his team, not only demonstrated the distinction between active memory and 
inactive memory, but also that was possible to disrupt a highly robust fear memory 
association depending on the state of the memory, active or inactive, at the time of applying 
an amnesic treatment such as ECS (Misanin et al., 1968).  
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In 1968, and due to the Zeitgeist, the novel findings of Misanin did not received much 
attention (Schwabe, Nader, & Pruessner, 2014). Added to this lack of attention, in 1976 a 
study was  published that failed to support the hypothesis of reconsolidation  (Squire, Slater 
& Chace, 1976).Squire results failed to demonstrate the hypothesis that reactivation of 
previously learned material before convulsive stimulation can cause amnesia  (Squire, 
Slater & Chace, 1976). These negative results helped plunge the theory of reconsolidation 
into the shadows. 
It was not until the year 2000, when this cue-dependent amnesia came into the spotlight of 
research again with the study of Karim Nader and his colleagues (2000). Using rats with a 
fear conditioning paradigm, they demonstrated again, that a memory can render labile again 
and susceptible of disruption by amnesic treatments. They showed that a consolidated fear 
memory returned to a labile or active state after a reminder and that an infusion of 
anysomicin, a protein synthesis inhibitor into the basolateral amygdala (BLA), a region 
implicated in fear learning,  produced amnesia of the original US-CS association (Nader,  
Schafe  & Le Doux, 2000). With these set of experiments, they not only showed that a 
consolidated memory can be susceptible of disruption by amnesic agents, but also they 
demonstrated for the first time that synthesis of proteins is needed to stabilize again the 
memory reactivated, and that this is a time dependent process.  
After Nader, reconsolidation has been demonstrated in several species with different 
memory paradigms. In humans, due to ethical reasons, it has been difficult to use invasive 
treatments such as the ones used in animals. Much of the evidence of human 
reconsolidation comes from non-invasive techniques that update memory instead of 
disrupting it during reconsolidation (Schiller & Phelps, 2011).  
Even thought, reconsolidation is an accepted stage of memory. Nevertheless, there are 
some studies that do not support the idea that retrieval after reactivation renders a memory 
labile again and needs protein synthesis to be fixed in a permanent state again. For 
example,  Lattal & Abel, (2004); Power, Berlau, McGaugh, & Steward, (2006) suggested 
that the disruption of a memory is transient and fully reversible. The main finding was that 
they showed impaired behavior caused by systemic injections of anysomicin (a protein 
synthesis inhibitor) after the acquisition of  contextual freezing in rats are maintained over 
the time, but if the injection of the anysomicin is after retrieval they are not long-lasting 
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(Lattal & Abel, 2004). Also, the rat´s freezing response was recovered spontaneously after 
21 days, although it was not evident in a test after 24 hours retrieval. The finding of this 
experiment also suggests that the injection of the protein inhibition synthesis has different 
effects if administered after acquisition of after retrieval (Lattal & Abel, 2004). 
Another study with rats showed the hypothesis that complete older consolidated memories 
are less sensitive to impairment when reactivated. They found that long-lasting memories 
(1 to 7 days ago; but not 14 or 28 days ago) are able to disrupt processes after reactivation. 
According to this study, the vulnerability of the memories for having been impaired 
decreases over the time passed between the original training and the recall. The explanation 
that the authors gave to their findings was that these recent long-term memories more able 
to be disrupted by protein synthesis inhibitors were not fully consolidated; so the degree of 
vulnerability of a reactivated memory changes with the time passed between initial learning 
and reactivation (Milekic & Alberini, 2002). 
Besides the time factor, there are other factors that seem to be important in the possibility to 
reconsolidate a memory, such as the strength of memory and the strength of the reactivation 
process (Squire, 2009). 
This new era of reconsolidation studies has been based on the findings made in the sixties, 
which established the basic criteria to be followed to reactivate a memory and manipulate 
it. In order to asses a successful protocol of reconsolidation; the consolidated memory must 
be reactivated by a reminder cue (Misanin et al., 1968; Rubin, Fried, & Franks, 1969). 
Second, the manipulation needed to altering reconsolidation must be administered post-
reactivation, rather than prior (Nader, Schafe & Le Doux, 2000); and finally, because 
reconsolidation is a time dependent process, memory should show the effects of the 
manipulation after a time-window, allowing reconsolidation to take place (usually tested 
after 24 hours) (Nader, Schafe  & Le Doux, 2000). 
Behavioral manipulations of reconsolidation in humans 
Extinction 
In humans, a behavioral procedure is obviously less invasive than a pharmacological 
manipulation. 
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Emotional memory is a crucial kind of memory in this thesis, but also in real life. Almost 
all experiences that we have during are life-time are coded in way or another by emotional 
arousal or valence. The autobiographical memories that we recollect along the years can be 
easily classified between positive or negative experiences. The emotional positive episodic 
memories are always to be kept and remembered, but negatives are otherwise quite 
different. 
 Emotional memories can lead to anxiety disorders. For example, a common anxiety 
disorder that is linked to traumatic memories is known as post-traumatic stress disorder 
(PTSD). This disorder and other linked to traumatic or negative memories are fully 
disturbing of one’s life; so an important implication of the findings in impairing memory 
reconsolidation in animals could be translated to treatments in humans.  
Extinction is one of the most successful treatments for anxiety disorders. These kinds of 
patients associate and act as is a feared stimulus (CS) would be followed by a negative 
outcome (US). One model, which allows scientist and therapist to study experimentally the 
acquisition and consolidation of fear memories, is the Pavlovian fear conditioning 
paradigm, that it has been described earlier. The extinction training repeatedly exposes the 
patient to the CS but in the absence of the aversive outcome, or in a safe environment. The 
main problem with extinction is that does not erase the fearful memory, but instead, creates 
a new competing safe memory, that inhibits the original fearful memory. However, often 
the fear returns, spontaneously (Bouton, 2004; Robbins, 1990), after presenting the US 
alone (reinstatement) (Rescorla & Heth, 1975) or by new context (renewal), different from 
the one that it was extinguished (Rodriguez et al., 1999).  
In humans exits the possibility to capitalize on reconsolidation as an update mechanism. 
Instead of trying to “erased” a memory, maybe it is possible to “re-write” that negative 
memory with a new memory, more positive, provided at the time of retrieval, and so it may 
be possible to permanently modify the fearful properties of the old negative memory. But, 
in animals for example, there is only one demonstration of altering fear memories by 
introducing non-fearful information. Using rats, Monfils, Cowansage, Klann, & LeDoux, 
(2009) were able to destabilized a fear memory and reinterpreted as safe with only one trial 
before extinction, and showed that this behavioral manipulation was able to permanently 
diminishes the fear memory.  Nevertheless, those results were only possible to achieved 
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using genetically modified mice and optogenetics (Liu et al., 2012; Ramirez et al., 
2013).Other studies that tried to modified fear memories with non-fearful information 
during consolidation have had mixed results (Myers, Ressler, & Davis, 2006; Schiller et al., 
2008). 
One of the first studies in humans was driven by Walker, Brakefield, & Hobson, (2003), 
using procedural learning, more specifically a motor skill finger-tapping task. With their 
study combining sleep and awake states during a 3 day protocol, they were able to showed 
three different stages of human motor memory after the initial encoding. Their behavioral 
study showed that waking reactivation is able to turn memory labile again, requiring 
subsequent reconsolidation. This study has been considered a convincing demonstration of 
human reconsolidation. However, in four direct replication attempts  Hardwicke, Taqi, & 
Shanks, (2016) did not observe the critical impairment effect that has previously been taken 
to indicate disruption of an existing motor memory trace. In three additional conceptual 
replications they explored the broader validity of reconsolidation-updating theory by using 
a declarative recall task and sequences similar to phone numbers or computer passwords. 
Rather than inducing vulnerability to interference, memory retrieval appeared to benefit the 
preservation of existing sequence knowledge relative to a no-retrieval control group. These 
findings suggest that memory retrieval followed by new learning does not reliably induce 
human memory updating via reconsolidation (Hardwicke et al., 2016). 
One controversial study was the one published by  Schiller et al., (2010). They evidenced 
that old fearful memories can be updated with new non-fearful information after 
reactivation. They design two experiments using the US-CS association. In one first 
experiment, they showed that extinction during reconsolidation window prevents 
spontaneous return of extinguished fear. In order to see if these results would last during 
time, they performed a second experiment, one year later. In this second experiment, they 
showed that blockade of the return of fear persists over a year, and that it was specific to 
the reactivated memories. One main difference with other studies done before with 
interference paradigm targeting motor or declarative memory was that those other studies 
showed that new information provided during reconsolidation could affect old memories by 
modifying or interfering with them, but not blocking them. The authors suggested that these 
differences could be due to the different nature of the neural systems supporting different 
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types of memory.  Declarative memory has a distributed cortical representation, while 
conditioned fear memories representation is localized in the amygdala, as mentioned 
previously.  
Due to the importance of being able to reduce emotional memories in humans with a 
behavioral paradigm, Soeter & Kindt, (2011) tried to replicated  Schiller et al., (2010) 
findings. They tried to demonstrate again that multiple unreinforced presentations allowed 
for updating of the more cognitive component of emotional memory in humans. Or in other 
words, an extinction procedure performed within the time-window of reconsolidation 
turned into the permanent erasure of the skin conductance response (i.e., declarative 
knowledge). 
The results that Soeter & Kindt, (2011) achieved following Schiller´s study (2010) were 
that a single retrieval trial prior to extinction did not attenuate the recovery of extinguished 
startle responding,  skin conductance response (SCR) or US expectancy ratings. The 
authors pointed that there were three differences in their study compared to Schiller´s 
(2010). One, the kind of stimulus used. In Schiller´s (2010), were geometric figures while 
in Soeter & Kindt, (2011) were fear relevant stimulus (spiders). Second, they employed a 
different reinforcement scheme during acquisition. Apparently, with their retrieval trial they 
were not able to activate the process of reconsolidation. And the third difference was the 
way of measuring the conditioning responses. Schiller assessed the response by subtracting 
the response to the CS+ (reinforced) and the CS- (not reinforced) while, Soeter & Kindt 
(2011), inferred the degree of fear from differential responding to the CS+ and CS-. Due to 
the no difference in responding to the different CS, the authors thought that it could indicate 
a generalization of fear to the control stimulus. 
The failure in replicating Schiller´s study (2010) put at a crossroads a valuable behavioral 
manipulation. Other experimental group (Oyarzún et al., 2012) decided to try again to 
reproduce Schiller´s study but with a modified version, using auditory aversive stimulus 
instead of electroshocks. The CS were geometric figures, but the statistical analysis was a 
within subjects design (Schiller used a between subjects design) because fewer number of 
patients are needed and because is more statistically powerful. They used two different 
auditory tones as US, each of it associated to a specific CS, so the association was stronger. 
What they found was that only the SCR for the CS that was reactivated before extinction 
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remained extinguished after reinstatement (re-exposure to the US). Their results supported 
Schiller´s previous findings, highlighting that extinction within the reconsolidation window 
can target fearful memories and prevent the reinstatement of fear.  
In an attempted to increase the clinical validity of the original study by Schiller (2010), and 
using a fear conditioning paradigm in two different experiments, one with fear relevant 
(fearful male faces) and the other with fear irrelevant stimuli (colored squares), Golkar, 
Bellander, Olsson, & Ohman, (2012), tried to erased fear memories. In order to do so, they 
designed a three consecutive day protocol, following reconsolidation criteria, where 
participants went through conditioning (Day 1); reactivation and extinction (Day 2) and 
reinstatement and re-extinction on Day 3. They used startle response, US expectancy 
ratings and SCR as dependent measures of fear. The results that this group found were that 
a single retrieval prior to extinction did not disrupt the recovery of extinguished 
conditioned fear responses, in line with the results others have obtained with their 
replication attempts (i.e.: Soeter & Kindt, 2011). On the other hand, these findings are 
contrary to previously published by other authors (Agren, Engman, et al., 2012; Oyarzún et 
al., 2012; Schiller et al., 2010).  Due to the wide range of possible clinical implications, the 
results of Schiller have received a significant amount of attention; but also, have been very 
controversial, given the difficulty of an overwhelming replication. One important point that 
Golkar et al., (2012) highlighted was that previous studies (Agren, Engman, et al., 2012; 
Oyarzún et al., 2012;  Schiller et al., 2010; Soeter & Kindt, 2011) have only included 
patients that were susceptible of extinction; in other words, they have previously made a 
selection of the healthy individuals, that may not represent the general population, or at 
least, not the clinical population. Agren, Furmark, Eriksson, & Fredrikson, (2012) studied 
the fear reconsolidation and allelic differences in serotonergic and dopaminergic genes in 
humans. They hypothesized that these contrary results might be due to specific subgroups 
in which the blocking is effective. Garpenstrand, Annas, & Ekblom, (2001) studied also, 
the dopaminergic and serotoninergic biological markers in relation to human fear 
conditioning, founding that 5-HTTLPR is associated with stronger fear acquisition.  
Another study that had examined human fear extinction was Klucken et al., (2016). They 
showed that a single presentation of a conditioned stimulus did not block the return of fear 
during re-extinction, suggesting that the effect of preventing the return of fear by disrupting 
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reconsolidation seems to be a more labile phenomenon than previously assumed. They 
were unable to replicated the results of Agren, Engman, et al., (2012); Agren, Furmark, et 
al., (2012); Schiller et al., (2010) but supported the results of Golkar et al., (2012); Soeter & 
Kindt, (2013); Soeter & Kindt, (2011). 
Other study combined behavioral and pharmacological manipulations of a differential fear 
conditioning procedure with three stimuli (CS) and was the one made by Thome et al., 
(2016) . Two of these CS+ were paired with an electric shock and US expectancy ratings, 
fear-potentiated startle, and skin conductance response as dependent measures. They 
observed differential fear responses to the reactivated and non-reactivated CS+ only in the 
pharmacological (propranolol) condition. Even more, the non-reactivated CS+ elicited 
stronger fear-potentiated startle-responses compared to the placebo group. Their results 
showed that none of the interventions prevented the return of the extinguished fear response 
after re-exposure to the unconditioned stimulus (Thome et al., 2016). 
The data of Klucken et al., (2016) and Thome et al., (2016) are in line with other studies 
mentioned previously that showed that disrupting reconsolidation with extinction does not 
prevent the return of extinguished fear and that the occurrence of reconsolidation may be 
constrained by boundary conditions such as differences in experimental manipulations and 
instructions. 
 Relative to extinction is important to highlighted what was said before; that the degree of 
vulnerability of a reactivated memory changes with the time passed between initial learning 
and reactivation (Milekic & Alberini, 2002). One study performed in animals showed that 
memory reconsolidation also depends on the strength and age of the memory, such that 
younger and weaker memories are more easily reconsolidated than older and stronger 
memories. But, this same study also showed that reconsolidation and extinction are two 
opposing processes triggered by memory retrieval and so have distinct molecular 
mechanism (Suzuki et al., 2004). Being different processes made also important take into 
account that if a reminder (to reactivate a memory) is exposed during a long time could 
trigger extinction instead of reconsolidation. The duration of the reminders is also a 
boundary condition depending on its duration (Pedreira & Maldonado, 2003).  
 
56 
 
Reconsolidation impairment in humans with pharmacological manipulations 
As said before, in animals reconsolidation is most usually studied using protein synthesis 
inhibitors (Alberini, 2005; Duvarci & Nader, 2004; Nader, Schafe & Le Doux, 2000) , 
which is not practical in humans. But instead, drugs that interact with the release of nor-
adrenaline (i.e.: propranolol) in the amygdala could be a successful treatment for disturbing 
emotional memories (and also, is one of the few drugs that can be used in both, animals and 
humans).  
The most frequently used pharmacological manipulation in human is the administration of 
the beta-blocker propranolol.  Its mechanism of action is through beta- adrenergic receptors 
that are coupled with the adenylyl cyclase-linked G-protein receptors governing the cAMP 
cascade that produced protein synthesis-dependent long-term memory formation 
(Przybyslawski, Roullet, & Sara, 1999). 
 Kindt et al., (2009), demonstrated that a beta adrenergic receptor antagonist, administered 
prior to memory reactivation (administered 90 min before due to the pharmacological 
features of propranolol), erased the startle fear response, while the skin conductance 
response (SCR) and the unconditioned stimulus (US) expectancy ratings remained 
invariable. The skin conductance response seems to primarily reflect anticipatory arousal, 
independently of the valence of the stimulus, while the startle response is considered to be 
more reliable and specific of fear, and operated aside of the cognitive level of fear learning. 
In summary, they showed that propranolol prior reactivation of a fear memory is able to 
diminish the fear memory expression in humans, leaving the declarative memory intact. As 
said before, there are different neural correlates for the different kinds of memories. So, 
while declarative memory is based on the hippocampal complex (Squire et al., 2004) the 
emotional encoding and expression of a fear response requires the amygdala complex 
(LeDoux, 2000). But, as LaBar & Cabeza, (2006) pointed in their review, both structures 
interact with each other. 
 But, what makes a memory labile again? In order to examine this question and the 
elements needed to return a memory labile again in order to initiate a reconsolidation 
process,  Sevenster, Beckers, & Kindt, (2012) followed the same design from Kindt et al. 
(2009), but, with the difference that they had one group that received the reactivation (day 
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2) without the shock electrodes attached. They did this arguing that there was no new 
information to be learned about the association, so the association between stimulus and 
shock had no reason to be updated. What they saw, was an increased in the startle response 
at reactivation, and that the subsequent administration of propranolol did not erased the fear 
response on day 3.  
Following these results, they decided to manipulate the expectancies of the participants by 
varying the acquisition reinforcement rate between groups (Sevenster, Beckers & Kindt, 
2013). So, two groups received complete reinforced differential conditioning and were, in 
addition, instructed of the contingency. The next day (day 2) the subjects were either shown 
a reinforced, or an unreinforced stimulus. A third group had acquisition partially reinforced 
and was shown a reinforced stimulus on day 2, but the complete reinforced group obviously 
was expecting the shock.  Propranolol was administered to all groups on day 2. On day 3, 
the memory was tested with extinction and reinstatement. Thus, they made a prediction 
error when they were shown the stimulus without shock on day 2. On day 3, their memory 
strength was highly impaired by propranolol. The second complete reinforced group, which 
was shown a reinforced stimulus on day 2, and did not make a prediction error, did not 
seem to have their memory affected by the propranolol. When the partially reinforced 
group was shown a reinforced stimulus on day 2, their expectancies of shock increased, 
they made a prediction error. This group also had their memory decreased by the 
propranolol. So, according to this study, it seems that prediction error is crucial for 
reactivating a memory, and also, these findings give support to the idea that reconsolidation 
may be a process to updated memory.  
Impairment of declarative memories 
In humans, and in emotional memories, it is being proved that the β adrenergic receptor 
antagonist propranolol impairs consolidation of declarative memory in humans (see Cahill 
& McGaugh, 1998) . 
 Brunet et al., (2008) tested the effect of the β-adrenergic blocker propranolol given within 
hours after the retrieval of memories of a traumatic event. They based their study on the 
evidence that indicates that propranolol given after a psychologically traumatic event 
reduces physiologic responses during subsequent mental imagery of the event.  
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Their subjects were patients with chronic post-traumatic stress disorder. They made them 
described their traumatic event during a script preparation session and then received a one-
day dose of propranolol or placebo, randomized and double-blind. Seven days later, they 
made the patients engaged in script-driven mental imagery of their traumatic event while 
heart rate, skin conductance, and left corrugator electromyogram were measured. Once they 
took those measures, they found that the physiologic responses were significantly smaller 
in the subjects who had received post-reactivation propranolol a week earlier. They showed 
that the physiological responses were decreased in a similar manner after reactivation than 
after the occurrence of the traumatic event.  
Tollenaar, Elzinga, Spinhoven, & Everaerd, (2009) decided to study the effects of 
propranolol and cortisol on healthy individuals, and how they respond physiologically to 
emotional (autobiographical) memories. They found no effect on the propranolol group on 
disrupting reconsolidation in conjunction with a retrieval session. In another study with 
healthy young men individuals, they found also no effect  when the memory of word lists 
were tested (Tollenaar, Elzinga, Spinhoven, & Everaerd, 2009a). 
In explanation of these negative outcomes of the memory of emotional scripts the authors 
suggested that maybe the scripts were no emotionally strong enough to  express an effect of 
propranolol or, maybe the dose was too low (the dose that the authors used in both studies 
were 80 mg, while in the majority of studies the dose of propranolol is 40 mg), or perhaps 
was not acting long enough in the body (the times that the authors used in their methods are 
according with the pharmacokinetics of propranolol; they waited on session 2 , the rigorous 
90 minutes, necessary for the amount of propranolol in blood to be at its peak, before doing 
the script imagery task).  
Trying to elucidated how is the brain mechanism underlying emotional memory 
reconsolidation and the effect of propranolol, Schwabe, Nader, Wolf, Beaudry, & 
Pruessner, (2012) designed a study with healthy individuals and fMRI. They administered 
beta adrenergic antagonist receptor propranolol or placebo before the reactivation of a 
previously learned material (emotional and neutral). During the reactivation time, subjects 
were at the scan, and so they did too during the memory test. As established in the protocol, 
on day 3 the memory was tested. They found that for the emotional pictures, propranolol 
during reactivation diminish subsequent memory, effect that did not appear with the neutral 
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pictures. The emotional impairment was associated to an increased activity in the amygdala 
and hippocampus for the remembered pictures at test. Also, the same neural structures were 
activated during memory reactivation (but not modulated by propranolol). As known 
before, memory reactivation alone or propranolol without reactivation had no effect on 
subsequent memory. In other words, their results suggested that the same brain areas that 
are activated during reactivation undergo changes in activity that is related to subsequent 
memory recall.  
Kroes, Strange, & Dolan, (2010) performed a study using emotionally aversive verbal 
stimuli (participants were exposed to 360 nouns: 300 neutral, 30 perceptual oddballs and 30 
emotionally aversive), a 3-day protocol and administration of propranolol or placebo. On 
day 2, after the administration of the propranolol/placebo the participants had the memory 
reactivation, that consisted on the presentation of the first three letters of the nouns encoded 
on day 1 (240 of the 360 nouns encoded on day 1: 200 neutral, 20 perceptual oddballs, and 
20 emotionally negative) and participants had to complete the words.  The propranolol 
group completed fewer emotional nouns on both day 2 and 3. The effect on day 3 cannot be 
described as reconsolidation effect, because retrieval did not happen on day 2. 
All the studies described above, attempt to reactivate a memory in order to destabilize it. 
But as seen, not all memory types appear to be susceptible and equally affected by 
reactivation and noradrenergic antagonist administration.  In animals studies a single 
element of the original memory was enough to trigger reactivation, but in humans the 
matter is considerable different. Dieuwke Sevenster, Beckers, & Kindt, (2013) considered 
that a prediction error is need it to destabilize a memory, but this prediction error is not 
always present, as happen for example when reactivating declarative memories. In this 
order, more knowledge is needed to assort the boundaries conditions of labilization. Despite 
the evidence that reconsolidation takes place in humans, there is controversy on what 
instances the labilization and reconsolidation process are triggered. What exactly is needed 
it to reactivated complex memories, as the ones integrating the PTSD? Is prediction error 
truly needed it? How long are the effects of reconsolidation and manipulation lasting? Are 
remote memories equally able to undergo reconsolidation after reactivation? Memories that 
depend on specific brain regions have the same susceptibility to reactivation? Is the same 
protocol and susceptibility for all kind of memories? 
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The other fundamental problem with the pharmacological manipulation of reconsolidation 
with propranolol is that it must be administered prior to reactivation (60- 90 minutes prior 
in order to reach its clinical peak), with violates the second criteria of reconsolidation 
(manipulation must be done after reactivation). If it’s given after reactivation the time 
window that allows these manipulations to take place is close. So, taking into account these 
boundary conditions in the use of propranolol in humans, is necessary another safe 
pharmacological manipulation in order to disrupt emotional memories. 
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Chapter 2 
The major neurotransmitters´ 
systems in the brain 
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2.1. Psychopharmacology of Human Memory 
The first studies analyzing the effects of psychological drugs on memory was driven by 
Jones, (1909); he “reports introspections obtained on three occasions when chloroform was 
administered to the author”. He identified two stages, first one, loss of sensitivity of the 
“sense organs”; and the second one, “disappearance of memory, imagery, associational 
processes, reason and isolated ideas”. Another study carried out by  Cattell, (1930), showed 
that 10 g of alcohol enhanced intelligence but impaired associative memory.  Few years 
later, Jones (1933) decided to analyze the effect of the antipyretics on learning due to the 
huge amount of people taking that drug at that moment, without considering adverse 
effects. Before Jones, (1933), the relationship between antipyretics and cognitive functions 
had already been analyzed by Münsterberg, (1892), and later by Macht, Isaacs, & 
Greenberg, (1918). Both authors found an increase in reaction times, with both, therapeutic 
doses or with exceedingly large doses of quinine (antipyrin).  
During the following years, the effects of the drugs on memory were studied according to 
the zeitgeist of each moment. Thus, the studies described below analyze the effects of 
psycho active drugs from a cognitive neuroscientific perspective, focusing on the major 
neurotransmitters systems of the human brain and their effects enhancing or impairing 
memory. The current overview of neurotransmitter effects will focus on neurotransmitter 
effects on fear conditioning and reconsolidation of emotional episodic memories in animal 
in humans, and in animals when necessary.  
The importance to learn that certain environmental stimuli can predict aversive events 
(Pavlovian fear conditioning) has an evolutionary role for survival, and equips the organism 
with a flexible association system to deal with changes contingencies between predictor and 
aversive events (Fanselow, 1994). But above all, disturbances in fear conditioning may play 
a key-role in disorders related to fear and anxiety in humans, such as panic disorder and 
specific phobias or post-traumatic stress disorder (Rosen & Schulkin, 1998; Wolpe, 1981). 
2.2. GABA 
It is well known that γ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter 
in the vertebrate central nervous system (Brioni, Nagahara, & McGaugh, 1989) and 
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modulates fear conditioning. It is synthesized primarily from glutamate by glutamate 
decarboxylase (GAD).   
Initially,  GABA was found to activate bicuculline-sensitive Cl- channels, but then, the 
presence of a novel receptor, insensitive to  antagonist such as bicuculline or the majority of 
the accepted GABA agonist (3-aminopropanesulphonic acid (3-APS) or isoguvacine) led to 
the actual denomination of the GABA receptors (GABAA, GABAB and GABAC receptors) 
(Bowery et al., 1980). The GABAA receptor (GABAAR) directly gates a Cl- ionophore and 
has modulatory binding sites for benzodiazepines, barbiturates, neurosteroids and ethanol, 
it is considered an ionotropic receptor (Bormann, 1988). The GABAB receptor couples to 
Ca2+ and K+ channels through G proteins and second messengers; baclofen is an agonist, 
and these receptors are insensitive to the drugs that modulate GABAAR (Bormann, 1988;  
Bowery, 1989). Finally, a third  ionotropic receptor was discovered due to the cis-4-amino-
crotonic acid (CACA), and was designated as GABAC (Johnston, 1996).   
2.2.1. GABAA receptors 
 GABAA receptors are the most abundant of the GABA receptors in the brain. The GABAA 
receptors are ion channels that increase membrane permeability for chloride and 
bicarbonate ions when activated by GABA and the selective agonist muscimol. They can be 
blocked by bicuculline and picrotoxin, and modulated by benzodiazepines, barbiturates, 
and  other central nervous system depressants that will not be discussed here (see Sieghart, 
1995). 
In brief, GABAA receptor activation results in the net entry of anions that trigger processes 
that make a postsynaptic neuron less likely to generate an action potential, a mechanism 
known as inhibitory postsynaptic potential (IPSP) (Purves et al., 2008). The enhancement 
in conductance (that causes shunting of excitatory inputs) and the hyperpolarization (that 
sums with depolarizations) turns out to be the ‘inhibitory’ effect of GABA, thereby 
reducing the probability that an action potential will be initiated (Purves et al., 2008). 
 GABAA receptors are pentameric (five protein subunits) assemblies of subunits that form a 
central ion channel (see Figure 2.1.). 
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Figure. 2.1. Hypothetical schematic model of the GABAA receptor. Most functional GABAA receptors 
are made up of two αsubunits, two β-subunits, and one γ-subunit or alternatively two α-subunits, one β-
subunit, and two γ-subunits, which together comprise the central ion channel. Reproduced from (Makkar, 
Zhang, & Cranney, 2010). 
 
2.2.2. GABAA receptors and fear conditioning 
 GABAA receptors have been related to fear learning, and it has been showed that inhibition 
of GABAA receptors facilitates learning; while administration of GABA agonists (i.e. 
benzodiazepines) impair learning (Dickinson-Anson & McGaugh, 1997) (see Table 2.1) by 
decreasing the expression of the conditioned response (CR) (Dickinson-Anson & 
McGaugh, 1997). Izquierdo et al., (1990) were able to show that the amnesic effects of 
administration of GABA agonist at the time of encoding can be reversed after the 
administration of flumazenil (BZD), which indicates that the effects of BZs are mediated by 
the specific BZs binding-site in the GABAA receptors.   
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        Table 2.1. GABA receptors and fear learning. 
 
Regarding to brain areas important for emotional memory; the basolateral amygdala (BLA) 
(see review LaBar & Cabeza, 2006), mediates the disruptive effects of GABA on the 
acquisition and consolidation of emotional (fear) memories (Da Cunha, Roozendaal, 
Vazdarjanova, & McGaugh, 1999) and the hippocampus is important in fear learning, when 
the CS is a context (Bast, Zhang, & Feldon, 2001; Paul W Frankland & Bontempi, 2006; 
Kim & Fanselow, 1992). GABA receptors are important for hippocampal-dependent 
learning (Zarrindast, Bakhsha, Rostami, & Shafaghi, 2002). For example, post-training 
infusion of midazolam (a GABA agonist) into the hippocampus impairs the retention of 
contextual fear memory (Gafford, Parsons, & Helmstetter, 2005). 
The facilitation of fear learning due to administration of a GABA antagonist is also driven 
by the increased release of nor-adrenaline (NA) (discussed later) and the associated 
activation of the β–adrenergic receptors in the BLA. More specifically, there is an 
interaction between the GABAergic and β-noradrenergic systems  in the regulation of 
memory storage (Introini-Collison, Castellano, & McGaugh, 1994). In order to support this 
hypothesis, Introini-Collison et al., (1994) demonstrated that the retention-impairing effects 
of muscimol (a mushroom that actuates as an agonist of the GABAergic system) were 
reversed by simultaneous administration of NA. The retention-enhancing effects of 
bicuculline (a GABA antagonist) were blocked by simultaneous administration of the β-
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noradrenergic antagonist clenbuterol (decreases NA activation of β-receptors) (Hatfield, 
Spanis, & McGaugh, 1999). The better understanding of this memory modulation driven by 
the amygdala and hippocampus (Hatfield et al., 1999; Roozendaal et al., 1999) could help 
to elucidate the  role of anesthesia on the disruption of reconsolidation of emotional 
episodic memories.  
Relative to other times of administration,  post-training administration of the GABA 
agonist muscimol (a type of mushroom) disrupts memory whether given systemically or 
locally into the amygdala or hippocampus (Ammassari-Teule, Pavone, & Castellano, 1991; 
Introini-Collison et al., 1994; Tano, Molina, Maldonado, & Pedreira, 2009). While, post-
training administration of GABAergic antagonists appears to facilitate memory 
consolidation (Dickinson-Anson & McGaugh, 1993).  
In extinction, administration of GABAAR agonist would interrupt the formation of the new 
competing memory, and would leave the original memory intact at the moment of recall 
(Akirav, 2007; Bustos, Maldonado, & Molina, 2009). Reduced GABA transmission 
facilitates the storage of the new competing (extinction) memories by enhancing the release 
of NA and activation of β-receptors (Berlau & McGaugh, 2006).  But, if it was co-
administrated simultaneously with propranolol (β –blocker), the effect was blocked.  
2.2.3. Post-consolidation modulation of memory 
GABA transmission is related to anxiety disorders in humans. This may have implications 
for the treatment of those disorders, particularly the ones associated with maladaptive and 
intrusive fear memories such as post-traumatic stress disorder (PTSD) or  social phobia 
(Ehlers & Clark, 2000; Hackmann, Clark, & McManus, 2000). GABA agonist (i.e.: 
benzodiazepines), mainly midazolam or diazepam (widely used for the treatment of anxiety 
symptoms) (Shader & Greenblatt, 1993) , could be administered to the patients immediately 
after a brief re-exposure to the fear-related stimuli in order to block the reconsolidation of 
fear memories (Makkar et al., 2010). But, in order to achieve reconsolidation, it is 
necessary to ensure that the reactivation  is brief, and that reduction in anxiety (i.e., within-
session extinction) does not occur throughout the re-exposure session (Makkar et al., 2010); 
otherwise the BZ will disrupt the extinction memory (not the reconsolidation due to the 
length of the cue exposure), leading to maintenance of fear and anxiety. Also, as mentioned 
before (see Chapter 1, section 1.5.), there are other conditions that affect the final results of 
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reconsolidation, such as the age of the fear memory (more age, more time of cue exposure 
would be need it, risking to not trigger reconsolidation but extinction) (Suzuki et al., 2004) 
and the drug dosage (that correlates with the age, more age, more drug dosage is need to 
alter a memory) (Bustos et al., 2009). 
Bustos, Maldonado, & Molina, (2006) examined the role of midazolam (MDZ) (GABA 
agonist) on memory reconsolidation using a contextual fear paradigm and the classical 3-
day protocol in rats. MDZ was administered immediately after reactivation, and 24 hours 
later led to reduced responding (Experiment 1) relative to controls. This impaired 
responding still evident 10 days later (Experiment 2). Zhang & Cranney, (2008) showed a 
reconsolidation impairment induced by systemic administration of midazolam right after 
reactivation. Also, Makkar et al. (2010) showed that administration of MDZ after 
reactivation produced an impairment of discrete cue auditory fear memory.  
As seen above, there are few examples of the use of GABAergic drugs and reconsolidation, 
and mainly all of them are experimented in animals (Bustos et al., 2006, 2009; Makkar et 
al., 2010; Zhang & Cranney, 2008). In relation to the study in humans, to my knowledge 
there is only one study, carried out by Rodríguez et al., (2013) in which it was 
demonstrated the increase of memory after the reactivation and the administration of a 
small dose of clonazepam (GABA agonist). The manipulation of reconsolidation through 
the increase in the GABAergic transmission by propofol administration in humans 
(described in Chapter 3) would be one of the first attempts to disrupt emotional episodic 
memories driven by the modulatory interaction effect between the GABA system and the 
nor-adrenergic system in the brain.  
2.2.4. Propofol (“milk of amnesia”) 
Many of the therapeutic actions of anesthetics depend on the GABAA receptors (Barnard et 
al., 1998). The GABAA receptors are modulated by general anesthetics of diverse chemical 
structures including pentobarbital, etomidate, and propofol (Barnard et al., 1998).  
One of the novel investigations that conforms this thesis is based on the role of the 
anesthetic propofol on reconsolidation of emotional episodic memories, so, due to that, 
there is going to be a major focus on the role of propofol and its interaction with GABAA 
receptors.  
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Propofol (2,6-diisopropylphenol) (to be described in Chapter 3) is an intravenous general 
anesthetic and hypnotic that is structurally unrelated to other anesthetics. Propofol it is 
widely used in general anesthesia (GA) due to its clinical benefits: rapid onset, clear 
emergence, and lack of cumulative effects. Propofol not only potentiates GABA-mediated 
inhibitory synaptic transmission, but is a direct agonist of GABAA receptors (Chen, Yang, 
& Chiu, 1999).  The mechanism of action it is not well determined, but it seems that 
propofol increases the Cl- conductance and enhance the opening probability of GABA-
activated channels (Hales & Lambert, 1992). Anterograde amnesia is one of the most 
important effects of anesthetics. For example, Cheng, (2006) showed that the dose of 
etomidate that causes amnesia is considerably lower than the dose that causes immobility. 
Before I highlighted the role of the BLA on emotional memories (see Chapter 1, section 
1.4.). The memory modulation effects of the amygdala occur partly through GABAergic 
mechanisms, for example, systemic administration of diazepam (GABA agonist) fails to 
cause amnesia if the BLA is lesioned (Tomaz, Dickinson-Anson, & McGaugh, 1992) 
(similar studies see Alkire, Vazdarjanova, Dickinson-Anson, White, & Cahill, 2001).   
The possibility to generalize those findings, or others like the one above to humans have 
been supported by studies with patients with amygdala damage (Adolphs et al., 1997; 
Cahill et al., 1995) and healthy subjects with human brain imaging (Cahill et al., 1996; 
Hamann et al., 1999), that have consistently confirmed the “memory modulation” view of 
the amygdala derived from the animal studies (McGaugh, 2000). 
In order to see the amnesic effects of anesthetic gas such as sevoflurane  could block human 
emotional memory, Alkire et al., (2008) designed a study using their previous findings 
about the involvement of the BLA in mediating the amnesia caused by the inhalational 
anesthetic agent sevoflurane through the activation of GABA receptors in an aversive 
training in rats (Alkire & Nathan, 2005). They showed that sevoflurane blocks the 
mnemonic boost associated with emotional arousal. Specifically this study reported that 
structural equation modeling of PET glucose data shows that 0.25% sevoflurane suppresses 
amygdala to hippocampal effective connectivity. The findings support the hypothesis that 
the amygdala and GABA receptors are involved in memory modulation by demonstrating 
that suppressed amygdala effectiveness produces a loss of emotional memory.  
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2.3. Glutamate 
Even though glutamate has been known to have an excitatory action on the mammalian 
brain since the 50´s (Curtis & Watkins, 1960; Hayashi, 1952), it was not until the 1970s 
that it did not attain recognition as the major excitatory neurotransmitter of the nervous 
system (Meldrum, 2000). Since then, glutamate has being on the center of the attention of 
several researchers due to its role in different processes, such as:  neural development, 
neurotoxicity, synaptic transmission and plasticity (Riedel, Platt, & Micheau, 2003) Almost 
as the same time (late 70´s), the three postsynaptic ionotropic receptors of glutamate were 
named based on their preferred agonist: N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate (Meldrum, 2000).  
Given that there are barely few drugs capable of differentiated between AMPA and kainate, 
they are usually named together as “non-NMDA” receptors (Wong, Mayer, Jane, & 
Watkins, 1994). NMDA receptor has attracted much attention due to its classical 
implication in memory (Curran & Weingartner, 2002). NMDA receptor, as the other two, 
incorporates ion channels, permeable to Na+ and Ca++.   In the 80´s more types of 
glutamatergic receptors of another family were proposed, the metabotropic receptors. The 
metabotropic receptors are couple to a G protein that can act in two ways; first releasing 
second messengers in the cytoplasm or second, influencing membrane ion channels by the 
release of G protein subunits (Schoepp & Conn, 1993). 
2.3.1. NMDA receptors 
Much of the research on NMDA receptors have been done in animals, implicating these 
receptors in memory. But the research on ketamine in humans has increased due to its 
strong amnestic effects, because of the possibility to be a putative model of schizophrenia 
and because of its abuse has expanded (Morgan & Curran, 2006). 
In humans, NMDA receptors are mainly localized in the cerebral cortex and hippocampus. 
In a study (Krystal et al., 1994)  with healthy participants using subanesthetics doses of 
ketamine, which is a non-competitive NMDA antagonist, the authors found, consistently 
with other studies, that ketamine dose dependently produced psychosis (paranoia, loose 
associations, tangentiality, ideas of reference and unusual thought content) in the 
volunteers, and higher doses produced perceptual alterations (relative to the body, time and 
the environment) and a sense of memory impairment.  
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Relative to encoding, researchers suggested an impairment of memory for information 
learnt during the period under the effects of the drug, without impairment of the 
information learned before the drug administration (intact retrieval). For impairment in 
recognition memory tasks see Honey et al. (2005) and Hetem et al. (2000); for recall tasks 
see Morgan et al. (2004); for other memory domains see Table 2.2. 
 
Table 2.2. Ketamine and memory effects. Different memory domain affected. 
 
Using functional magnetic resonance imaging with healthy volunteers, Honey et al., (2005) 
were able to characterize the effects of ketamine on frontal and hippocampal responses to 
memory encoding and retrieval. A reduce activation in hippocampal and left PFC was 
observed when information encoded prior to ketamine infusion was retrieved. 
To summarize, ketamine has been shown to produce impairments in encoding episodic 
memory (C. J. A. Morgan & Curran, 2006).   
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Memantine is a moderate affinity uncompetitive NMDA receptor channel blocker 
(Kornhuber, Bormann, Retz, Hübers, & Riederer, 1989), that is licensed for severe 
Alzheimer´s disease.  
It has been shown that low doses of the NMDA receptor antagonist memantine enhance 
learning in animals with inherently poor levels of performance (Mondadori, Weiskrantz, 
Buerki, Petschke, & Fagg, 1989). 
2.3.2. Other glutamate receptors 
AMPA receptors (non-NMDA receptors) mediate the fast, immediate postsynaptic response 
to glutamate release. These receptors were found throughout the brain, with “high 
expression levels in cerebral cortex, basal ganglia, thalamus and hypothalamus, 
hippocampus, cerebellum and spinal cord” (Riedel et al., 2003, p.19). 
The main problem with AMPA and its analogues is that when injected into the brain, they 
are neurotoxic, even at very low doses. This effect has prevented their use in behavioural 
pharmacology.  
The metabotropic receptors (mGluRs) appear important for synaptic plasticity but drugs 
targeting these receptors are currently unavailable for human use.    
2.3.4. Post-consolidation modulation of memory 
As happens with the GABAergic drugs, the use of glutamatergic drugs in studies targeting 
reconsolidation in humans is inexistent. In animals is different.  Wouda et al., (2010) 
examine whether alcohol-related memories are susceptible to disruption by the β-
adrenergic receptor antagonist propranolol and the NMDA receptor antagonist MK801 
following their reactivation. Both propranolol and MK801 administration upon reactivation 
did not reduce alcohol seeking after the first reactivation test. The authors tried repeated 
three times the post-reactivation treatments, and found that propranolol diminishes the 
alcohol seeking conductance. They also found a transient effect of post-reactivation MK801 
treatment; alcohol seeking was reduced the following day, but not 7 days after treatment. 
The effects over time of post-reactivation manipulation of the NMDA receptor are less 
pronounced than the effects of blockade of β-adrenoceptors. These results and the ones 
achieved by other investigators such as (Lee & Everitt, 2008; Milton, Lee, Butler, Gardner, 
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& Everitt, 2008) demonstrated that NMDA receptor plays a (time-limited) role in 
reconsolidation of memories (Wouda et al., 2010). 
2.4. Acetylcholine  
In 1914 Dale observed two types of response to acetylcholine, which led to the discovery of 
the nicotinic and muscarinic receptors (Dale, 1914). 
2.4.1 Nicotinic receptors 
The nicotinic receptors are ligand gated ion channels (Karlin & Akabas, 1995). There are 
several subtypes of nicotinic receptors, with different pharmacological properties, and with 
different distribution through the brain.  
In studies with animals, nicotine has been found to improve learning and memory on a 
variety of tasks. Relative to memory, there are several studies that suggest memory 
enhancing properties (antagonists of the nicotinic receptors such as mecamylamine impair 
memory function) (Hasselmo, 2006). The behavioral evidence for this nicotinic 
enhancement of memory function might come from enhancement of afferent input to 
cortical structures where memories are encoded (Hasselmo, 2006). In humans, there have 
being some preliminary studies that have found that some aspects of the cognitive deficit in 
Alzheimer's disease can be attenuated by nicotine.  
2.4.2. Muscarinic receptors 
The muscarinic receptors are found in the periphery (muscles) and in the central nervous 
system of the mammalians, especially in the cortex and hippocampus, where it has been 
shown that are involved in motor control, temperature regulation, cardiovascular regulation, 
and memory (Caulfield & Birdsall, 1998). 
The muscarinic receptors are transmembrane spanning G-protein metabotropic receptors 
(M1- M5). Their agonists apart from ACh, are carbochol and pilocarpine, and antagonized 
by scopolamine and atropine.  
Drachman et al., (1974) performed one of the first experimental studies in human subjects 
using scopolamine, methscopolamine bromide (a peripherally acting scopolamine analogue, 
that does not cross the blood-brain barrier), and physostigmine (a centrally acting 
anticholinesterase agent) to study the relationship of the cholinergic system of the brain to 
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memory and cognitive functions. Their results demonstrated that subjects that received 
scopolamine showed memory encoding impairment and retrieval. Neither methscopolamine 
nor physostigmine produced any changes in memory or other cognitive functions. (see 
Table 2.3.) 
 
Table 2.3. Scopolamine effects on memory phases. Scopolamine is a cholinergic muscarinic antagonist.  
 
The cholinergic muscarinic antagonist scopolamine has been the drug most widely used to 
induce amnesia in experimental subjects, with a loss of cognitive abilities similar to that 
observed in old untreated subjects (Blokland, 1996). 
2.4.3. The cholinergic Hypothesis of Alzheimer´s disease 
Alzheimer's disease (AD) is a progressive neurodegenerative condition. The conclusive 
diagnostic markers that can be observed in postmortem brains with AD are: intracellular 
neurofibrillary tangles (paired helical filaments containing the microtubule associated 
hyperphosphorylated protein tau) and extracellular neuritic senile plaques (with amyloid 
peptide fibrils in the core, derived from amyloid precursor protein; APP), with seems to 
drive the primary degenerative effects of the AD (Delacourte & Defossez, 1986). Apart 
from these pathological markers, in the AD´s brain can be observed also cellular atrophy 
and cell loss (mainly pyramidal cells), which derivate into a neurochemical abnormal 
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functioning, with the more severe reduction of activity in the cholinergic system that 
innervates the cortex and hippocampus (Coyle, Price, & Delong, 1983). 
The importance of the cholinergic function in aging and dementia was deduced from the 
fact that the administration of antagonist (scopolamine) or lesions of the cholinergic nuclei 
were related to cognitive deficits, similar as those observed in aging and AD (Bartus, 
1978). Other findings such as, the reduce choline uptake (Rylett, Ball, & Colhoun, 1983), 
the impairment in ACh release (Nilsson, Nordberg, Hardy, & Wester, 1986) and the loss of 
cholinergic cells in the basal forebrain, specifically in the nucleus basalis of Meynert 
(Whitehouse, Price, Struble, & Clark, 1982); all together led to the development of the 
cholinergic theory of the Alzheimer´s disease, which attributed the degeneration of the 
cholinergic pathways from the nucleus basalis of Meynert to the cortex and hippocampus 
with the cognitive deterioration associated with the AD (Bartus, Dean, Beer, & Lippa, 
1982). In addition, clinical studies have reported a positive correlation between the extent 
of the cholinergic depletion with the number of diffuse plaques in the non-demented elderly 
(Beach, Honer, & Hughes, 1997). 
Since 1997, the acetyl-cholinesterase inhibitors (AChEI) (donepezil, galantamine and 
rivastigmine) have been the first line pharmacotherapy to treat mild to moderate AD. These 
drugs produce the inhibition of the breakdown of the ACh by blocking the enzyme 
acetylcholinesterase (Birks, 2006).  
2.5. Dopamine  
Dopamine (DA) is the predominant catecholamine neurotransmitter in the mammalian 
brain. DA has a variety of functions including locomotor activity, cognition, emotion, 
positive reinforcement, food intake, and endocrine regulation. DA also plays multiple roles 
in the periphery as a modulator of cardiovascular function, catecholamine release, hormone 
secretion, vascular tone, renal function, and gastrointestinal motility (Missale, Nash, 
Robinson, Jaber & Caron, 1998) . 
DA has been a subject of intensive research, due to its involvement in several pathological 
disorders such as Parkinson´s disease, Tourette´s syndrome and psychiatric disorders, like 
schizophrenia. For example, DA receptor agonist are the reference treatment for 
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hypokinesia of Parkinson´s disease, or DA antagonist have been proved to be effective 
blocking hallucinations and delusions in schizophrenic patients (Matthysse, 1973).   
In the mammalian CNS, most dopaminergic neurons are found in the substantia nigra (SN), 
pars compacta, and the ventral tegmental area (VTA). The projections from the SN to the 
dorsal striatum named the nigro-striatal dopaminergic system; the efferent projections from 
the VTA to the prefrontal cortex (PFC) named the mesocortical pathway and the 
projections to the limbic structures mainly, ventral striatum and nucleus accumbens (NAcc) 
but also to the amygdala and the hippocampus formed the mesolimbic dopaminergic system 
(Schott & Düzel, 2008).  
2.5.1. DA and memory 
Although DA has been most studied in the context of reinforcement learning, 
mesolimbocortical DA has a critical role in episodic learning and memory. It has been 
observed learning and memory performance deficits in animals with dopaminergic lesions 
(Missale et al., 1998).  
These mesolimbic pathway sends input to the hippocampus (mainly CA1 region and the 
subiculum), which express DA receptors of the D1 type (D1 and D5) receptors. Long-term 
potentiation (LTP) at the CA1 region of the hippocampus is an accepted cellular model for 
hippocampus-dependent memory processes. While the critical step for induction LTP is the 
activation of NMDA glutamate receptors, dopaminergic receptors seem to have a 
modulatory role (Huang & Kandel, 1995). The amygdala is a major target of midbrain 
dopaminergic neurons and is implicated in learning and memory processes. Fried et al., 
(2001) demonstrated the limbic DA release during associative learning in humans. They did 
it while carrying out a study with invasive recordings in epileptic patients undergoing pre-
surgical evaluation, in order to identify the epileptogenic focus for potential surgical 
resection.  
The main criticism with the Fried et al., (2001) study was the low number of participants. 
Investigations in healthy humans are restricted to noninvasive approaches, mainly using the 
effect of pharmacological compounds and its effects. Knecht et al., (2004) gave 100mg of 
the dopamine precursor levodopa (L-dopa) or placebo to forty healthy individuals. They 
demonstrated that the precursor L-dopa enhanced significantly the speed, overall success, 
and long-term retention of newly learned lists of pseudo-words in a dose-dependent 
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manner. The same group also made a direct comparison between D-amphetamine, 
DA/noradrenaline reuptake inhibitor and L-dopa, comparing the learning enhancing effects 
of d-amphetamine with a more selective dopaminergic substance (L-dopa). They found that 
both pharmacological agents enhanced the associative verbal learning task compared to 
placebo (Breitenstein, Flöel, et al., 2006); but the administration of pergolide, a DA 
receptor agonist (D1/D2), produced an impairment in performance when compared to 
placebo (Breitenstein, Korsukewitz, et al., 2006). The explanation of these contradictory 
results might be due to the tonic DA receptor occupancy which leads to a dulled 
endogenous DA signal or to the inhibition of endogenous DA release by presynaptic auto 
inhibitory D2 DA receptors (Breitenstein, Korsukewitz, et al., 2006). Unreliable results in 
humans.  
2.6. Cortisol 
Stress can be defined as a state “in which the individual perceives a real or anticipated 
challenge to homeostasis, which requires some sort of adaptive response” (Wolf, 2008, 
p.513). Our brain has the ability to respond to different types of stressors. For example, 
physical stressors (trauma, cold, injuries) engage the brainstem and hypothalamic regions 
(de Kloet, Joëls, & Holsboer, 2005), psychological stressors (social interaction, public 
speak, …), recruit brain regions related to emotion, such as the amygdala and the prefrontal 
cortex, learning and memory depend on the hippocampus (Newcomer, Craft, Hershey, 
Askins, & Bardgett, 1994) and decision making relays on the prefrontal cortex (de Kloet et 
al., 2005; Bruce S McEwen, 2007; McGaugh, 2004b). 
The initial response to stress is in neurons in the spinal cord that signal to the adrenal 
medulla [this sympathetic activation represents the “fight or flight” response (Cannon, 
1915)], which release adrenalin and noradrenaline, but these hormones cannot cross the 
blood barrier easily. The second step of stress leads to activation of the hypothalamic-
pituitary-adrenal (HPA) axis resulting in the increased release of hormones, such as 
corticotropin-releasing hormone (CRH) from the hypothalamus, into the portal circulation. 
These hormones act on the pituitary to secret adrenocorticotropic hormone (ACTH) that 
acts on the adrenal cortex to initiate the synthesis and releases of glucocorticoids (GCs), 
more specifically cortisol (or corticosterone in rodents).  
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Corticosteroid effects on the brain and cognition can change from adaptive into 
maladaptive when actions via both receptor types (mineralocorticoid and glucocorticoid) 
are dysfunctional for a prolonged time (van Stegeren, 2009). Mineralocorticoid receptor 
(MR) affinity is high enough to activate the receptor for periods of time close to 1 hour, 
between hormone secretory firings of 20-minutes duration. Glucocorticoid receptor (GR) 
has less affinity, so this receptor needs time to be activated in a progressive way while 
stress and circadian-induced increases corticosteroid secretory bursts (van Stegeren, 2009). 
Low corticosteroid levels are associated with the induction of LTP in the hippocampus, 
which leads to memory formation (Diamond, Bennett, Fleshner, & Rose, 1992; Martin et 
al., 2000). By contrast, high levels of corticosteroid, stress or exposure to a new 
environment have been related to impair LTP and to induce log-term depression (LTD) 
(Kim & Diamond, 2002; Pavlides, Ogawa, Kimura, & McEwen, 1996).    
MRs are implicated in the appraisal process and the onset of the stress response. While, 
GRs that are only activated by large amounts of cortisol, determinates the stress reactions, 
mobilizes the energy resources needed for these actions, and facilitates recovery. Relative 
to memory, GR promotes memory storage in advance of future events (de Kloet et al., 
2005). 
2.6.1 Cortisol and memory 
 Classically, the impact of stress on memory has been considered as largely disruptive 
(Lupien et al., 1994; Newcomer et al., 1994). Exposing subjects directly to cortisol or to 
psychosocial manipulation like public speaking can be prejudicial to the functioning of the 
hippocampus resulting in memory deficits (Newcomer et al., 1994; Payne, Nadel, Allen, 
Thomas, & Jacobs, 2002). In spite of this general vision, other studies demonstrate that 
elevated levels of stress are able to enhance memory for emotionally arousing experiences 
(Cahill, Gorski, & Le, 2003; Cahill & McGaugh, 1998). 
Emotional information is different than neutral information in terms of processing. As 
described before (see Chapter 1, see section 1.4.), this facilitation has a survival benefit for 
the individual, so can remember more easily the relevant information. But this facilitation 
also can turns from adaptive into maladaptive (psychiatric disorders). Different psychiatric 
disorders have at their core alterations in emotional memory or emotional learning. BLA 
and noradrenergic activation (see section 2.6.) is fundamental in this facilitation of 
80 
 
emotional memory to be remembered.  It seems that GC-mediated enhanced memory 
consolidation depends on beta adrenergic activation of the BLA, lesions or administration 
of beta blockers impair the memory enhancing effects of GC (McGaugh & Roozendaal, 
2002). Cortisol and nor-adrenaline interact together in the BLA for enhancing emotional 
memory (Cahill & McGaugh, 1998; McGaugh, 2000; Roozendaal, 2003). But, elevated 
levels of cortisol impair the functioning of the hippocampus and prefrontal cortex, key-role 
structures to memory for neutral materials (Kim & Diamond, 2002). 
Buchanan & Lovallo, (2001) administrated cortisol (20 mg) or placebo before participants 
were exposed to pictures varying in emotional arousal. Memory for the pictures was tested 
one week later. They showed that elevated cortisol levels during memory encoding enhance 
the long-term recall performance of emotionally arousing pictures compare to neutral 
pictures. 
Cahill, Gorski, & Le, (2003) administered cold pressor stress (CPS) or a control procedure 
to participants after they viewed slides of emotional or neutral content, and tested memory 
one week later. CPS, that elevated salivary cortisol levels, enhances memory for the 
emotional slides compared with the controls, without affecting memory for the neutral 
slides. These results are in line with the view that arousal interacts with post-learning stress 
hormone-related activity at encoding to modulate memory consolidation. 
But, it could not be that easy. Other authors have reached the opposite conclusions. 
Rimmele, Domes, Mathiak, & Hautzinger, (2003) administered hydrocortisone (25mg) or 
placebo and then presented to the participants either an emotionally arousing or a neutral 
story. Memory for the story was tested one week later. In all memory tests, the emotionally 
aspects of the emotional story were remembered better by the subjects who viewed the 
emotional story; leading to the indication that arousal enhances memory. Also, cortisol 
enhanced memory for details of the neutral story version, but impaired memory for details 
of the emotionally arousing version. Abercrombie, Kalin, Thurow, Rosenkranz, & 
Davidson, (2003) also failed to find the interaction between cortisol and arousal in a 
memory study. 
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Maheu, Joober, Beaulieu, & Lupien, (2004)  in a study with metyrapone (cortisol synthesis 
inhibitor) with neutral and emotional stories, found that metyrapone decreased long term 
memory for both types of stories.  
Kuhlmann & Wolf, (2006) conducted another study and showed that cortisol enhanced 
consolidation of emotional stimuli while also impairing consolidation of neutral stimuli, 
without difference in immediate memory recall performance between the cortisol and the 
placebo groups. Their data also showed that the cortisol effect increases over time. 
Therefore, they suggested that memory consolidation of neutral and emotional stimuli are 
modulated by GR. But the “stress effect on encoding could not be mediated via cortisol 
since glucocorticoids are secreted with a delay of several minutes after stressor onset but 
rather via neurotransmitters such as dopamine or nor-adrenaline”(Schwabe & Wolf, 2010a, 
p.187).  
2.6.2. Post – consolidation modulation of memory 
Relative to the main topic of this thesis there are few studies analyzing the effect of cortisol 
on reconsolidation of fear memories or autobiographical memories. The possibility of being 
able to disrupt or facilitate the reconsolidation of emotional memory by stress exposure has 
important implications for the treatment of anxiety disorders such as post-traumatic stress 
disorder and of drug-of-abuse memories. As seen before, the effects of stress (impairment 
or enhancement) on memory depend on many factors, such as age, gender, features of the 
stressor (time of exposure, type, duration), the task and the stimuli assessed (see review 
McEwen, 2007). The role of the neural regions involved in emotional memory in 
consolidation and reconsolidation has been described already, being the BLA, hippocampus 
and the PFC the main ones. BLA is a key region that regulates the effects of stress and 
glucocorticoids on memory formation, consolidation, and reconsolidation. Schwabe & 
Wolf, (2010a) showed a memory impairing effect of learning under stress in humans. 
Taubenfeld, Riceberg, New, & Alberini, (2009) have shown that systemic post-reactivation 
administration of the GR antagonist RU38486 impaired the reconsolidation of inhibitory 
avoidance. The sum of these results and others such as the ones achieved by Nikzad, 
Vafaei, Rashidy-Pour, & Haghighi, (2011) indicate that hippocampal GRs are required for 
reconsolidation of fear-based memory. 
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Schwabe & Wolf, (2010b) made a study were participants recalled positive, negative and 
neutral episodes from their recent past and were afterwards exposed to a stressor (the cold 
pressor test) or to a non-arousing control condition. In this stressor, participants were asked 
to immerse their right hand up to and including the wrist for 3 min into ice water (0–2 °C). 
Stress after memory reactivation impaired the memory for the neutral episodes 1 week 
later, whereas the subsequent memory for the emotional episodes was not affected by stress 
after reactivation. Reactivation per se or stress without prior memory reactivation had no 
effect on memory performance. They suggested that these findings showed that the effect 
of stress on memory reconsolidation is opposite to the stress effect on memory 
consolidation supporting the view that consolidation and reconsolidation are distinct 
processes. 
2.7. Nor-adrenaline and Adrenaline 
Noradrenaline is formed in the body from the amino acid tyrosine, and adrenaline 
synthesized from nor-adrenaline (Kalat, 1992). Both compounds exert similar 
pharmacological actions, and are classified as sympathomimetic agents. 
Nor-adrenaline, is released either as a hormone from the adrenal medulla into the blood or 
as a neurotransmitter in the brain (Tully & Bolshakov, 2010). At the level of the CNS, nor-
adrenaline neurons can be found through the nervous system, but the majority of these 
neurons are in the LC (the primary source of nor-adrenaline in the brain) that has 
projections to the amygdala, hippocampus and neocortex (Vermetten & Bremner, 2002). 
NA was initially associated with memory processing by Kety, (1972), and has different 
roles in the CNS: charge of acquire sensory information, and also, modulates and increases 
the processing of emotional relevant and salient information via its action on sensory, 
attentional, motor and memory processes (van Stegeren, 2008). 
NA activates two major categories of receptors, α (α1 and α2) and β (β1, β2 and β3); with 
subtypes in each group. The mechanism of action of NA is through affecting the 
excitability by blocking a Ca2+ -dependent K+ current. NA can enhance or reduce 
excitatory responses to glutamate, depending on its concentration (Sara, 2009; Wikberg, 
1982) (see Table 2.4.). 
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Table 2.4. Descriptions for key NA pharmacologic agents. Adapted and reproduced from Chamberlain, 
Müller, Blackwell, Robbins, & Sahakian, (2006). 
 
Different studies indicate that the brain functioning of NA is via activation of  β-
adrenoceptors on the ascending vagus nerve that projects to the nucleus of the solitary tract 
(NTS) (McGaugh & Roozendaal, 2009; Williams & McGaugh, 1993). The NTS has direct 
and indirect projections to the locus coeruleus that produces that activation of the nor-
adrenergic system (McGaugh & Roozendaal, 2002). The results of numerous experiments 
implicate the amygdala in acquisition and retention of memory for emotionally charged 
events (see reviews LeDoux, 2000; Maren & Quirk, 2004).  Also, it has been showed the 
involvement of the basolateral amygdala in the regulation of consolidation of memories in 
other regions of the brain (McGaugh, 2004b; McGaugh et al., 1996). The contribution of 
the amygdala to modulating memory consolidation critically depends on activation of β-
adrenoceptors in the BLA (Ferry & McGaugh, 1999; Power et al., 2002). The activation of 
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the NA of the BLA via emotional arousal produces posterior induction of cortisol that 
facilitates memory consolidation, but also interacts with other transmitters and  
neuromodulators in the amygdala or the hippocampus to facilitate long- term memory 
formation (for review see McGaugh & Roozendaal, 2009). For example, animals studies 
evidence the role of drugs that are capable of modulating emotional memory, such as 
GABAergic agonists and antagonists, by controlling the level of NE within the amygdala 
(Hatfield et al., 1999; Roozendaal & McGaugh, 1996). 
In humans, the facilitating role of NA in consolidation of emotional memories charged with 
negative (or positive) valence has mostly been attributed to the activation of β -adrenergic 
receptors. To summarize the effects on consolidation, Cahill et al. (1994) administered 
propranolol (β1β2-antagonist) prior to neutral and emotional stimuli. The prior 
administration of propranolol is done in order to maximize β-adrenergic blockade at the 
time of the initial encoding. They showed reduced recognition and recall for the emotional 
component of the story in the arousal condition after 1 week. These findings have been 
replicated by several studies (Maheu et al., 2004; Reist, Duffy, Fujimoto, & Cahill, 2001; 
van Stegeren, Everaerd, Cahill, McGaugh, & Gooren, 1998) (see Table 2.5.).  So, the 
hypothesis that enhanced memory associated with emotional experiences involves 
activation of the β-adrenergic system is being extensively supported by the finding in 
human subjects that β-adrenergic receptor blockers like propranolol selectively impaired 
memory for emotional events. Also, it has been found that the effect involved the activation 
of central β-adrenergic receptors (but not peripheral) (van Stegeren, Everaerd, Cahill, 
McGaugh, & Gooren, 1998). 
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Table 2.5. Human studies on noradrenergic modulation of emotional memory. Abbreviations: PLC 
(placebo); EM (emotional memory); iv (intravenous); fMRI (functional magnetic resonance imaging). 
Adapted and reproduced from Chamberlain, Müller, Blackwell, Robbins, & Sahakian, (2006).  
 
Another study, using similar stimulus material as the one used in Cahill et al. (1994) and 
the  administration of 20 mg yohimbine (which stimulates central noradrenergic activity via 
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blockade of the α2-adrenergic autoreceptor) or 50 mg of metoprolol (β1-receptor blocker) 
found similar results. Yohimbine significantly elevated, and metoprolol reduced mean heart 
rate during the slide presentation relative to placebo, thus confirming the efficacy of the 
pharmacological manipulation. One week later, in a ‘surprise’ test, memory for the slides 
was tested. Yohimbine treated subjects recalled significantly more and metoprolol subjects 
fewer slides relative to placebo. Authors reached to the conclusion that the noradrenergic 
system results in the enhancement and blockade in a reduction of recall and recognition of 
emotional material in man (O’Carroll, Drysdale, Cahill, Shajahan, & Ebmeier, 1999). 
Contradictory results were found in another study using yohimbine, but the dose was 
administered after slide presentation and not prior (Southwick et al., 2002). Other studies 
relative to clonidine and working memory: Jäkälä et al., (1999); Coull, Middleton, Robbins, 
& Sahakian, (1995). 
Relative to the studies in humans is important to take gender into account. There are 
differences driven by gender due to the differential hemispheric amygdala specialization. 
For example it has been suggested that emotional arousal enhances memory for central 
story information in men and peripheral details in women (Cahill & van Stegeren, 2003). 
Using neuroimaging, there is, for example, one study that used fMRI to investigate the 
effects of short-term treatment with reboxetine (a NA reuptake inhibitor that blocks the 
action of the NA transporter), on emotional facial processing in healthy volunteers. 
Reboxetine was associated with a reduced amygdala response to fearful faces and increased 
activation to happy vs neutral facial expressions in the right fusiform gyrus, compare to 
placebo treatment and in the absence of changes in mood. These results showed that 
reboxetine modulates the neural substrates of emotional processing, increasing emotional 
memory for positively valence stimuli, highlighting a possible mechanism by which drug 
treatment could compensate negative bias in depression and anxiety (Norbury, Mackay, 
Cowen, Goodwin, & Harmer, 2007). 
More studies using fMRI have shown for example that successful encoding of emotionally 
aversive nouns activates the left amygdala, and this effect was abolished by administration 
of propranolol. Recognition of emotional noun words was found to engage the left 
hippocampus, but this effect was null when β -adrenergic blockade was used at the time of 
encoding (Strange & Dolan, 2004). In another study, volunteers undertook fMRI while 
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viewing affective pictures (van Stegeren et al., 2005). Viewing neutral pictures did not 
increase amygdala activation relative to baseline while emotional pictures did. After 
receiving 80 mg of propranolol the activation after emotional stimuli was reduced (van 
Stegeren et al., 2005). These neuroimaging findings are consistent with an important role 
for NA- mediated modulation of amygdala at the level of encoding, in particular, and 
during consolidation. 
2.7.1. Post – consolidation modulation of memory 
From a clinical perspective, the possible applicability of β-blockers for the treatment of 
PTSD comes from the data suggesting that the β-adrenergic system represents a putative 
target for the treatment of PTSD (Pitman et al., 2002); therapeutic target that is also 
supported by neuroimaging evidence (van Stegeren et al., 2005). 
For example, Brunet et al., (2008)  (see Chapter 1, section 1.5) made one of the first 
attempts in the evaluation of the effects of reconsolidation in the treatment of psychiatric 
disorders such us phobias, addictions or PTSD by using propranolol with reactivation of 
autobiographical trauma memories. After continuing the treatment with propranolol once a 
week during six weeks, patients in a one week and four-month follow-up did not meet the 
criteria for PTSD. Also there were no differences observed between physiological 
responding measured post-treatment (heart rate, skin conductance response and left 
corrugator electromyogram) and at follow-up (Brunet et al., 2011, 2014). 
As a result of these positive results, the possibility of being able to weakening consolidated 
memories after reactivation by pharmacological agents, extended to another type of 
disorders in which the emotional memory was in the root of the disease. Soeter & Kindt, 
(2015) in a double-blind study administered a single dose of propranolol after the 
reactivation (exposure to a spider) with individuals that have acquired their spider fear 
outside of the laboratory context, or placebo. According to the authors, the disruption of 
reconsolidation by propranolol transformed an avoidance behavior into a more approaching 
behavior in participants with spider phobia, but without affecting the self-declared fear. 
These results remained during 3 months to 1 year follow-up. Unfortunately, attempts to 
modify addiction behaviors with propranolol did not have the same success (Lonergan, 
Saumier, Tremblay, Kieffer, & Brunet, 2016; Pachas, Gilman, Orr, Hoeppner, & Evins, 
2015), or they achieved a transient success, as was reported for craving in cocaine-
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dependent addicts that benefited from the reduced cue-elicit craving less than a week 
(Saladin et al., 2013).  
Regarding other adrenoceptors, Pussinen & Sirviö, (1998) reported a role of the α1-
adrenergic receptor in long-term potentiation induction in animal models. However, the 
role of the stimulation of this receptor with these memory phases 
(consolidation/reconsolidation) remains unclear. Few studies have corroborated the 
participation of α1Rs in consolidation and reconsolidation of emotional memories 
(Bernardi, Ryabinin, Berger, & Lattal, 2009; Ferry & McGaugh, 1999). In the case of the 
α2-adrenoceptor, Gazarini, Stern, Carobrez, & Bertoglio, (2013) showed that administration 
of α2-adrenoceptor antagonist yohimbine was able to potentiate fear memory trace 
consolidation and reconsolidation in rats;  and that the α2-adrenoceptor agonist clonidine, as 
opposed to yohimbine, mitigates fear expression by weakening memory consolidation and 
reconsolidation.  
Adding the studies presented in the previous chapter (Chapter 1, section 1.5), to those 
presented in this section, we can observe that the results of the different studies are 
confusing as to the feasibility of developing a treatment based on the weakening of episodic 
emotional memories through the use of different treatments, being the most analyzed, the 
use of propranolol. 
Likewise, there are several conditions that favor the search for another manipulation for 
episodic memories. These unfavorable conditions are, for example, the fact that β-blockers 
diminish fear-related responses, leaving basically episodic memory intact, which would be 
of incredible therapeutic value in the treatment of certain psychiatric disorders such as 
PTSD or addictions (Kroes, Schiller, LeDoux, & Phelps, 2016). But the fact that episodic 
memory is left intact can lead to relapses in the underlying disorder. Another factor that 
argues against the use of propranolol in studies of interruption of reconsolidation of 
episodic memories is that previously described in section 1.5., Chapter 1. This factor refers 
to the fact that the use of β-blocker violates two of the basic criteria, which makes it 
difficult to use for reconsolidation (Kroes et al., 2016). The third factor that makes less 
acceptable the use of propranolol in this type of studies or future therapies is the fact that its 
effectiveness has been demonstrated only in studies with memories related to a short period 
of time, but not with more remote memories (Kroes et al., 2016). Therefore, the study 
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presented in Chapter 3 is based on the application of anesthetic agents and not on beta 
blockers in the disruption of emotional episodic memories in humans. 
2.7.2. Nor-adrenaline and memory modulation by motor system 
Much of the episodic memories we form in our daily life are encoded whilst we are 
physically interacting with the environment. The idea of voluntary movements being 
modulating memory processes is in line with recent experiments that increasingly suggest 
that simulations, situations, and bodily states play central roles in cognition (Rubin, 2006). 
Our body is influenced by our mind, and our mind is influenced by our body. This idea has 
led to the development of a series of studies and experiments showing that different kinds 
of bodies think differently (Casasanto, 2009, 2011). The several evidence existent about the 
influence of the motor system on the mind can be integrated as the embodied cognition 
approach (for review see Rosenbaum, (2005). This approach argues that physical properties 
of the human body, mainly the perceptual and motor systems, influence cognition 
(Barsalou, 2008; Fischer & Zwaan, 2008). Cohen, (1981), asked participants to perform a 
list of actions, to watch someone else performing those actions or to just hear or read the 
instructions of the actions. In a subsequent test he saw that the ones that perform the actions 
or saw others doing it had better recall than the ones that simple read or heard the actions. 
Later those experimental conditions were referred as self- or subject-performed tasks 
(SPT), experimenter-performed tasks (EPT), and verbal tasks (VT), respectively. Other 
studies, such as the one driven by Denis, Engelkamp, & Mohr, (1991) observed similar 
results, better memory for SPT compared to actions that were being imagined. Later, Cohen 
and Engelkamp joined efforts and began a new field of research: “memory of action 
events” ( see review Engelkamp & Cohen, 1991). “The enactment effect” was one of their 
first findings, and reflects two main ideas: A) when we perform an action, the underlying 
mental representation is more complex than verbal phrases, a finding that can be related 
with the levels of processing proposed by Craik & Lockhart, (1972); and B) enacted actions 
activates the motor system; while other kinds of encoding are unable to do it.  
90 
 
 
Figure 2.2. Embodied cognition approach. Schematic resume of the embodied cognition approach, authors 
and contributions. 
 
Remembering a stimulus specifically produces greater activation in modal areas than 
remembering in generally (Garoff, Slotnick, & Schacter, 2005). Simulating a scene at 
encoding that extends the boundary of a studied picture produces reconstructive error later 
at retrieval (Intraub, Gottesman, & Bills, 1998). Pulvermüller, (2005) found that “when 
participants simply read the word for an action, the motor system becomes active to 
represent its meaning. More specifically, verbs for head, arm, and leg actions produce head, 
arm, and leg simulations in the respective areas of the motor system”.  
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The MTL has been related to episodic memory (see Chapter 1, section 1.3). Central regions 
of the MTL, such as the hippocampus, have been linked to navigation and spatial memory 
(Maguire et al., 1998; O’keefe & Nadel, 1978). Several findings suggest that hippocampal 
theta oscillations are engaged during spatial navigation and are supposed to mediate spatial 
memory formation (Cornwell, Johnson, Holroyd, Carver, & Grillon, 2008). Human 
hippocampal intracranial recordings have shown increased activity during movement 
(Caplan et al., 2003; Ekstrom et al., 2005). A more directly link between motor system and 
hippocampus is been showed in a study using fMRI to measure human cerebral activity 
associated with motor cognitive processes during the  performing of a delayed-associative 
task (Thoenissen, Zilles, & Toni, 2002). Other area that has been linked to episodic 
memory-modulation is the locus coeruleus (LC), which is the main source of NA in the 
brain (LaBar & Cabeza, 2006; Strange & Dolan, 2004; Strange et al., 2003; Tully & 
Bolshakov, 2010).   
Besides the traditional view of the role of the LC activated by emotional arousal which 
produces NA release to the brain and the subsequent memory enhancement (for Review see 
Tully & Bolshakov, 2010), other studies have suggested that the LC is active while we take 
a commitment to act or in goal-directed events (Bouret & Richmond, 2009), regulating the 
behavioral outcome of decisional processes (Clayton, Rajkowski, Cohen, & Aston-Jones, 
2004) Taken into account all these evidences and the contributions of other theoretical 
approaches, the main subjacent question is if actions enhance or impair memory, and 
through which neural correlates.  
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Chapter 3 
The effect of sedation on 
reconsolidation of emotional episodic 
memory in humans 
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3.1. Introduction 
Upon encoding, memories undergo a time-dependent process known as consolidation (see 
Chapter 1). Prior to consolidation, memories are sensitive to disruption by, for example, 
electroconvulsive therapy (ECT) (Duncan, 1949; Glickman, 1961) and protein-synthesis 
inhibition (Agranoff, Davis, & Brink, 1966; Flexner et al., 1965). Traditionally memories 
after consolidation have been thought to be relatively insensitive to disruption (McGaugh, 
2000). For decades, this has been a central dogma in the neuroscience of memory. 
However, the concept of reconsolidation challenges this idea (Nader, Schafe, & LeDoux, 
2000). Reconsolidation refers to the process of memories changing from a rather fixed to a 
labile state upon reactivation (i.e. what happens during memory retrieval). Therefore, 
reactivated memories are susceptible to manipulation, once again requiring a time-
dependent re-stabilization process (Nader et al., 2000). 
Recently, electroconvulsive therapy (ECT) was applied following memory reactivation in 
patients with therapy-resistant unipolar depression. Results showed a disruption for the 
reactivated, but not for the non-reactivated memories for an emotional episode (Kroes et al., 
2014). Importantly, this effect was observed only for the group that had been tested after 24 
h, not for the group tested immediately after ECT recovering.  
These findings were important because the ECT study met critical criteria generated from 
non-human animal studies, thus providing compelling evidence for the reconsolidation 
phenomena in humans. These criteria consist of: (1) consolidated memories must be 
reactivated by a reminder cue; (2) the manipulation aimed at altering reconsolidation must 
be provided post-reactivation, rather than pre-reactivation; and (3) reconsolidation is a 
time-dependent process and memory should therefore be affected after a time window 
allowing reconsolidation to take place—usually after 24 h—rather than immediately 
(McGaugh, 2000; Nader et al., 2000; Williams et al., 2007). Thus, the time-dependence of 
reconsolidation impairment observed in this previous study, i.e. the effect is present at 24 h 
but not 90 min, is in line with animal studies of reconsolidation suggesting similar neural 
processes. 
Although these results provided evidence for reconsolidation of emotional episodic 
memories in humans, there is a clear limitation in interpreting these data. ECT comprises 
the application of both short-acting general anesthesia (GA) and cranial electrical 
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stimulation to evoke generalized seizure activity. It was simply not possible to elucidate 
whether reconsolidation impairment was due to the ECT or the general anesthesia. If the 
GA is responsible, targeted memory disruption in psychiatric patients could be done 
without ECT, which is an invasive procedure, particularly given recent evidence that frontal 
ECT alters functional connectivity of the frontal lobes (Perrin et al., 2012). 
3.2. Hypothesis 
Based on the data available it’s hypothesized that the GA impairs the reconsolidation of 
emotional episodic memories by acting on the GABAergic system.  
3.3. Methods and materials 
In this section, prior to explaining in detail the procedure followed to engage 
reconsolidation, the stimulus material for the encoding session, as well as the general 
anesthetics used at the time of the reactivation session to manipulate memory are going to 
be described. In order to assess the evaluation of the functioning cognition of the 
participants, a screening test was administered, the Digit Symbol Substitution Test (DSST), 
that is described as well in this methods and material section.  
3.3.1. Participants 
Participants were recruited from the Hospital Clínico San Carlos, Madrid. A total of 50 
psychiatrically healthy volunteers (Table 3.1.) from the gastroenterology clinic, with an age 
range 30-45 years (both ages included), normal or corrected to normal vision and hearing 
participated in the study. All participants were free of neurological or psychiatric 
medication, only under stable pharmacological treatment related to gastric ailments (22 out 
of 50 participants). Participants were asked to join the study since they were undergoing 
brief general anesthesia (GA) for a routine endoscopy procedure (colonoscopy: 24, 
gastroscopy: 19 or both procedures: 7). The Ethical committee of the Hospital Clínico San 
Carlos approved the study and all participants were informed of the procedures to be 
carried out before they provided written informed consent. Participants were pseudo-
randomly assigned to one of the two groups (A and B), matched for age (group A mean 
age: 38, 88; s.e.m. 0, 90) and group B mean age: 39, 08; s.e.m.: 0, 97), gender (15 men per 
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group) and educational level (years of education group A mean: 14, 44; s.e.m.: 0, 60 and 
group B mean: 14, 75; s.e.m.: 0, 53).  
 
Table 3.1. Participant’s demographics and clinical details. Twenty five patients per group completed the 
study. One patient was withdrawn from the study because he was considered an outlier in the performance of 
the DSST. Groups A and B did not differ in any demographical variable (age, gender, years of schooling or 
type of endoscopy procedure), or in terms of the amount of other anesthetic (midazolam or alfentanyl) 
administered. Although, there is a significant difference (* p<0.05) in the amount of propofol administered, 
there is no correlation between this amount (kg/mg) of propofol and the memory scores on both groups. a  Chi 
squared, b unpaired t-test. 
 
97 
 
One week after learning two emotionally aversive slide-show story memories (see Figure 
3.3) for one of the two stories was reactivated. Immediately following memory reactivation, 
patients in groups A and B were anaesthetized and had their routine endoscopy procedure. 
Memory was tested one day after reactivation and anesthesia in group A. In contrast, group 
B was tested ~27-105 min after reactivation and anesthesia. 
 
Figure 3.1. Study design. Patients were assigned to one of the two groups (A or B).  During a first study 
session both groups were shown two emotional slide-show stories. During a second session memory for one 
of the two stories was reactivated. Immediately after memory reactivation patient in groups A and B received 
anesthesia. In patients of group B memory was tested immediately upon recovery from anesthesia (Test, 
blue). In patients of group A memory was tested one day after reactivation (Test, red). 
 
3.3.1.1. Exclusion criteria 
Subjects were electable because they were undergoing an endoscopy procedure that would 
need the use of GA. All subjects gave informed consent, but previously participants had to 
meet none of the exclusion criteria (Table 3.2.). These included that participants were free 
of neurological or psychiatric history or any anesthesia (propofol, midazolam or alfentanil) 
contraindications (nevertheless, medical doctors at the hospital were in charge of tested 
possible contraindications in the used of GA). 
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Table 3.2. Exclusion criteria. Participants had to meet none of these exclusion criteria in order to be 
electable for participate in the study.  
 
3.3.2. Stimulus material 
3.3.2.1 Stories 
The stimulus material was the same as used in Kroes et al., (2014). During an initial 
learning session, participants viewed picture series of two high-arousing stories with 
negative valence on a 16” laptop computer screen. Each story consisted of 11 slides. Each 
slide was shown for 20 seconds with a total presentation time of 3.6 minutes for each story. 
Further, each slide was accompanied by an auditory narrative, forming an episode. One of 
the negative arousing stories was used before by Cahill and colleagues (Cahill & McGaugh, 
1994, 1995; note that although a neutral version exists also, we only used the negative 
arousing version of the Cahill story) , from now on named as the “Story 1”, and depicted a 
mother taking his young son to visit his father at work (see Figure 3.2.a). The second story 
was developed by Kroes et al. (2014) and involves two sisters that go to a bar, for now on 
referred as the “Story 2” (see Figure 3.2.b). Story 2 consists of modern digital photographs, 
whereas Story 1 contained scanned analogue images. To avoid any interference due to the 
learning of two stories in a short period of time, the narrative in the Story 1 was taped by a 
male voice, and the story 2 was recorded with a female voice (Kroes et al., 2014).  Both 
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stories were adapted to the Spanish language and were identical in structure (11 sentences, 
one per slide in both stories), grammar, arousing[(meanStory1=1,1, s.e.m.= 0,48; 
meanStory2=1,18, s.e.m.=0,55), t(20)= -0,13, p=0,90] and neutral words [(meanStory1= 13,54, 
s.e.m.= 1,60; meanStory2= 14,09, s.e.m.= 1,12), t(20)= -0,28, p=0,78], similar in 
word[(meanStory1= 14,64, s.e.m.= 1,43; meanStory2= 15,27, s.e.m.= 1,39), t(20)= -0,32, 
p=0,75] and syllable count, and voice emphasis[(meanStory1= 2,64, s.e.m.= 0,58; meanStory2= 
2,23, s.e.m.= 0,49), t(20)=0,48, p=0,64]. 
Both stories were divided into 3 phases. Phase 1 was composed of slides 1 through 4 and 
was of emotionally neutral content. Phase 2 was composed of slides 5 to 8, and comprised 
the negative emotional part of the stories, and Phase 3 consisted of slides 9 to 11 and was 
again of neutral content.  
 
          
 
Figure 3.2.a 
 
“A mother and her 
son leave their house 
in the morning” 
Story 1 
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Figure 3.2.b  
Figure 3.2. (a and b) Patients were presented with two slide shows that form arousing episodic stories of 
negative valence. Top: the original Cahill Story now named as “Story 1”, bottom: the newly developed story 
by Kroes et al., (2014), now named as “Story 2”. Both stories consist of 11 slides and each slide is 
accompanied by an auditory narrative presented via computer speakers. 
 
3.3.3 Memory reactivation 
Accumulating evidence indicates that consolidated, apparently fixed memories might re-
enter a labile state after the presentation of a cue-reminder (process that it is known as 
reactivation), thus requiring to be re-stabilized again (a process that is known as 
reconsolidation) (Dudai, 2006; Nadel & Land, 2000; Sara, 2000). 
The material used to reactivate a memory where photographs of the first slide of each story. 
The presentation of one or the other story was balanced across subjects with a 50% of 
probability of appearance each. Parts of this slide, however, were masked by black-and-
“Two sisters leave 
from the apartment 
around midnight” 
Story 2 
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white checkerboard patterns (see Figure 3.3.). Patients were asked three questions on what 
was visible behind the mask. After the patient answered the question, the related part of the 
mask was removed, and the entire slide was visible after all three questions were answered.  
 
Figure 3.3. Reactivation material. Participants were presented with the first slide of one of the two stories, 
to reactivate memory and initiate reconsolidation. As seen above, the parts of the slide were covered by black 
and white chessboard patterns. Participants were asked three questions about what was hidden behind the 
patterns. Once they answered the question, the mask was removed. After all three questions, the entire slide 
was visible. 
 
3.3.4. Anesthesia 
3.3.4.1. Propofol 
In the early 1970s, different studies leaded to the development of a new and safe injectable 
anesthetic, with excellent anxiolytic properties but with no significant analgesic effects 
(therefore an opioid is usually administered concomitantly) derived from phenol with 
potent hypnotic properties, the molecule 2,6-di-isopropylphenol (Kay & Stephenson, 1980), 
chemically unrelated to other anesthetics (Short & Bufalari, 1999). Since then, the use of 
propofol (2,6-di-isopropylphenol compound) has been extended in clinical practice, as one 
of the most popular intravenous (IV) anesthetic for the induction and maintenance of 
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general anesthesia (Short & Bufalari, 1999) and in ambulatory surgeries in outpatients 
(Trapani, Altomare, Liso, Sanna, & Biggio, 2000). Different studies have shown that 
propofol possesses antiepileptic properties. Moreover, several studies have shown that 
propofol may be useful in patients resistant to other antiepileptic drugs such as BDZs, 
barbiturates, or other epileptic drugs (Al-Hader, Hasan, & Hasan, 1992; De Riu et al., 
1992). 
Propofol is stable at room temperature and is not light sensitive. The formulation usually 
consists of 1% propofol in a parental nutritional agent consisting of 10% soybean oil, 
2.25% glycerol and 1.2% purified egg phosphatide. It has a pH between 7- 8,5 and appears 
as a slightly viscous milky white substance (Short & Bufalari, 1999). Propofol is also an 
agent with antioxidant, anti-inflammatory and bronchodilating properties (Marik, 2004).  
3.3.4.1.1 Pharmacodynamics 
Propofol was a breakthrough because of its rapid onset of action due to rapid uptake into 
the central nervous system (CNS), the short duration of action and rapid smooth emergence 
mainly because of its rapid redistribution, due to its lipophilic nature, from the brain to 
other tissues and efficient elimination by metabolism (Zoran, Riedesel, & Dyer, 1993) (see 
table 3.2.). Another property that has made propofol gained a great acceptance is because of 
the quality and rate of recovery whether it is given by bolus or continuous infusion (Hall & 
Chambers, 1987). 
Propofol is a cardiovascular depressant and also, it is been associated with respiratory 
depressant effects (reduced tidal volume and apnea), lowered cerebral blood flow that is 
accompanied by reduced requirement of oxygen and decreased intracranial pressure (ICP) 
(Bryson, Fulton, & Faulds, 1995). Like other anaesthetic agents, has anticonvulsant 
(mediated by GABA receptors) and neuroexcitatory activity (unknown origin); also has 
amnesic properties (less marked that BZDs) (see Table 3.1.) (Bryson et al., 1995). 
Propofol also has neuroprotective properties during focal ischemia. Also when 
administered in large doses produces burst suppression in the electroencephalogram, that is 
why it is used in neurosurgical procedures for neuroprotection (Miller, Pardo, & Stoelting, 
2011).  
 
103 
 
3.3.4.1.2. Mechanism of action 
Some of the pharmacological actions of propofol are mediated by the inhibitory central 
GABAergic transmission (see Chapter 2). Within the different types of GABA receptors, 
the most propofol sensitive ones are GABAA receptors. Another study, reported that the 
amnesic effect of propofol seems to involve protein expression in the hippocampus, 
occurring through a network interaction with the BLA; being this key-region responsible of 
the anesthetic-induced amnesia (Ren, Zhang, Xue, Zhao, & Yu, 2008). Also, animal studies 
have shown that propofol activates GABAA-receptors present in the locus coeruleus (LC), a 
small pontine nucleus that contains the major concentration of noradrenergic bodies in the 
brain, resulting in a decrease firing rate of nor-adrenergic neurons. Peduto, Concas, 
Santoro, Biggio, & Gessa, (1991) showed that propofol exerts its modulatory action by 
interacting in a different side from BZDs, at the GABA receptor. The GABAA-receptors of 
the  LC neurons do not contain the γ subunits, which make them insensitive to 
benzodiazepines, and unable to enhance the propofol-induced responses  (Chen et al., 1999) 
via co-administration of benzodiazepines at the time of anesthesia. 
Also, it is been shown that propofol decreased ACh release at the frontal cortex and 
hippocampus, and that this effect was blocked by bicuculline; on the other hand, release 
from the striatum was not affected (Kikuchi, Wang, Sato, & Okumura, 1998; Sanna et al., 
1999). Excitatory glutamate receptors are also sensitive to propofol, while kainate receptors 
seem to be insensitive; NMDA receptors are negatively modulated by propofol, but this 
sensitivity appears to be low (Klein et al., 1993; Orser, Bertlik, Wang, & MacDonald, 
1995). Other authors have also suggested that propofol inhibits M1 receptors (Murasaki et 
al., 2003). Taken into account all these data, it can be inferred that the mechanism of action 
of propofol is rather complex, and at the clinical level, seems that the general anesthetic 
action of propofol is the sum of all its interactions with different neurotransmitter systems 
(Trapani et al., 2000).  
There is one factor that not always has been taken into account: gender. Gender appears to 
be an important factor to count with in recovery from anesthesia. Usually, it is been 
reported that women experienced more episodes of awareness (three times more frequent in 
women than in men). Gan et al., (1999) performed a multicenter study, they compared the 
wake up and recovery times of 274 adults. They found consistently evidence that women 
woke up faster than men; and that men had significantly prolonged recovery times, without 
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any differences in the dosage. This factor should be considered with respect to the 
pharmacodynamics and pharmacokinetic of propofol in the clinical practice.  
3.3.4.1.3. Pharmacokinetics 
The induction of anesthesia can be achieved by administration of doses of 40 mg every 10 
seconds. The dose in adults usually has a range between 2- 2.5 mg/ kg (Langley & Heel, 
1988). As said before, propofol can maintain anesthesia through continuous infusion (6 to 
12 mg/kg /h) or with bolus injection (20-50mg) (Bryson et al., 1995). The induction of the 
anesthesia  by propofol in combination with tranquilizers, sedatives, or analgesics is a very 
extensive practice (Morgan & Legge, 1989; Weaver & Raptopoulos, 1990). For example, 
the co-administration of propofol and midazolam is widely used in pre-anesthesia (Trapani 
et al., 2000). In order to achieve a total IV anesthesia the combined propofol with opioid 
agonist such as alfentanil administration is commonly applied in surgical practice (Trapani 
et al., 2000). 
The propofol is characterized by a fast distribution from the blood into tissues and a rapid 
metabolic clearance that produces a rapid onset and a short duration of action. Propofol is 
rapidly and extensively distributed to well perfused tissue (including the brain), then to 
muscle and to fat tissue. It is metabolized primarily in the liver and the half-life is 30 to 60 
minutes  (Bryson et al., 1995) (see Table 3.3.).  Propofol is mainly eliminated by hepatic 
conjugation to inactive metabolites and excreted by the kidney (Simons et al., 1988). 
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Table 3.3. Pharmacology of propofol. Pharmacodynamics and pharmacokinetic properties of propofol. 
Adapted from    Carrillo-Esper, Garnica-Escamilla, & Bautista-León, (2010). 
 
3.3.4.1.4. Complications associated with the use of propofol 
Propofol has been administered successfully to millions of patients, with a remarkably 
safety record. Even so, there is a very rare but also extremely serious complication known 
as “propofol infusion syndrome”. This syndrome is associated with a high dose of propofol 
infusion, and affects the pediatric patients to a greater extent. This syndrome is 
characterized by a severe metabolic acidosis, Rhabdomyolysis (breakdown of muscle 
fibers) and cardiovascular collapse frequency leading to death (Vasile, Rasulo, Candiani, & 
Latronico, 2003). 
 In 1995, the Centers for Disease Control and Prevention (CDC) were informed of a 
disproportionate increase in bloodstream infections, surgical site infections, and febrile 
episodes following surgical procedures in a cohort of 62 patients (Bennett et al., 1995). 
After an investigation, it was possible to relate the occurrence of this outbreak with 
contaminated "multipurpose" vials and syringes containing propofol. Subsequently, other 
outbreaks were reported (Bach & Motsch, 1996; Henry, Plante-Jenkins, & Ostrowska, 
2001; McNeil, Lasker, Lott, & Jarvis, 1999). Since then, it is recommended the addition of 
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a preservative to retard bacterial and fungal growth and to manipulated propofol in sterile 
conditions (Marik, 2004). 
Nevertheless, the most common complaint with the use of propofol is the pain at the 
injection site, with an incidence range between 28,5% (small veins) to 6% (large veins) of 
the patients (Mackenzie & Grant, 1987). For other side effects: see Table 3.4. 
 
Table 3.4. Propofol side effects. Adapted from Carrillo-Esper, Garnica-Escamilla, & Bautista-León, (2010). 
 
3.3.4.2. Midazolam 
Midazolam is a short-acting BZD with a unique chemical structure that is widely used as a 
preoperative agent due to its hypnotic, anxiolytic and sedative effects (Miller et al., 2011).  
MDZ has greater hypnotic effect and is 1,5-2 times as potent as diazepam (Reves, Fragen, 
Vinik, & Greenblatt, 1985), because interferes with GABA reuptake (Griffin III, Kaye, 
Bueno, & Kaye, 2013). 
3.3.4.2.1. Pharmacodynamics 
Midazolam has the properties of BZs:  anxiolytic, muscle relaxant, anticonvulsant, sedative, 
hypnotic, and anterograde amnesia (Miller et al., 2011). BZD receptors have been identified 
in the heart and skeletal muscle, although the predominance appears to be in the central 
nervous system (Kanto, Aaltonen, Erkkola, & Äärimaa, 1984), where MDZ´s affinity is 
approximately twice the affinity of diazepam (Grote, Doenicke, Kugler, Suttmann, & Loos, 
1981; Kanto, 1985). BZDs have a low incidence of respiratory depression due to the low 
concentration of binding sites in the brainstem (J. Kanto et al., 1984).  
The maximum clinical effect after IV infusion is reached in approximately 3 minutes 
(Amrein, Cano, Eckert, & Coassolo, 1980). 
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3.3.4.2.2. Mechanism of action 
As other BZDs, MDZ enhances the inhibitory action of the GABA, by augmenting Cl-; 
which in turns, prevent the cell to initiate an action potential (see also Chapter 2). There are 
specific binding sites on the γ-subunit of GABAA receptors, with the greater density being 
in the cerebral cortex. Midazolam action can readily be terminated by administration of the 
BDZ antagonist flumazenil (Miller et al., 2011).  
3.3.4.2.3. Pharmacokinetics 
After IV infusion, the onset of sedation is quite rapid, with maximum clinical effects seen 
in approximately 3 min (Amrein et al., 1980). This rapid onset is due to the high 
lipophilicity of midazolam at physiologic pH (Pieri et al., 1980).  This high lipophilicity 
couple with its fast clearance and elimination, which is the reason of it short time of action 
(Pieri et al., 1980).  
The volume of distribution (Vd) is 1-2.5 L/kg in normal healthy individuals but is greater in  
women than in men, in the elderly, and during pregnancy (Greenblatt & Abernethy, 1985; 
Reves et al., 1985), also obese patients have an increased Vd as a result of enhanced 
distribution to peripheral adipose tissues (Greenblatt & Abernethy, 1985; Reves et al., 
1985).  The time of action ranges between 60-120 minutes, and the elimination is fast also, 
with a half –life of 1-4 h (Dundee & Wilson, 1980). MDZ is metabolized in the liver and 
excreted via the urine (Heizmann & Ziegler, 1980). The total plasma clearance is higher in 
supine position due to the increase hepatic blood flow by about 40-60%  (Daneshmend, 
Jackson, & Roberts, 1981). The termination of the effect after one single dose of IV 
administration is fast due to the rapid distribution rate and clearance, and also is due to its 
lipid solubility, which leads to rapid redistribution from the brain to inactive tissue sites 
(Miller et al., 2011).  Generally, midazolam levels in the circulation are no measurable after 
5-6 hours of a single dose (Miller et al., 2011).  
3.3.4.2.4. Complications associated with the use of midazolam 
The incidence of adverse effects of midazolam is low, and even more in only one dosage 
treatment. Nevertheless has been associated with respiratory depression, cardiac arrest, and 
death, particularly when used in combination with opioids. See also Table 3.5. 
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Table 3.5. Midazolam side effects. Adapted from Kanto, (1985). 
 
3.3.4.3. Alfentanil 
Alfentanil is a synthetic tetrazole (phenylpiperidine), an opiate agonist (Van Bever, 
Niemegeers, Schellekens, & Janssen, 1975)  considered a major component of general 
anesthesia derivate of fentanyl (Ausems, Hug Jr, & de Lange, 1983; Bovill, Warren, 
Schuller, van Wezel, & Hoeneveld, 1984; De Lange & De Bruijn, 1982). Alfentanil has a 
fast onset of action (approx.. 2 minutes),  but is about eight times less potent than fentanyl 
(Howie, McSweeney, Lingam, & Maschke, 1985; White, Coe, Shafer, & Sung, 1986).  
3.3.4.3.1. Pharmacodynamics 
The binding of alfentanil to the opiate receptors inhibits the activity of adenylcyclase, 
manifesting itself as a hyperpolarization of the neuron, resulting in the suppression of 
spontaneous evoked responses. It may interfere with the transport of calcium ions through 
the membrane, and interfere with the release of neurotransmitters such as acetylcholine, 
dopamine or noradrenaline. Depression of cholinergic transmission in the CNS may play an 
important role in the analgesic effect as well as in side effects (Miller et al., 2011). 
Alfentanil does not alter the responses of the afferent nerve endings to noxious stimuli or 
alter the conduction of nerve impulses along the peripheral nerves (Stoelting & Hiller, 
1991). 
3.3.4.3.2. Mechanism of action 
Opioids induce anesthesia via interaction with opiate receptors in the CNS, due to a 
nonspecific mechanism related to the lipid solubility of the opioid (Dodson & Miller, 
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1985). The opioid receptors are transmembrane proteins whose activation induces reduction 
of spontaneous neuronal activity. These receptors are mainly found in the central nervous 
system (the anterior cingulate cortex, the lateral prefrontal cortex and the periaqueductal 
and periventricular gray matter), but also in other peripheral tissues(Ortiz & Lora-Tamayo, 
2009) .  
Alfentanil has a small volume of distribution that in addition to its non-ionized form with a 
physiological pH, allowed it to cross easily the blood-brain barrier (Ortiz & Lora-Tamayo, 
2009).  
3.3.4.3.3. Pharmacokinetics 
Alfentanil is considered as a short-acting drug (Miller et al., 2011). If administered IV, 
alfentanil has a onset of action that appears in 1-2 min with a peak effect in 1-2 min with a 
duration of action of around 10-15 min (Ortiz & Lora-Tamayo, 2009). 
Alfentanil has a smaller volume of distribution, lower total body clearance, and shorter 
half-life than fentanyl (Fragen et al., 1983; Hull, 1983; Mather, 1983). 
After IV injection, there is a rapid decline of plasma concentration during the first 15 
minutes, with almost total elimination from plasma in around 60 minutes (Camu, Gepts, 
Rucquoi, & Heykants, 1982). The metabolism is through the cytochrome P-450 in the liver, 
and it is excreted by urine. The mean clearance time for alfentanil is 70 to 98 minutes (Ortiz 
& Lora-Tamayo, 2009). 
3.3.4.3.4. Complications associated with the use of alfentanil 
 
Table 3.6. Alfentanil side effects. Adapted from Reitz, (1986). 
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3.3.5 Digit symbol substitution test (DSST) 
DSST (Wechsler, 1997) is a brief cognitive screening test of nine digit-symbol pairs and 
115 symbols that all participants had to pass to assess any group differences in general 
cognitive functioning at the time of story encoding and memory testing (see Figure 3.4.) 
The performance of the test consists of writing underneath of each symbol the number 
associated as fast as possible and with less errors as possible. The DSST was administered 
prior to the initial study session and prior to memory testing.  
 
Figure 3.4. Digit Symbol Substitution Test (DSST). Adapted from Wechsler, (1997). 
 
3.3.6. Multiple choice memory test 
Following the order of the 11 presented slides; 3–5 multiple-choice questions were posed 
per slide with 4 answer options. Each story has a total of 40 questions. An example of one 
of the questions is: “Who is depicted on the slide 2? a) Mother, b) Son, c) Mother and son, 
d) Mother and son, and another person in the background”. Questions have been selected 
on the basis of presence of variability and the absence of ceiling or floor effects in pilot 
studies (Kroes et al., 2014). Scores are expressed as percentage of correct responses. 
Memory performance on the first slide for both stories has been excluded from the memory 
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score, as this slide was used for memory reactivation. Testing memory for both stories 
required approximately 1 h.  
3.3.7 Procedures 
Once all the methods and material have been disclosure, the descriptions of the different 
experimental phases are as following:  
Experimental Phases: 
Emotional Memory Encoding. Once each participant arrived at the hospital, exactly one 
week before their endoscopy appointment, they were conducted at the consultation room 
where session 1 and 3 (Figure 3.1.) took place. After given written consent, they performed 
the Digit Symbol Substitution Test (DSST), a short screening test to avoid any cognitive 
malfunctioning. Then, all patients were exposed to the two emotionally aversive slide-show 
stories displayed on a computer screen. The slides were accompanied by the narration 
presented via computer loud speakers through the integrated device High Definition Audio 
(mean: 62 dB, in a range between 42-80 dB at 15 cm of distance). For each participant, the 
order of the two stories was randomized to safeguard against any learning differences due 
to the order of story presentation. Encoding session of both stories comprised 
approximately 15 minutes.  
Memory Reactivation. This session took place 1 week after the encoding session. Once 
the participant was supine in the hospital endoscopy room and the intravenous (IV) cannula 
placed, memory for one of the two stories was reactivated. Which of the two stories was 
reactivated was counterbalanced across participants within each Group (that is, for 12 
subjects in each Group, Story 1 was reactivated). To reactivate the memory and initiate a 
reconsolidation process, patients were presented with the first slide of one of the two 
stories. As said in the previous section (section 3.3.3.), parts of this slide, however, were 
masked by black-and-white checkerboard patterns. Patients were asked three questions on 
what was visible behind the mask. After the patient answered the question, the related part 
of the mask was removed, and the entire slide was visible after all three questions were 
answered. Answers were provided by free recall and recorded with a tape recorder by the 
investigator. If the patient was unable to answer freely, a two-alternative forced choice 
question was posed. Reactivation score was calculated as the number of questions answered 
correctly by free recall × 2 + the number of correctly answered questions by multiple 
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choice. Immediately following memory reactivation all patients received propofol and 
underwent their endoscopy. The reactivation session required approximately 1-2 minutes. 
General Anesthesia. All participants received propofol (2,6-diisopropylphenon); initial 
dose:  10-40 mg, additional doses: IV dose of 25-75 mcg/kg per minute; or incremental IV 
bolus doses of 10-20 mg. Furthermore, 27 of the 50 participants received additional agents, 
which included midazolam or phenylpiperidine derivatives, (fentanyl, alfentanil or 
remifentanil). 
Memory Testing. Memory for both stories was tested after 24h (Group A) or after 27-105 
minutes (Group B) using a multiple choice memory test. Following the order of the 11 
presented slides; 3–5 multiple-choice questions were posed per slide with 4 answer options. 
An example of one of the questions is: “Who is depicted on the slide 2? a) Mother, b) Son, 
c) Mother and son, d) Mother and son, and another person in the background”. Questions 
have been selected on the basis of presence of variability and the absence of ceiling or floor 
effects in pilot studies(Kroes et al., 2014). Scores are expressed as percentage of correct 
responses. Memory performance on the first slide for both stories has been excluded from 
the memory score, as this slide was used for memory reactivation. Testing memory for both 
stories required approximately 1 h.  
3.3.8. Results 
3.3.8.1 Participants 
A total of 50 participants completed the study (group A, N=25; group B, N=25). One of the 
participants of group B was discarded from further analysis because of an atypical 
difference between the encoding and the memory testing performance in the DSST which 
could indicate that this patient was still under the influence of the GA. Groups A and B did 
not differ in any demographical variable (age, gender, years of schooling or type of 
endoscopy procedure) (see Table 3.1). 
3.3.8.2 Anesthesia 
There was no group differences in terms of the amount of other anesthetic (midazolam or 
alfentanil) administered. Although, there is a significant difference (* p<0.05) in the 
amount of propofol administered, there is no correlation between this amount (kg/mg) of 
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propofol and the memory scores on both groups (rtotalReactivated=0,17, p=0,25; 
rtotalNonreactivated=0,03, p=0,86) (see Table 3.1). 
 
3.3.8.3 Memory reactivation does not differ between groups 
Both groups showed memory reactivation being the performance at reactivation above 
chance level (33%, dashed line). Group A (red) mean: 4.2, s.e.m.: 0.30; group B (blue) 
mean: 3.87, s.e.m.: 0.34.  
 
 
Figure 3.5. Memory reactivation scores for groups A and B. No significant differences between groups. 
Dashed line indicates chance level (33%).  
 
3.3.8.4. No difference in general cognitive functioning between groups as assessed by 
the DSST 
The DSST was administered two times, one before the encoding of both stories and the 
other one, before the recognition memory test. There is a significant effect of learning in 
the performance of the DSST in Group A (p<0.05), between the encoding administration 
and the recognition test administration. For Group B, there is no effect of learning in the 
performance probably because the participants remained under the effects of GA at the time 
of the recognition test administration. Between groups there is no difference in general 
cognitive functioning.  
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Figure 3.6. Digit Symbol Subsitution Test (DSST) performance for Group A and B.  The DSST is a 
brief screening cognitive test, used in this study to avoid any group differences in general cognitive 
functioning. Group A (red) has a significant effect of learning (* p<0.05), while group B (blue) has not, 
probably because pacientes remained under the effects of anesthesia. 
 
3.3.8.5 Anesthesia disrupts reactivated emotional memory 
Both stories consisted of three phases whereby Phase 1 (slides 1-4) and Phase 3 (slides 9-
11) were of neutral content. The middle part of the stories, Phase 2 (slides 5-8), had an 
emotional content. We first performed a Group (A, B) by Reactivation (yes, no) by Phase 
(1,2,3) repeated measures ANOVA (rmANOVA). Thereby, the quadratic contrast of Phase 
entered into the model as we hypothesized a specific memory effect on the emotional part 
of the stories that would be expressed by a quadratic contrast (phase 1 > phase 2 < phase 3). 
We observed a three way interaction of Group by Reactivation by quadratic Phase contrast 
at trend level [F (1,47)=3.03, p=0.09]. Given our hypothesis, the reactivation-dependent 
memory effect should be present only in group A and not in group B. Therefore, we fitted 
an rmANOVA with an interaction term of Reactivation by quadratic Phase contrast for 
each group separately. 
Group A showed a significant Reactivation by quadratic Phase contrast [F(1, 24) = 6.51, p = 
0.018] , whereas this effect was absent in group B [F(1, 24)  < 0, p = 0.98].  
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For the reactivated story in group A, there is a significant quadratic Phase contrast   [F 
(1,24)=5.73, p=0.025] (Figure 3.7); while for the non-reactivated story the quadratic phase 
contrast is not significant [F(1,24)= 5.77, p=0.46] (Figure 3.8). This memory impairment for 
the emotional part of the story (Phase 2) is further reflected by significant differences 
between the not reactivated and reactivated versions of the stories [tphase2 (24)= -3.05, p= 
0.006]. In contrast, for the neutral parts of the stories (Phases 1&3) reactivation did not 
result in any memory decline [t phase1 (24)= -0.56, p= 0.58; t phase3(24)= -1.20, p=0.91]. 
 
 
Figure 3.7.Group A (red) (n=25 subjects): General Anesthesia disrupts reconsolidation of the emotional 
phase (Phase 2) of the reactivated story if tested after 24 hours. Memory scores expressed in percentage 
correct for the different phases of and the non-reactivated story. There is a significant impairment of the 
memory of the emotional phase of the reactivated story (* p<0.05). --- Indicates chance level. 
 
Figure 3.8 Group B (blue) (n=24):General anesthesia does not diminish emotional memory of the 
reactivated Story if tested immediately after recovery of GA. Memory scores expressed in percentage 
correct for the different phases of the reactivated and the non-reactivated story. 
 
 
Possible group differences in propofol dose may have contributed to the specific memory 
effects for group A.  Indeed, a two-sample t-test revealed a significant propofol dose 
difference between groups [t(47)=2.04, p= 0.05], group A having received a higher dose 
(mean= 3.02 mg/ kg, s.e.m.=0.25) than group B (mean=2.37 mg/ kg, s.e.m.=0.19). 
However, there was no linear association between the dose of propofol and Phase 2 
(emotional) recognition scores in group A (rreactivated =0.22; p=0.3; rnon-reactivated= -0.007; 
p=0.97), and in group B (rreactivated =0.12; p=0.56; rnon-reactivated=-0.005; p=0.98). Therefore, 
Figure 3.7. Group A (n=25 subjects)                                                         Figure 3.8. Group B (n=24 subjects) 
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the specific memory impairment for the emotional story part in the reactivated group A 
cannot be accounted for by propofol dose (see Figure 3.9.).  
 
Figure 3.9. Dose of propofol and memory score in phase 2 (emotional) for groups A (red) and B (blue). 
Linear correlation between the amount of propofol (mg/kg) and the percentage of memory score for Phase 2 
(emotional) of the reactivated and no reactivated story, in both groups (A & B). There is no linear relationship 
between both variables; the memory impairment in Phase 2 in the reactivated story of Group A does not  
depend on the amount of propofol. 
 
An alternative or additional explanation is that the emotional memory decrease is driven by 
vagal nerve stimulation. Vagal stimulation can occur either at the time of passing the 
endoscopy in to oesophagus or the stretching of the sigmoid mesentery during colonoscopy. 
These effects would be additive in those individuals undergoing both gastro- and 
colonoscopy. Given that reconsolidation effects in Group A are equivalent across the 3 
interventions [F(1,44)=1,36;  p= 0,26], it is unlikely that vagal stimulation contributes to the 
memory effects we observe. 
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3.4. Discussion 
This data provides evidence of the disruption of emotional episodic memories by 
administration of the anesthetic propofol after reactivation. The results satisfy critical 
criteria for account reconsolidation in humans. Also, it is shown that the memory 
impairment is not due to any new learning at the time of reactivation that could produce 
interference at the time of retrieval, but relative to the administration of a GABA agonist 
such as propofol.  
Previously, pharmacological manipulation of reconsolidation in humans has focused on the 
β-adrenoceptor blocker propranolol. The potential clinical risk of using β-blockers to 
manipulate reconsolidation is lower than other pharmacological interventions such as the 
one used in this study (propofol). As mentioned before (see Chapter 1 and 2), memory 
reactivation and propranolol oral intake are able to affect some threat-related responses 
(i.e.: startle responses), without affecting the  conscious knowledge (i.e.: episodic memory) 
of the fear (Kindt et al., 2009). Apart from the benefit of reducing the physical responses 
related to fear, we should not overlook the fact that many psychiatric disorders (i.e.: PTSD, 
addictions) have episodic memory at their etiological basis. This episodic memory may 
contribute to the negative symptoms experienced, or to a possible relapse of the 
physiological fear-related responses. So, it is desirable to alter these episodic memories as 
well. Several studies have administered propranolol to target reactivated episodic 
memories. Nevertheless, there are two basic problems when trying to alter memories with 
propranolol that cannot be ignored. Due to its pharmacological features, propranolol needs 
approximately 90 minutes to reach its maximum peak in plasma, which forces 
experimenters to administer the manipulation before reactivation. This prior manipulation 
violates one of the three critical criteria of reconsolidation, which states that in order to 
achieve reconsolidation, manipulations have to be done immediately after reactivation. 
However, as we have pointed out, if the administration of propranolol is performed after 
manipulation, it takes 90 minutes to reach the maximum effect of the drug, which exceeds 
the time-window available for the reactivation and manipulation of a memory, thus 
violating other of the three critical criteria. 
Nevertheless, studies with clinical populations (i.e.: PTSD), have suggested the use of β-
blockers (i.e.: propranolol) to block reconsolidation as a novel treatment for PTSD, 
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characterized by maladaptive emotional episodic memories (Wood et al., 2015). In the 
Brunet et al., (2008, 2011, 2014) studies using propranolol and a script-driven imagery 
technique with PTSD patients, the experimenters showed reduced levels of skin 
conductance response (but not below PTSD cut-off levels) and a reduction of PTSD 
symptoms. Reductions were maintained over the course of six weeks follow up. However,  
attempts to replicate these results (Wood et al., 2015) failed to support successful reduction 
of PTSD symptoms with blockade of reconsolidation, demonstrating the limited success of 
treating this psychiatric disorder by combining propranolol and memory reactivation.  
The oral dose of propranolol that can be well-forward by humans (because of its 
hypotensive effects) is typically 40-80 mg. this dose may, however, be insufficient to exert 
a cognitive effect (reconsolidation). However, administration of propranolol that produces 
no lag in time to peak effect would be intravenous route, but is not possible, since 
intravenous (IV) administration is only prescribed for patients with life-threatening.  
The emotional effect on memory involves the integrity of the basolateral nucleus of the 
amygdala (Quirarte, Roozendaal, & McGaugh, 1997), which is thought to enhance memory 
consolidation via interaction with other structures such as the hippocampus (Packard, 
Cahill, & McGaugh, 1994). The effectiveness of noradrenergic antagonist in 
reconsolidation of emotional episodic memories is limited (Muravieva & Alberini, 2010).It 
is unclear, if this limitation is due to the targeted brain regions or to the intrinsic properties 
of the propranolol, or both.  
In a previous study, using ECT with therapy-resistant unipolar depression patients, an 
impairment of the reactivated episodic memory following the critical criteria of 
reconsolidation was shown (Kroes et al., 2014). Prior to ECT, an anesthetic, etomidate, was 
administered, to minimize ECT adverse effects. Nevertheless, it was not possible to 
elucidate whether reconsolidation impairment was due to the ECT or to the general 
anesthesia (GA). The hypothesis presented in this thesis was that if the GA was 
responsible, targeted memory reconsolidation in psychiatric patients could be done without 
ECT, which is an invasive procedure. Even more, there is recent evidence that frontal ECT 
alters functional connectivity of the frontal lobes (Perrin et al., 2012). For its part, 
etomidate is generally used in short surgical procedures due to its benign hemodynamic 
effects, but suppresses adrenal function transiently, and thereby suppressing cortisol levels, 
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even after a single bolus (Forman, 2011; Hohl et al., 2010). The adrenal suppression lasts 6-
8 hours after a single bolus (Allolio, Stuttmann, Leonhard, Fischer, & Winkelmann, 1984; 
Fragen, Shanks, Molteni, & Avram, 1984); or more than 24 hours after etomidate infusion 
(Wanscher, Tønnesen, Hüttel, & Larsen, 1985). Cortisol levels impair memory retrieval at 
both, very low or very high levels, but not intermediate levels. The shape of the relationship 
between cortisol levels and memory retrieval is like an inverted-U, and it is originated by 
the different affinity of the mineralocorticoid receptors (MR) and the glucocorticoid 
receptors (GR). (Rimmele, Besedovsky, Lange, & Born, 2013). Given this modulatory role 
of cortisol on memory it is important to control for this.  
Thereby, to test the hypothesis, it was decided not to use etomidate, but propofol. Propofol 
is one of the IV anesthetic of choice in ambulatory procedures for outpatients due to its 
rapid induction of anesthesia and recovery (Trapani et al., 2000). The mechanism of action 
is similar to other anesthetic agents (i.e.: etomidate), resulting in a positive modulation of 
the inhibitory function of GABA through GABAA receptors (Trapani et al., 2000). As 
described above, we have been able to impair emotional memory with a single dose of 
propofol, following all critical criteria of reconsolidation.  
Animal studies suggest that BLA lesions do not produce memory impairment effects when 
propofol is administered, demonstrating that BLA is a key brain region that mediates 
anesthetic-induced amnesia (Alkire, Vazdarjanova, Dickinson-Anson, White and Cahill, 
2001). It has also been suggested that anesthetics that act on GABAA receptors (i.e., 
propofol) decrease NA from noradrenergic LC neurons (Kushikata, Hirota, Yoshida, & 
Kubota, 2002; Kushikata, Yoshida, Kudo, Kudo, & Hirota, 2011). 
There is increasing evidence that BLA is not a place for storing emotionally modulated 
memories (Paré, 2003), but may facilitate storage in other regions of the brain, such as the 
hippocampus through efferent connections. Specifically, there is a study in humans that 
reported that the structural equation modeling of PET glucose data shows that 0.25% of 
sevoflurane suppresses the amygdala to effective hippocampal connectivity (Alkire et al., 
2008). If a similar mechanism exists for the reconsolidation process, it is possible to infer 
that the mechanism behind the deterioration of episodic emotional memories by propofol 
after reactivation is through the BLA and its connections with the hippocampus. Basolateral 
amygdala is a brain region that is tightly regulated by a small population of GABA 
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inhibitory neurons (Prager, Bergstrom, Wynn, & Braga, 2016). Moreover, disruptions in 
GABAergic control of the BLA after trauma results in hyper excitability that manifests 
itself behaviorally as an increase in anxiety or emotional dysregulation (Prager et al., 2016), 
and correlates positively with PTSD symptom severity (Shin & Liberzon, 2010). The 
modulating effect of GABA on the release of NA would specifically affect the 
reconsolidation of the emotional memories, producing a more evident deterioration of the 
same memories by the suppression of the connection between BLA and the hippocampus 
due to the anesthesia.  
One of the boundary conditions of reconsolidation pertains to temporal parameters, such as 
the age of the memory; older memories seem to be more resistant to undergo 
reconsolidation (Golkar et al., 2012), making the application of reconsolidation difficult to 
translate to real life clinical therapies. A limitation of this study is that it was not tested if 
the memory impairment lasts over time. A third experimental group would have been 
needed, with a longer time interval between the reactivation session and the memory test 
session (i.e.: an interval of one week) to test if our impairment is not temporary, but long-
lasting.  
A second limitation is that a single dose of propofol affects recent (one week) emotional 
memories. However, the memories of real life, which underlie psychiatric disorders, are 
often old. The repetition of the reactivation and the treatment can be beneficial to modify 
older memories. Addressing the number of sessions required to achieve maximum 
effectiveness is necessary. That is, for older memories, a certain minimum number of 
sessions may be necessary, and there may be a maximum number of sessions above which 
there is no further therapeutic benefit (Brunet et al., 2011, 2014). Another challenge when it 
comes to reactivating real life memories is to find the right “cue” that would elicit 
reconsolidation. For this, today it is possible to employ virtual reality. Virtual reality could 
be a useful tool for reactivating individual memories with a combination of script-driven 
imaging techniques, making it possible to individualize the process and find the specific 
cues (in features and time of presentation) to reactivated specific memory real-life trauma.  
Future studies are needed to improve the understanding of the reconsolidation process and 
how it works in real life and to delineate the criteria and critical factors needed to make 
reconsolidation and the underlying processes in the treatment of clinical populations more 
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efficient and useful. One further marked question is whether positive valance emotional 
memories are affected as well.  
The results presented in this thesis bring closer the possibility of modifying certain types of 
memories. Once in their lives a large proportion of the general population is exposed to 
situations in which their lives or those of others may be endangered. The traumatic 
experience can leave a memory footprint that entails dysregulated emotional learning that  
contributes to anxiety disorders (Ressler & Mayberg, 2007; Williams et al., 2007).   
Anxiety is a frequent response to recalling negative episodic memories (McNally, 2003), 
and usually it is at the core symptom of certain disorders driven by amygdala-centric fear 
pathways, such as specific phobias or post-traumatic stress disorder (PTSD) see (Garakani, 
Mathew & Charney, 2006).The aim of this study was to find a technique to reduce 
unwanted and maladaptive memories in a relatively non-invasive way, by reactivating these 
memories before a dose of general anaesthetic is administered. Although the results 
presented here pertain to decreasing memory in healthy individuals, they provide an 
empirical basis that a routine anaesthetic procedure, that is available worldwide, could 
potentially be used to treat or support treatment of disorders such as PTSD, addictions, 
phobias and obsessive-compulsive disorder. The benefit of the patients could not only be an 
improvement in their daily life, but also reduce the social stigma attached to mental illness 
by showing it to be (at least partly) an abnormal memory process that can be treated with 
the same pharmacological agent you would have if your appendix were to be surgically 
removed. 
3.5. Conclusions 
We hypothesized that the impairment of memory shown in our previous work using ECT 
would be due to the anesthesia and not to the ECT itself, or the posterior seizures (Kroes et 
al., 2014). Using a single dose of a routine anesthetic, propofol, and following critical 
criteria of reconsolidation, we have been able to reveal an impairment of memory relative 
to the emotional phase of the story compared to neutral phases. This memory impairment 
has been showed only for the reactivated story, and only if tested 24 hours after reactivation 
(Group A), not after a short period of time (Group B). 
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Chapter 4 
Administration of a β-adrenoceptor 
antagonist to block the action-induced 
episodic memory enhancement 
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4.1. Introduction 
To address how movement modulates episodic memory in humans our group (Yebra et al., 
2017; submitted) has performed a set of experiments related to the encoding of a visual 
stimulus in the context of simultaneous voluntary movement in comparison to withholding 
a movement (a Go-NoGo task, via button press if indicated by contextual cues; described 
below). The initial behavioural experiments, performed previously by Yebra et al., (2017, 
submitted), have shown that voluntary movement can enhance memory encoding. Also, it 
has been described that this mnemonic boost is not regulated by an effect of anticipated 
financial reward, as should be expected according with recent data suggesting that the 
expectation of reward influences memory performance, enhancing memory for events that 
are worth acting for (Koster, Guitart-Masip, Dolan, & Düzel, 2015). Likewise, those 
previous experiments shown that inhibiting (“NoGo condition”) an action does not impair 
the subsequent episodic memory. To ensure that the memory impairment was not related to 
inhibitory activity, a variable temporal asynchrony in the presentation of the stimuli was 
employed. Previous electrophysiological studies (Falkenstein, Hoormann, & Hohnsbein, 
1999; Kiefer, Marzinzik, Weisbrod, Scherg, & Spitzer, 1998; Mecklinger, Parra, & 
Waldhauser, 2008) of the effect of response inhibition on event related potentials (ERP) 
have shown changes in the amplitude and topography of different waveforms during 
response inhibition at ~200-300 ms. So Yebra et al., (2017, submitted) manipulated the 
stimulus presentation time at different 250 ms time windows. The time windows 
presentation had 3 different onsets of the stimuli, at 0s, at 250 ms and at 500 ms (0-250, 
250-500, 500-750 ms) for both conditions (Go and NoGo). The colored background frame 
that indicated the instruction to press or not a button was presented from 0 to 750 ms. The 
results showed no higher memory impairment for the NoGo memory for the 0-250 ms 
presentation, which would be predicted by a NoGo-induced memory impairment 
(Falkenstein et al., 1999; Kiefer et al., 1998; Mecklinger et al., 2008).  
A range of subsequent experiments were done, in order to assess the underlying neural 
mechanism behind the memory enhacement including fMRI, pupilometry and manipulation 
of stimulus arousal. Recent data have linked parahippocampal-locus coeruleus connectivity 
to memory in healthy individuals (Jacobs et al., 2015). The results obtained in the fMRI 
study by Yebra et al. (2017, under revision) supported the action-induced memory 
enhancement associated to an increased LC activity coupled with the parahippocampal 
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gyrus (PHG). Also, pupilometry data, that associates pupil diameter and neural activity in 
the LC (Joshi, Li, Kalwani, & Gold, 2016), linked the memory enhancement with LC 
activation. Thus, both fMRI and pupilometry indicated an underlying noradrenergic 
mechanism. NA is behind the memory enhacement for emotionally adverse relative to 
neutral events  (LaBar & Cabeza, 2006; Strange & Dolan, 2004; Tully & Bolshakov, 2010). 
Based on the Yerkes-Dodson law (Yerkes & Dodson, 1908), that establish an inverted-U 
shaped for the relationship between arousal and cognitive performance, Yebra et al., (2017, 
submitted) performed a last experiment with emotionally negative and neutral stimuli. It 
was hypothesized that if during encoding, two features of the stimuli (emotionality and Go 
cue) that increase NA release happen at the same time, the encoding performance would be 
predictable due to the influence of the NA. The results indicated that the action-induced 
episodic memory enhancement was modulated by emotion.   All results together provided 
evidence that the memory enhancement associated to movement (Go-press button) during 
encoding was associated with increased LC activity, and its interaction to medial temporal 
structures through a noradrenergic (NA) mechanism. Nevertheless, pharmacological 
evidence is needed in order to ensure the involvement of NA in the modulation of the 
episodic memory driven by movement. Propranolol is a non-selective β-adrenergic 
antagonist. At therapeutic doses, propranolol slightly decreases heart rate (approx. 15%) 
and the supraventricular conduction of cardiac output (15 to 20%) (Johnson, Roberts, 
Sobieszek, & Straughan, 1969). Cardiac work, oxygen consumption and secretion of renin 
(an enzyme that helps to regulate the body’s water balance and blood pressure level) are 
also decreased (Johnson et al., 1969). Propranolol is lipid soluble and also has sodium 
channel blocking effects. Propranolol crosses easily the blood–brain barrier with effects in 
the central nervous system, besides its peripheral activity (Steenen et al., 2016).   
Propranolol is virtually completely absorbed after oral administration from the 
gastrointestinal tract (Paterson, Conolly, Dollery, Hayes, & Cooper, 1970). However, after 
high first pass metabolism and hepatic tissue binding, the total bioavailability is only 
approx. 30%, and varies greatly between individuals (take into consideration when used in 
pilot studies with healthy population) (Frishman, 1979; Goodman, 1996). Maximum peak 
plasma concentrations of propranolol are seen at approximately 90 minutes after oral 
administration (Lowenthal, Briggs, Gibson, Nelson, & Cirksena, 1974; Parsons, Kaye, 
Raymond, Trounce, & Turner, 1976; Paterson et al., 1970; Shand & Rangno, 1972). 
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Administration of food does not significantly change the time to peak levels in healthy 
individuals (Melander, Danielson, Scherstén, & Wåhlin, 1977).  
About 90 to 95 % of the drug is bound to plasma proteins. The volume of distribution (Vd) 
is 3.9 L/kg,  (approximately 200 L in an adult) (Paterson et al., 1970).The plasma half-life 
(t1/2) is 3 to 6 hours. The total body clearance is 800 mL/minute/1.73 m2. Propranolol is 
extensively metabolized by the liver, being completely eliminated after oral administration 
in 48 hours. This hepatic metabolism can be saturated, which would increase the 
bioavailability when overdoses (Paterson et al., 1970).  
4.2. Hypothesis 
Taking an action, produces activation of the LC and NA release;  if the action-induced 
memory enhancement is related to the connections between the LC and the 
parahippocampal gyrus, and modulated by the NA system, then, should be block by the 
administration of a non-selective central β-adrenergic antagonist.  
Our hypothesis was that β-adrenergic blockade would modulate the Go-induced memory 
enhancement at encoding. For this reason, it was important that the propranolol had washed 
out before the recognition test. However the prior studies, presented in Yebra et al., (2017, 
submitted), involved only one hour delay between study and test. We therefore were 
required to perform pilot studies of the psychological task prior to performing the 
psychopharmacological study with the 24 hour interval between study and test. The new 
design of this experiment involves changing the stimulus type, from black and white 
objects to color pictures taken from the International Affecting Picture System (IAPS) 
database. Only neutral items from this database were taken. To ensure a correct percentage 
of correct recognition performance after 24 hour delay we also reduced the number of 
stimuli from 91 in prior studies by Yebra et al., (2017, submitted) to 68 in the current study. 
After the first 17 subjects were piloted, we realized that a number of the neutral IAPS 
stimuli belong to the same semantic category and that this was influencing recognition and 
false alarms rates. These stimuli were replaced with other stimuli and the pilot continued 
for a further 8 subjects.  
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4.3. Methods and materials 
In this section, prior to explaining in detail the procedure of the administration of 
propranolol before the performance of a GoNoGo task, the participants and the stimulus 
material for the encoding and memory session will be described. In order to ensure 
maximum safety of the participants, different measures of the blood pressure (BP), as well 
as an electrocardiogram (ECG) were performed, and will be described as well in this 
methods and material section.  
4.3.1. Participants 
Participants were recruited from the Hospital Nacional de Parapléjicos, Toledo. A total of 
32 psychiatrically and neurologically healthy volunteers (16 females and 16 males) (Table 
3.1.) from the Nursing and Physiotherapy schools of the Universidad de Castilla-La 
Mancha, with an age range 18-30 years (both ages included) (mean: 21,25, SD: 1,88), 
normal or corrected to normal vision and hearing participated in the study. All participants 
were free of neurological or psychiatric medication, or any other medications 
contraindicated with the use of propranolol (see Exclusion Criteria, section 4.3.2.). 
Participants were asked to join the study, and gave written informed consent; they all 
received 40 euros as expenses of transportation at the end of the study (day 2). The Ethical 
committee of the Hospital Nacional de Parapléjicos approved the study and all participants 
were informed of the procedures to be carried out before they provided written informed 
consent. Participants were randomly assigned to one of the two conditions (Placebo or 
Propranolol) in a double-blind procedure. Randomization was carried out by envelopes 
balanced for gender and previously randomized. Both groups showed similar age [Placebo 
group (mean: 21,l2; s.e.m.: 0,45) and Propranolol group (mean: 21,37; s.e.m.: 0,50)], and 
educational level [years of schooling: placebo group (mean: 14, 56; s.e.m.: 0, 22) and 
propranolol group (mean: 15,00; s.e.m.: 0, 20)] (see Table 4.1.).  
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Table 4.1. Participant´s demographics and clinical details. Thirty two participants (sixteen per group) 
completed the study. Groups were balanced for gender prior to randomization. Placebo group and Propranolol 
group did not differ in any demographical variable (age or years of schooling). Both groups did not differ in 
systolic/diastolic BP at the baseline or at the recognition session, but at the time of the encoding task, 90 
minutes after pill administration, there is a significant difference in systolic (p=0,001), diastolic (p=0,003) and 
heart rate (p=0,000)  between propranolol and placebo group, evidencing the effectiveness of the 
pharmacological manipulation. a Independent (unpaired) samples t-test.  
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4.3.1.1. Exclusion criteria 
 
 
Table 4.2. Exclusion criteria. 
 
4.3.2. Procedure 
Once the participants arrived at the hospital, a baseline electrocardiogram (ECG) and blood 
pressure (BP) measurements were performed to ensure no contraindication to beta-
blockade. This task was carried out in the Internal Medicine Service of the Hospital 
Nacional de Parapléjicos and was organized by the head of that service. Participants took 
the pill (propranolol 40mg or placebo) administered by the experimenter in charge of the 
study at the hospital in a double-blind condition. In view of the kinetics of propranolol’s 
peak plasma concentration (1–2 h), the “Go-NoGo” task started 90 min after drug 
administration. The surprise memory recognition task of the pictures was performed the 
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next day (24 hours after), but previously blood pressure was taken again, once the 
participants arrived at the hospital (see Figure 4.1.; see Table 4.1.).  
 
 
Figure 4.1. Study design. During day 1, once participants arrived at the hospital, ECG (electrocardiogram) 
and BP (blood pressure) were taken by the internal medical service of the hospital. Once the measurements 
were taken, the experimenter in charge, in a double-bling design study, gave the participants propranolol 40 
mg or placebo. After 90 min, participants performed the computer task. On day 2, BP was taken again, and 
then a surprise memory task was displayed in the computer. Once participants finished the memory task, they 
received 40 euros in expenses of transportation and left the hospital. Figure:  To take BP, participants were 
lying on a stretcher with their upper body reclined at a 45-degree tilt. 
 
4.3.3. Experimental Phases 
4.3.3.1. “Go-NoGo” task 
For the visual stimulus encoding a total of 68 gray-scale photographs of objects (from the 
International Affective Picture System (IAPS) database) were presented in randomized 
order. Image presentation time was 250 ms, with a variable ISI (interstimulus interval) from 
2.3 to 3.3 seconds. Participants were instructed to press a button (“Go” trials) when the 
images were presented with a particular color frame (yellow or blue). The condition of the 
“Go” or “NoGo” was determined by the color of the frame, and this condition was balanced 
across participants. Both colors of the frame (Go vs NoGo condition) had the same 
probability of appearance (i.e.:  both at 50% probability). Participants were instructed to 
look at the center of the computer screen. Before the task began, the instructions would be 
displayed at the computer screen, and participants had as much time as they needed to learn 
the instructions. After, the stimuli presentation would begin. All images would be displayed 
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with 22-23 degrees of visual angle at a viewing distance of approx. 30-50 cm, on a 16-inch 
computer screen. 
4.3.3.2. Recognition task 
Participants returned the following day (24 hours later) to perform a surprise recognition 
test. A total of 136 images (the 68 that were presented at the time of encoding and 68 new 
“foils”) were presented in randomized order with no frames on a black background. The ISI 
was from 2.8 to 3.3 seconds. Participants were not aware of this test, since they were told at 
the time of the instructions that they would repeat the same task as day 1 but without the 
influence of the drug. The task was carried out in the same room and with the same 
computer as in the previous day. Participants were required to indicate whether they 
remember (R), were familiar with (K) or did not remember (forgotten, F) the image from 
the encoding phase (see Figure 4.2.).  
As exclusion criteria, only participants performing over 50% of correct button press for the 
Go and 50% of correct not- button press for the NoGo condition were included in the study 
(for exact number of participants, see below).  
 
 
Figure 4.2. Instructions for the surprise recognition task. The keys corresponding to the Remember 
condition (“La recuerdo”), Familiarity condition (“Me suena) and the Forgotten condition (“No la recuerdo”) 
instructions were randomized. 
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4.3.4. Results 
4.3.4.1. Participants 
A total of 32 participants completed the study (Propranolol group, N=16; Placebo group, 
N=16). One of the participants from the placebo group (placebo final N=15), and two 
participants from the propranolol group (propranolol final N=14) were discarded from 
further analysis because of a low performance (≤ 50%) of correct button press for the Go 
condition.  
4.3.4.2. Propranolol versus placebo 
 Figure 4.3. shows that the administration of the treatment [propranolol (blue) or placebo 
(orange)] was effective. The systolic blood pressure (SysBP) (mmHg) at the time of 
encoding (90 min after the pill intake) of the images is significantly different between both 
groups [t(27)=3,908, *p=0,001] (see Figure 4.3.). In the propranolol group, the difference 
between systolic BP at the time of encoding is significantly different when compared to 
baseline [t(13)= 5,07; p= 0,000] and when compared to the systolic BP at the time of 
recognition [t(13)= -3,28; p= 0,006]. There was no difference systolic BP at baseline vs at 
recognition test [t(13)= 0,26; p=0,79]. In the placebo group, there was no difference in 
SysBPs among the 3 measurements.  
 
Figure 4.3. Systolic blood pressure (BP) (mmHg) at the time of the encoding. After 90 minutes of the pill 
intake, there is a significance difference in the systolic BP (mmHg) (*p< 0,001) between the placebo group 
(orange) and the propranolol group (blue) when performing the encoding task. 
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4.3.4.3. Performance at the encoding task 
There is no significant main effect or interaction of treatment in a rmANOVA (Groups x 
condition), F(1,27)=0,19, p=0,67 (see table 4.3.); (see Figure 4.4.).  
 
Table 4.3. Performance at encoding. 
 
Figure 4.4. Performance at encoding. Percentage of correct press Go and correct Non-press NoGo.  
There is no significant effect of treatment in the performance of the encoding task (p>0,05). Error bars pertain 
to the standard error of the mean (s.e.m.) 
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There is no significant difference between groups in the reaction time (RT) at the encoding, 
t(27)=1,25, p=0,22 (see table 4.4., Figure 4.5.). 
 
Table 4.4. Reaction time at encoding. 
 
 
Figure 4.5. Reaction time at encoding. There is no significant difference between placebo and propranolol 
groups.  
 
4.3.4.4. Recognition main effect of memory does not differ between groups 
In an rmANOVA [(Go remembered and NoGo remembered) x (placebo vs. propranolol)] 
there was no group main effect at the recognition memory test [F(1,27)= 0,12; p= 0,74] (see 
table 4.5.); (see Figure 4.6) 
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Table 4.5. Performance at Recognition task. Percentage of correct remembered minus false alarms, for the 
Go and NoGo stimuli.  
 
 
Figure 4.6. Recognition memory test. Recognition memory test (%) (correct hits minus false alarms) for 
the Go and NoGo condition. There is no significance difference between propranolol-placebo groups (p>0,05) in any of 
the recognition measures. Error bars pertain to s.e.m. 
 
There is also, no significant difference between groups for the familiarity (K)  Go-NoGo 
memory performance (p>0,05). 
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4.3.4.5. Significant linear correlation between Systolic BP and Go minus NoGo 
difference in recognition memory 
BP was measured at three different time points. At the baseline measurement, there is no 
significant difference between both groups (p>0,05). At the time of encoding, 90 minutes 
after the pill intake, there is a significance difference in systolic BP between both groups 
(see Table 4.1., Figure 4.3.) (p< 0,001), which indicates that the pharmacological treatment 
had exerted a hypotensive effect.  
However, possible differences in systolic BP, a measure of sympathetic tone, may 
contribute to the memory effects. Indeed, there is a linear correlation between systolic BP 
and memory score (“Go minus NoGo” correct remember) (r =0, 38; p =0,042) collapsing 
across therapeutic groups (see Figure 4.7.). Therefore, the specific memory impairment for 
the “Go” condition can be accounted for by the BP, but without specific effect of the 
treatment condition.  
 
 
Figure 4.7. Significant linear correlation between the “Go minus NoGo” recognition score and the 
systolic BP. The lower is the systolic BP, the lower is the “Go” remember percentage. Propranolol group 
(Blue); Placebo group (orange).  
 
Moreover, the linear correlation between the Go minus NoGo recognition score and the 
systolic BP at the time of the encoding is significant for the placebo group (rplacebo= 0,60, 
p=0,018). While, in the propranolol group, this relationship is not significant 
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(rpropranolol=0,40, p=0,165) (see Figure 4.8.). Even though the placebo group did not show 
the expected Go-NoGo effect on memory, there is a significant relationship between the 
arousal experienced by the participants (higher arousal is indicated by higher systolic BP) 
and the memory performance; higher arousal is related with better memory for the Go 
stimuli. In the propranolol group, this relationship between systolic BP at the time of 
encoding and memory is blocked by the administration of the drug.  
  
 
Figure 4.8. Placebo group (orange) Significant linear correlation between the “Go minus NoGo” 
recognition score and the systolic BP; Propranolol group (blue) non-significant linear correlation 
between the “Go minus NoGo” recognition score and the systolic BP at the time of encoding .The greater 
is the systolic BP, the greater is the “Go” remember percentage in the placebo group (*p<0,05).  
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Figure 4.9. Median split of the systolic blood pressure for each group (placebo, orange; propranolol, 
blue). Median split to separate each group into high and low systolic blood pressure, and the recognition 
memory (%) for the Go and NoGo stimuli. Higher is the SysBP, higher recognition memory for Go stimuli in 
both groups (placebo and propranolol). Abbreviations: SysBP, systolic blood pressure.  
 
In order to demonstrate the relationship between higher BP and higher recognition memory 
(%) for the Go stimuli a median split (to form high and low systolic BP groups, for 
compare the recognition memory for the Go and NoGo stimuli) was done for each group 
(see Figure 4.9.). The higher is the SysBP, higher is the recognition memory for the Go 
stimuli. While the lower is the SysBP, the Go-NoGo effect disappears, and the memory for 
the Go stimuli is lower than for the NoGo in both groups (placebo and propranolol).  
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4.4. Discussion 
In previous studies (Yebra et al, 2017, submitted) (see also chapter 2, section 2.7.) a 
consistent boost of memory for the “Go” stimuli has been shown, compared to the “NoGo” 
condition. This memory enhancement was linked to the action of a button press during the 
encoding session, and related to an enhacement of NA from the LC. As highlighted before, 
LC is the major source of NA to the majority of brain regions, including MTL. Besides the 
facilitation role of the NA in the interaction of different brain structures in charge of 
different cognitive domains; LC and the related NA released take part in the encoding of 
relevant events (Cahill, Prins, Weber & McGaugh, 1994). LC  is also known to have a key-
role in memory consolidation and retrieval (Sara, 2009). Using f-MRI measurements, 
Yebra et al., (2017, submitted) were able to show a functional relationship between the LC 
and the parahippocampal gyrus (PHG) during successful encoding of the Go stimuli 
compared to the NoGo stimuli. PHG is a relevant brain area for episodic memory, related to 
successful encoding and retrieval (Eichenbaum & Lipton, 2008). This functional 
connectivity is in line with another study that has related LC and MTL functional 
association during memory processes for neutral stimuli in healthy individuals (Jacobs et 
al., 2015). Nevertheless, in order to ensure that the “Go” memory enhacement was related 
to this functional relationship of the LC and PHG trough the NA released, pupilometry 
measurements were taken. Pupilometry dilation has been considered as an indirect measure 
of LC activation (Alnaes et al., 2014; Murphy, O’connell, O’sullivan, Robertson, & 
Balsters, 2014). With these two independent measures, the relationship between LC-PHG 
pathway activation by movement and the subsequent memory enhacement, modulated by 
NA, was set up.  
The ultimate measure to probe this memory enhacement pathway was through 
pharmacological challenge. So, the hypothesis of the memory enhacement for the “Go” 
stimuli blockade by administration of a β-adrenoceptor antagonist was tested.  
The results for the placebo group are not in line with the previous results presented in 
Yebra et al., (2017, submitted) and that lead to the generation of the tested hypothesis. The 
placebo group did not show the enhacement effect for the “Go” stimuli due to movement. 
This in despite a pilot group of subjects with no pharmacological challenge showing a 
trending towards better Go than NoGo memory on the same version of this task.  
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Before this study, another experiment using the “Go NoGo” task with neutral or emotional 
stimuli (Yebra et al., 2017) shown that the memory for the “NoGo” emotional stimuli was 
higher than for the “Go” emotional stimuli; while for the neutral stimuli results were in the 
opposite line (better memory for “Go” neutral stimuli than for “NoGo” neutral stimuli). 
This results concord with inverted-U relationship between arousal (noradrenergic activity) 
and cognitive performance describe by the Yerkes-Dodson law  (Yerkes & Dodson, 1908). 
Low levels of NA transmission lead to memory (cognitive) impairment. Likewise, very 
high levels of NA also produce memory impairment; while optimal (medium) NA levels 
produce memory enhacement (see Figure 4.10.).  
 
 
Figure 4.10. Memory enhacement is modulated by emotion. The Yerkes and Dodson law (Yerkes & 
Dodson, 1908) establish the modulation of memory via NA. The ends of the curve indicate very low or very 
high NA transmission, which leads to a memory impairment. Medium levels of NA (optimal levels) 
transmission produce a memory enhacement. Yebra et al. (2017) conducted an experiment with emotional and 
neutral stimuli presented while performing a “GoNoGo” task. “Go” encoding produces higher released on NA 
than “NoGo” encoding, which modulates memory in the recognition task. But if the NA released by the “Go” 
movement is added to the released produce by the encoding of an emotional stimulus, a high amount of NA is 
released, turning into memory impairment. This addition does not occur in the “NoGo” emotional encoding, 
which results in better memory for the stimuli. The effect is described as an inverted-U shaped, modulated by 
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NA levels. Abbreviations: NoGoE (NoGo emotional); GoE (Go emotional); [NA] (nor-adrenaline 
concentration).   
If we translate this Yerkes and Dobson law to the study presented in this thesis, participants 
who received placebo should show increased memory for the “Go” images compared to the 
“NoGo” images, while for the propranolol group, should not be difference in the memory 
performance between both conditions, due to the effect of the β-blocker in the release of 
NA during encoding (see Figure 4.11.). Nevertheless, the results presented showed equal 
memory performance for the placebo conditions [t(14)=-0,005, p=0,99]; while in the 
propranolol group, the “NoGo” memory has a numerically greater impairment than the 
memory for the “Go”, being that the expectancies were exactly the opposite [t(13)=0,54, 
p=0,60]  (see Figure 4.11.) .  
 
 
 
Figure 4.11. (a,b). Memory performance (a) expected and (b) obtained. According to the Yerkes and 
Dobson law, we should have expected better memory for the Go vs NoGo stimuli in the placebo group; but an 
impairment in memory for the “Go” condition in the propranolol group (part a of the figure). The results 
obtained shown equal memory for the placebo group, but memory impairment for the “NoGo” condition vs. 
the “Go” images (part b of the figure). Abbreviations: NoGoP (NoGo placebo); GoP (Go placebo); NoGoProp 
(NoGo propranolol); GoP (Go propranolol).  
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The fact that healthy subjects with low blood pressures did not participate, made the sample 
less diverse and representative. This selection bias may be affecting the propranolol group 
and lessen the effect of the drug on memory performance. While a higher release of NA in 
the placebo group, may be the underlying reason for the equalization of memory outcomes 
in both conditions. A possible solution should be to increase the sample as well as the dose 
of propranolol to correct the bias. 
Nevertheless, when analyzing the linear relationship between arousal and memory for both 
groups separately, the placebo group shown that the higher is the arousal experienced by 
the participant, the greater is the memory for the Go stimuli, while in the propranolol group 
this relationship was not present. This experiment has shown evidence of the relationship 
between action-induced memory and arousal, and that the administration of a β-
adrenoceptor antagonist has been able to block this effect of arousal on memory. 
Nevertheless, in order to avoid some bias and deepen in the knowledge of the relationship 
between motor and memory system, further studies are needed, with greater sample size.  
This first pharmacological attempt of modulating the action-induced memory performance 
would make closer the possibility of understand the relationship of two different systems in 
the brain, with the subsequent benefits in the quality of life of many people. Understanding 
how we are able to enhance memory while making a movement would benefit not only 
current concepts regarding teaching, but also could benefit different treatment approaches 
in dementias.  
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Chapter 5 
General discussion 
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5.1. General discussion 
In this thesis, I demonstrate that we can pharmacologically manipulate different memory 
processes in humans. During the last decades, part of the research in memory has been 
centred in the viability of modifying memories, enhancing or impairing, in an effective, fast 
and lasting way. For the sake of scientific completeness the possibility of replication and 
validation of the achieved findings is mandatory; even more when dealing with humans and 
with the possibility of improving someone´s daily life.  
Pharmacological manipulation is among one of the last frontiers to cross when studying the 
possibility of a novel treatment for memory. Generally, the less invasive the modification, 
the less is the risk for the potential patient. Nevertheless, when dealing with neurological 
and psychiatric disorders, in most cases it is the most effective treatment. Likewise, 
pharmacological studies are needed in order to confirm a hypothesis, elucidate a 
neurobiological mechanism, or to continue with the study of novel discoveries. 
In this thesis, two replications of two studies have been presented, along with an advance of 
the underlying mechanism. On one hand, pharmacological manipulation of memory has 
been tested in order to diminish it; while, on the other hand, a drug has been used to test the 
reliability of a new pathway to increase memory in humans. 
Diminishing disturbing memories 
The possibility of offering a different or coadjutant treatment to those already available for 
disturbing memories opens a window of opportunity for the recovery and reinsertions of 
patients with psychiatric disorders derived from poorly adaptive or traumatic memories. 
The disorder that has obtained the most visibility for this type of therapeutic targets has 
been post-traumatic stress disorder (PTSD). However, the potential benefit in other 
disorders related to episodic memory such as addiction or phobias, is on the horizon.  
One of the principal contributions of this thesis has been to broaden the knowledge about 
the mechanism underlying the modification of disturbed or maladaptive memories that are 
at the core of several psychiatric disorders through the investigation of innovative methods. 
We have focused our attention on PTSD; however, the possibility of transferring these 
findings to other psychiatric disorders, thus reducing the suffering at a personal, family and 
social level of many people, makes it necessary to continue investigating the mechanisms 
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of memory modification described here. The realization of studies with clinical populations 
should be considered as the next step to help answer all the questions that can be raised 
now, or in the future. 
Augmenting memory 
The second study presented in this thesis, measures the influence of the motor system on 
the episodic memory. Prior to this pharmacological study, a set of experiments had been 
performed with a Go-NoGo task and its influence in a subsequent recognition task of 
images. Those experiments highlighted the key-role of the NA system in a subsequent 
enhancement of memory engaged by taking an action at the time of encoding. Nevertheless, 
the results obtained opened a series of questions related to the design of the tested paradigm 
and the drug used to influence the neural mechanism involved in this enhacement of 
memory.  
After summarizing and discussing the findings achieved in the two investigations we have 
carried out, we will present open questions that can be analysed and answered in future 
studies.  
5.2. Summary of findings 
The purpose of this thesis was to amplify the knowledge about the mechanism of how 
emotion influences memory and how to diminish this influence, contributing to the 
development of new treatments for psychiatric disorders. Likewise, we have deepened the 
knowledge regarding the relative mechanism to neural bases that contribute to the memory 
enhancement following movement.   
The first chapter of this thesis describes the classical theories on memory, and how new 
knowledge acquired recently has transformed and developed them. The second chapter 
focuses on the major neurotransmitters’ systems in the brain and its relationship with 
memory and emotion, describing the most important human and animal studies when 
needed. The third chapter is centered in the reconsolidation hypothesis which postulates 
that upon reactivation, memories can become labile and susceptible to manipulation, 
requiring a new restabilization process in order to maintain them. We showed evidence of 
the reconsolidation process using general anesthesia on emotional episodic memories, and 
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how they can be diminished upon reactivation in a long lasting way, following the 
reconsolidation criteria.  
The fourth chapter analyzed how taking an action enhances episodic memory, but 
inhibiting action does not impair it; i used a pharmacological manipulation to demonstrate 
the effect of the motor system on memory. The purpose of the study was to test the 
hypothesis of the involvement of the medial temporal structures in this enhacement of 
memory by the action of the NA released from the LC. It was not possible to show a direct 
correlation between the pharmacological manipulation and the blocking of the memory 
enhacement; nevertheless, a correlation between the arousal experienced by the subjects, 
translated in systolic blood pressures and the percentage of correct remembered stimuli was 
showed.  
5.3. Challenging the classical view of memory 
Since William Hamilton (1859), the division of the processes of memory formation has 
included four steps: encoding, consolidation, storage and retrieval. After the initial 
encoding, the labile and unstable information is set and ceases to be modifiable, in a 
process known as consolidation. Subsequently, memories are stored in different brain areas 
as time passes, and can be retrieved at will; but cannot be altered since they are considered 
immutable. The research presented in this thesis contributes to challenging this classical 
view of memory by adding new knowledge and evidence against the immutability of 
memories. After consolidation, a memory can be activated again by presenting a reminder 
cue, rendering the memory unstable again; susceptible to modification and in need of a 
restabilization process in order to be maintained.  
The work in this thesis contributes to expand the current evidence on the theory of 
reconsolidation by presenting data showing that, in humans, it is possible to render labile an 
episodic memory again, and, critically to manipulate it with general anesthesia, reducing 
the targeted emotional memory traces. Upon reactivation and subsequent manipulation, the 
memory trace requires a restabilization process, in accordance to the reconsolidation 
theory. 
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The special case of emotional memory 
When referring to emotional memory, one of the neural structures in charge is the 
amygdala, and more specifically, the basolateral nucleus of the amygdala (BLA). In 
addition to the specific role of the BLA in the encoding of emotional arousing material, 
other brain regions enter in the process, such as the hippocampus. The role of the 
hippocampus in emotional memories becomes determinant if a context is involved in 
memory, besides its role in the formation of episodic memory. As it was highlighted in 
chapter 2, the noradrenaline released from the Locus Coeruleus (LC) modulates the 
retrieval of emotional memory. Also, NA is thought to be involved in the efferent 
connection between the amygdala and the hippocampus that contributes to the 
consolidation of episodic memories.  
Anxiety disorders are extremely common amid the general population (Kessler et al., 
2005), and they are usually attached to an excessive fear of specific objects or situations 
(APA, 2000). But among all of them, the best example of a maladaptive emotional memory 
behind a mental disorder is PTSD.  
Individuals, who have been exposed to an event that involved the threat of severe injury or 
death; or react with intense horror or fear to a specific situation, are vulnerable to developed 
PTSD (APA, 2000). Among the symptoms, there is the re-experience of the traumatic event 
across nightmares, intrusive thoughts, flashbacks, distress and excessive physiological 
arousal (hyper arousal, exaggerated startle, concentration, as well as sleep difficulties) in 
response to reminders of trauma (APA 2000; Shin & Liberzon, 2010).   
Reconsolidation of emotional memories  
Since the first demonstration of reconsolidation, emotional memories have been involved. 
The first attempt of reconsolidation impairment was directed at memories dependent of the 
amygdala in rats (Nader, Schafe,  & Le Doux, 2000; Nader & Hardt, 2009). 
Due to NA activity in the brain, the majority of the attempts and demonstrations of 
blocking reconsolidation in humans have been made using β-blockers; it is been shown that 
blocking noradrenaline in the amygdala or hippocampus can disrupt memories following 
reactivation (Dȩbiec & Ledoux, 2004; Debiec et al., 2002; Lonergan & Pitman, 2013; 
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Poundja, Sanche, Tremblay, & Brunet, 2012; Saladin et al., 2013; Schwabe et al., 2012). 
Nevertheless, since the attempts to replicate the findings with clinical populations failed, a 
different manipulation of the reactivated memories has been suggested (Muravieva & 
Alberini, 2010). The work presented in this thesis has added knowledge to the 
understanding of reconsolidation, and has suggested that the interaction between the 
amygdala and hippocampus is not only regulated by the noradrenergic system, but also by 
the GABA system.  
5.3.1.. Proposal of a different mechanism when blocking reconsolidation 
The process behind the amnesia induced by anesthesia remains unclear. The importance of 
understanding this process is fundamental since amnesia is one of the most important side 
effects of general anesthesia (Trapani et al., 2000). Classically, it has been supposed that 
the neural structure behind this amnesia-induced by anesthesia was the hippocampus. In 
chapter 1, the key role of the hippocampus and other medial temporal lobe structures on 
memory was presented. Nevertheless, the hippocampus cannot be working alone in the 
induction of amnesia, and it has been suggested that it works, among others, with the 
amygdala, and more particularly, with the basolateral nucleus of the amygdala (BLA) 
(Alkire et al., 2008, 2001; Alkire & Nathan, 2005; Tomaz et al., 1992).  
There is plenty of evidence about the modulatory role of the BLA in the consolidation of 
emotional episodic memories in the hippocampus (McGaugh, 2004b). Findings with 
posttraining electrical stimulation showed that the amygdala is able to enhance or impair 
memory, depending on the features and parameters of the stimulation (Gold, Edwards, & 
McGaugh, 1975); indicating that the amygdala is not a mere place to impair memory, but a 
neural structure that modulates memory consolidation.  This modulatory effect can be 
exerted because during the consolidation process, there is a time-window during which, 
memories remain in a labile state; before they are fixed and become invulnerable. 
Nevertheless the amygdala does not work alone but through its projections (afferent and 
efferent) to other brain regions: hippocampus, frontal cortex regions (particularly ventral- 
and dorsal PFC) and LC (Petrovich et al., 2001; Pitkänen, Pikkarainen, Nurminen, & 
Ylinen, 2000; Price, 2003; Rosene & Van Hoesen, 1977). Different neurocircuitry models 
have linked the amygdala, hippocampus and PFC to the persistence of the traumatic 
memories in PTSD (Rauch et al., 2000; Rauch, Shin, Whalen, & Pitman, 1998).  
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For example, several studies have indicated increased amygdala activation in PTSD 
patients compared to control groups in a script-driven imagery task (Shin et al., 1999, 
2004).  Supporting this role of the amygdala in PTSD, other studies have showed that 
amygdala activation correlates positively with PTSD symptom severity (Armony, Corbo, 
Clément, & Brunet, 2005; Etkin & Wager, 2007). With respect to the hippocampus, 
humans studies have revealed hippocampal abnormalities in structure (decreased size) and 
hypoactivation (Bremner et al., 2003; Etkin & Wager, 2007; Geuze, Vermetten, & 
Bremner, 2005; Nemeroff et al., 2009; Sakamoto et al., 2005); as well as, hypoactivation of 
the PFC, in traumatic script driven imagery (Bremner et al., 1999; Britton, Phan, Taylor, 
Fig, & Liberzon, 2005; Etkin & Wager, 2007; Lanius et al., 2001) (see Table 5.1.) 
 
Table 5.1. PTSD brain areas. Brain areas related to PTSD in humans. Abbreviations: PFC, prefrontal 
cortex.  
 
In relation to neurotransmitters, GABA is the principal inhibitory neurotransmitter in the 
brain, controlling excitability in several brain regions, including the amygdala (Pitkänen et 
al., 2000). The GABAergic system it is also implicated in the pathogenesis of anxiety 
disorders, including PTSD. But even more, low levels of GABA in plasma after a traumatic 
experience are considered as a predictive factor of developing PTSD (Vaiva et al., 2004).  
Deficiencies in the GABAergic transmission in the BLA produces the  BLA 
152 
 
hyperresponsiveness that is thought to contribute to the development of PTSD ( for review 
see Prager, Bergstrom, Wynn, & Braga, 2016). Likewise, reductions in the GABA content 
in the hippocampus have been found in animal studies (Harvey, Oosthuizen, Brand, 
Wegener, & Stein, 2004); findings that have been showed also in PTSD patients (Bremner 
et al., 2000).  
The BLA receives extensive NA innervation from the LC (Pitkänen et al., 2000), and the 
two neurotransmitter systems (NA and GABA) influence one another in BLA-related 
memory processes (Li, Nishijo, Ono, Ohtani, & Ohtani, 2002). It has been shown that 
administration of a GABAA antagonist enhances NA release in the amygdala, while a 
GABAA agonist administration diminishes NA release (Chen et al., 1999; Hatfield et al., 
1999). Also, this interaction between both neurotransmitter systems (NA facilitates GABA 
inhibition transmission) has been shown in other brain regions, such as the hippocampus 
and neocortex (Bennett, Huguenard, & Prince, 1998; Kawaguchi & Shindou, 1998; 
Madison & Nicoll, 1986).  
In a correctly functioning amygdala, this NA facilitation of GABA would be translated into 
either suppression of memory formation (by suppressing excitatory activity); or would help 
an optimal consolidation of a memory trace (by modulating the excitatory activity).  
Nevertheless, in a hyperresponsive amygdala (as happens in PTSD) the NA facilitation of 
GABA transmission is blocked, which leads to an enhacement of memory for events with 
almost no emotional significance, while emotionally charged memories may result in an 
“overconsolidation” (Braga, Aroniadou-Anderjaska, Manion, Hough, & He, 2004).  
Reconsolidation is a process that renders memory labile again. The type of memory 
affected by the manipulation of reconsolidation is related to the brain area affected, and the 
dependency of the memory in that particular area would determine the manipulation effect 
on memory.  
Previously, we had hypothesized that the administration of an anesthetic such as propofol 
would affect the reconsolidation of emotional memories. If the BLA is lesioned, then, the 
amnesic effect of propofol is not shown (Alkire et al., 2001).  Moreover, a study has 
presented results that indicated that propofol, through the interaction between the BLA and 
the hippocampus, is able to impair memory consolidation (Ren et al., 2008).  
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The GA propofol could be exerting its effect on the reactivated memory through the BLA. 
The impairment of the memory trace could be due to the blockage of the efferent 
connections between the amygdala and the hippocampus. Likewise, the administration of a 
GABAA agonist after the re-activation of an emotional memory (BLA-related memory), 
may suppress the memory trace formation, due to the suppression of excitation. Both 
effects, the suppression of the efferent connections between both memory-related structures 
and the inhibition of the excitation due to the GABA enhacement, may result in a 
deterioration of the memory traces previously reactivated. Thus, emotional memory will be 
impaired.  
5.4. Relationship between arousal and memory enhancement 
In the study presented in chapter 4, a previously tested memory paradigm has been 
replicated and extended. The parameters of the Go-NoGo task used were set up before by 
Yebra et al., (2017, submitted). Nevertheless, this study went one step forward, by testing 
the hypothesis of the blockade via β-adrenoceptor antagonist administration of a novel 
neurological pathway that results in a boost of episodic memory by performing an action 
that is unrelated to the encoded material.  
Nevertheless, it was not possible to ascertain with the pharmacological manipulation the 
action-induced episodic memory enhancement driven by the noradrenergic system. But, it 
was possible to support that action’s inhibition did not impair the episodic memory. 
Previous studies showed an inhibition-induced forgetting (Chiu & Egner, 2014, 2015). 
Using a Go-NoGo task, Chiu & Egner, (2014) found that NoGo cues were less remembered 
than Go cues. The interpretation provided was that higher resources demand for response 
inhibition when the NoGo trials were presented resulted in a higher demand of the NoGo 
network; which resulted in unsuccessful memory encoding for those stimuli. They 
attributed the memory impairment to a temporary loss of attention due to a task-set 
updating (Dreisbach & Wenke, 2011). When replicating their results with fMRI (Chiu & 
Egner, 2015), the higher resources demand by NoGo-inhibition resulted in a negative 
correlation with the activity in the brain regions associated to memory encoding. They 
focused their attention on the ventrolateral prefrontal cortex (VLPFC), as the brain region 
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responsible for the encoding of the NoGo trials; finding a negative correlation between the 
activation of this brain area and the inhibitory demand of the NoGo cues.  
Nevertheless, as said (chapter 4), there is new evidence of exactly the opposite effect on the 
memory of the stimuli presented in a Go-NoGo task. Across a series of experiments, Yebra 
et al., (2017, submitted) showed that the memory for the Go (taken an action) stimuli 
compared to the NoGo (action inhibition) stimuli, was enhanced. This memory enhacement 
for the Go condition was thought to involve the noradrenergic mechanism. The 
involvement of the LC (main source of NA in the brain) was demonstrated by fMRI and 
pupilometry recordings. To confirm the involvement of the noradrenergic system in the 
enhacement of memory by taking an action, a final experiment was performed, using 
emotional and neutral stimuli. The results were as predicted, the emotionally aversive 
stimuli, which recruit the NE system, modulated the mnemonic enhacement provided by 
taking an action, when compared to neutral stimuli of the Go condition. The conclusion of 
the study was that taking action boosts episodic memory encoding via a noradrenergic 
mechanism. Nevertheless, it is difficult to validate these results with behavioral data and 
indirect measures of NA alone. 
In the pharmacological study presented previously (chapter 4), a non-selective β-blocker 
(propranolol) was used. The propranolol´s pharmacological features were described 
previously. 
Once the propranolol reached its maximum plasma peak, the experimental group performed 
the Go-NoGo task. As the experiment was a double-blind design, all participants had to 
wait 90 minutes after the baseline blood pressure and ECG measures were taken. The 
results obtained were unable to confirm the main hypothesis of the involvement of the 
noradrenergic system on the action-induced memory enhancement. Nevertheless, the 
memory impairment due to action inhibition was not shown either. One interesting result 
that points toward the noradrenergic mechanism underlying memory enhancement by 
taking an action was the correlation shown between systolic BP and memory for Go-
stimuli. This correlation indicated a possible relationship between arousal and memory. 
Thus the participants with higher levels of arousal showed better memory for the Go-
stimuli compared to the NoGo stimuli. Higher levels of arousal, translated into higher 
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levels of systolic BP, may indicate a higher release of NA that could be linked to a greater 
activation of the LC. 
The boost of episodic memory driven by a NA mechanism remains a strong hypothesis, but 
different experimental design issues should be solved in future studies.   
NA and memory disorders 
Dysfunction of LC is related to different memory disorders, being Alzheimer´s disease 
(AD) the most widespread worldwide. 
As said before (chapter 2), the brainstem nucleus LC is the primary source of NA in the 
CNS (Berridge & Waterhouse, 2003). LC and its connections to the parahippocampal gyrus 
(PHG) and amygdala are associated with successful memory performance in encoding and 
recall in healthy older subjects (Jacobs et al., 2015), but especially when the encoded 
material is emotional rather than neutral (Sterpenich et al., 2006).  
Contemporary theories about AD are linking a reduced functional connectivity between LC 
and parahippocampal gyrus (PHG) in prodromal (early stages, symptoms) AD patients 
(Jacobs et al., 2015). Early AD is characterized by LC degeneration which produces NA 
dysfunction (Grudzien et al., 2007; Missonnier, Ragot, Derouesné, Guez, & Renault, 1999). 
The LC degeneration and excitability deregulations seem to be related to an abnormal 
response to stressful stimuli, producing increase in amyloid beta (Aβ) deposition (Ross, 
McGonigle, & Van Bockstaele, 2015). 
Nevertheless, it seems that early AD patients may be able to recruit an existing connection 
between LC and MTL to maintain memory function (Jacobs et al., 2015). This recruitment 
is what has been termed a cognitive reserve. A cognitive reserve, as said, is a term that 
defines the differences between people´s susceptibility to the deficits produced by AD 
(Stern, 2012). It is possible to differentiate two types: brain reserve, which mentions the 
differences in brain structure that may help facing the diseased by increasing the tolerance 
to it; and cognitive reserve, that refers to the lifelong experiences, education, occupation 
and leisure activities that may help maintaining memory function in prodromal AD (Stern, 
2012). Cognitive reserve may be behind the adaptive functional reorganization observed in 
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AD patients with better memory performance, providing a compensatory mechanism to 
counteract early AD deficits (Jacobs et al., 2015).  
The possibility of boosting episodic memory by taking an action via noradrenergic system 
may have important implications for potential clinical interventions in the early stages of 
AD; moreover, understanding the mechanism behind this memory enhacement could 
provide different pharmacological approaches than those available so far. 
5.5. Limitations and outstanding questions 
The two studies presented in this thesis have raised questions that need to be answered. As 
exposed, we have achieved unexpected results, or in future studies we have to deal with 
some limitations that may be affecting the results.  
5.5.1. Reconsolidation of emotional episodic memories using general anesthesia 
When talking about amnesia, it remains controversial whether the perceived memory loss is 
due to a malfunction in the consolidation process (a problem of storage) or to an impaired 
retrieval (Miller & Springer, 1974; Nader & Wang, 2006). The same diatribe is held when 
talking about reconsolidation; with the available data at the moment it is not possible to 
know if the impairment is due to storage or retrieval deficits, since both points of view are 
able to give an explanation about the recovery or not from amnesia (Miller & Springer, 
1974; Nader & Wang, 2006). Nevertheless, some studies have suggested that the recovery 
from amnesia in new learning is due to storage impairment (Lattal & Abel, 2004; Squire, 
2006) but the recovery of the reactivation-induced amnesia is due to retrieval impairment 
(McGaugh, 2004a; Rudy, Biedenkapp, Moineau, & Bolding, 2006). 
One of the limitations of our study is the inability to demonstrate if our memory 
impairment lasts over time; or if the memory trace would be recovered. Therefore, and as 
suggested before in chapter 3, another experimental group would be needed, with a longer 
interval before testing, and a follow up of the results. Another question is if our results 
would be similar in clinical population. The memory tested here is a memory from an 
experimental context, and not a real-life memory, from a traumatic experience. When 
talking about clinical populations, we tend to focus on PTSD. Nevertheless, the application 
of the results achieved here would be interesting for other mental disorders. But, would GA 
induced reconsolidation impairment in psychiatric patients? One of the main differences is 
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that real life memories that are at the core of a disorder such as the PTSD are often old 
memories that have been reactivated several times, and can be mixed with more than one 
memory trace. This complexity needs to be examined in order to make an effective 
treatment. 
Many of the so-called ‘boundary conditions’ that would make reconsolidation unable to 
take place have been described in chapters 1 and 3 (for review see Tronson & Taylor, 
2007). 
To make a memory labile again, it is necessary a strong enough cue-reminder, to activate 
that particular memory trace. But, the complexity of real-life memories makes possible that 
more than a cue-reminder are able to activate those memories. This characteristic of 
memory reactivation is called generalization stimuli, and refers to the possibility that cues 
perceptually or conceptually similar to the cues involved in the real memory can trigger 
reconsolidation as well. Nowadays, it is possible to solve this limitation of the 
generalization stimuli, by recreating the original circumstances and the specific cue-
reminder of the memory trace with virtual reality. Virtual reality can be a very useful tool 
that needs to be tested in order to be able to get the most out of it.  It is also possible that 
the appearance of a very strong cue-reminder activates a memory trace that was thought to 
be impaired. The necessity of analyzing more closely the reminders that can be able to 
trigger a memory are fundamental if we want to achieve a durable and reliable treatment.  
When taking into consideration that real life memories are able to have more than a single 
memory trace, but an interconnection of different traces, it is possible that reconsolidation 
only attenuates part of those traces, but not all of them, producing a partial memory trace 
disruption. In that case, it is necessary to asses if several reactivations and manipulations 
would add effects and disrupt all the memory traces and the connections. For example 
propofol could be administered multiple times with multiple reactivations (analogous to 
repeated ECT sessions in depression or schizophrenia). It is also important to consider than 
even though a memory trace is not expressed, that does not mean that it does not exist. 
Recent findings, have been able to demonstrate that a memory that is thought to be erased 
can be recovered (Gisquet-Verrier et al., 2015). Future studies should focus on memory 
traces, and its characteristics and properties, to ensure how and what can activate a memory 
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trace again, and how exactly make a durable disruption, over time and personal 
circumstances.  
Other limitation that would make very complicated to translate reconsolidation from the 
laboratories to the clinical patients is the resistance that chronic stress-enhanced fear 
memories, as the ones in PTSD, seem to have (Hoffman et al., 2015). It has been 
hypothesized that traumatic memories in PTSD are “over consolidated” due to the 
influenced of stress hormones at the time of the traumatic experience (Pitman, 1989), 
posing a challenge when targeting this type of trauma-memories. Not every person that 
experienced a trauma develops PTSD (Breslau, 2001); hence there are individual 
differences to be taken into account, as well as the possible functional alterations in the fear 
neurocircuitry that may be supporting and developing PTSD (Hoffman et al., 2015).  
If the limitations and boundary conditions can be solved by future research, the possibility 
of offering a treatment reachable to wide-scale administration would help to redefine not 
only how general population perceives mental disorders but also the stigma attached to 
them, by showing that a mental disorder is treatable in the same way as other health 
diseases affecting other body regions.  
5.5.2. Blocking the action induced memory enhancement with β- blockers 
Different design problems when trying to block the action-induced memory enhancement 
with β- blockers were pointed out before. They should be solved in order to be able to 
increase the validity and reliability of the results obtained in the experiment described in 
chapter 4. One of the most important limitations of the study was the selection bias 
described in chapter 4. As said, in order to provide maximum security to the participants 
involved in the study, participants with low blood pressure (BP) were discarded.  
To solve this selection bias, future studies should extend the range of the BP accepted, 
making the sample more representative of the population. Another possibility could be 
maintaining the BP range observed in this study, but increasing the amount of the drug. 
Another limitation that should be taken into account is the bioavailability of the drug.  
Bioavailability refers to the percentage of the administered dose of unchanged drug that is 
able to reach the systemic circulation. As noticed before, after administration, propranolol’s 
total bioavailability is only approximately 30%, and varies greatly between individuals. 
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This loss in bioavailability is due to the route of administration (oral administration) and 
first pass metabolism (Frishman, 1979; Goodman, 1996). The only route of administration 
that would assure 100% of bioavailability is intravenous (IV) administration. However, IV 
propranolol is not accepted in healthy subjects, only used in case of life-threatening 
arrhythmias. This bioavailability must be considered when calculating dosages for oral 
administration. 
Adding limitations, a selection bias and the loss of part of the bioavailability due to oral 
administration, maybe an increase in the dosage of the drug, as well as increasing the size 
of the sample should be considered, in order to be able to show more clear results when 
testing the hypothesis.  
5.6. Clinical implications 
When performing the experiments described in this thesis, clinical implications were 
always the final goal.  
Memory is one the faculties of the brain that makes us who we are. A dysregulation of 
memory, whether due to a loss or an excess of it, causes severe changes in both, the person 
suffering and the family, as well as great harm to society, in the forms of productivity 
losses and healthcare costs. 
Both studies presented in this thesis, have the aim to increase the knowledge of the 
understanding of different diseases that affect our central nervous system. Not only the 
underlying mechanism but also to change of perception that the general population has over 
the disorders that affect the brain.  
Nowadays, it seems that the percentage of persons affected with a memory disorder, in the 
form of a psychiatric disorder or a neurodegenerative disorder, is augmenting. It could be 
related to the society we are integrated in, and to the increase of life expectancy. Whatever 
it is, the need for a cure is mandatory.  
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